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De tijd 
 
Soms droom ik dat zij stilstaat 
Om van haar te genieten 
Het moment dat nooit voorbij gaat 
 
En andere keren hoop ik  
Dat zij sneller vooruit loopt 
Naar daar waar ik niet weet 
Maar vooruit zodat ik vergeet 
 
Heel langzaam of heel snel 
Een ding weet ik wel 
Hoe ik haar bekijk 
Verandert niet haar voortbestaan 
Zij zal niet bij mij blijven 
Zij zal ook vergaan 
 
Maar haar effect is niet onbemerkt 
Zij raakt mij altijd even aan 
In dat wat ik voel, wat ik denk 
En hoe ik me beweeg 
Met gevoel blijf ik achter 
Soms vol, soms leeg 
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Diabetes mellitus is a public health problem, which has reached pandemic proportions. 
The global prevalence of diabetes is expected to increase with 39% between 2000 and 
2030, increasing absolute numbers to 366 million people (1). 
 Diabetes mellitus is a multi-factorial disease, characterized by hyperglycemia, 
resulting from a disturbed insulin secretion, insulin action or both. The long-term 
effects of diabetes mellitus include increased risk on complications such as foot ulcers, 
retinopathy, nephropathy and neuropathy. Even more problematic is the fact that 70-
80% of people with diabetes die of cardiovascular disease (2). From a public health 
perspective, diabetes and its complications are relevant for treatment and prevention 
due to the related human suffering and disability and the huge socio-economic costs (3, 
4) through premature morbidity (5) and mortality (6, 7). Clearly, there would be great 
benefits if research could provide evidence for effective prevention measures. The 
introduction of this thesis is composed of three main sections. First, the diagnosis and 
pathogenesis of type 2 diabetes are discussed, including the impaired glucose toler-
ance state (paragraph 1). The second section focuses on the prevention of type 2 
diabetes by the use of different lifestyle intervention strategies and includes some 
aspects of implementation (paragraph 2). In the third section several mechanisms are 
discussed that may underlie the development of type 2 diabetes and that may be 
responsible for the lifestyle intervention-induced improvement in metabolic profile 
(paragraph 3). Finally, an outline is given of the chapters covering the present thesis 
(paragraph 4). 
1. Type 2 Diabetes Mellitus 
Several forms of diabetes exist of which type 1 and type 2 diabetes mellitus are the 
most common. Type 1 diabetes mellitus accounts for approximately 15% of all diabe-
tes cases and results from pancreatic beta-cell dysfunction, causing insulin deficiency, 
and leading to the requirement of exogenously administrated insulin for survival. Type 
2 diabetes mellitus is the most common form of diabetes accounting for approximately 
85% of all cases. Type 2 diabetes mellitus results when pancreatic beta-cells fail to 
compensate for insulin resistance through an increased secretion of insulin by the 
beta-cells of the pancreas. Already several years ago, large scale analysis in 22 cohorts 
in Europe by the Diabetes Epidemiology Collaborative analysis Of Diagnosis criteria in 
Europe (DECODE) study group, showed a J shaped relationship, rather than showing a 
threshold effect, between high fasting glucose levels and all-cause mortality (8). 
Interestingly, all-cause mortality risks were similar in subjects with fasting glucose 
levels ш 7.0 mmol/l and in subjects with high 2-hr glucose levels of 10.01-11.09 mmol/l, 
when testing almost 30,000 people for their hazard ratio for death. Compared to the J 
shape of fasting glucose, the relationship between 2-hr glucose levels and cardiovascu-
lar mortality seemed to be graded and increasing (8). Overall, there seems to be a 
continuously graded risk for mortality with increasing glucose levels. 
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1.1 Diagnosis 
In general, diagnosis is based upon the presence of clinical symptoms and gross hyper-
glycemia during a visit at the general medical practice. Indications for a visit at the 
general medical practice include diabetes symptoms like itching, tiredness, blurred 
vision and unintended weight loss. However, at present, health checks may be a 
reason for a visit. In the prediabetic state, in which symptoms are mostly absent, an 
oral glucose tolerance test (OGTT) can be performed (9). This is a blood glucose meas-
urement during fasting and 2 hours after a 75-gram glucose bolus, dissolved in 250 ml 
water. According to the WHO, results can be interpreted as normal glucose tolerance 
(NGT), impaired glucose tolerance (IGT), impaired fasting glucose (IFG) and type 2 
diabetes (table 1.1). 
 
Table 1.1 WHO criteria for the diagnosis of impaired glucose metabolism (1999). 
 WHO 1998  WHO 1985 
 Whole 
blood 
Venous 
plasma 
Capillary* 
(whole blood)
 Whole 
blood 
Venous 
plasma 
Capillary 
(whole blood) 
 
Diabetes mellitus 
      
Fasting or ш 6.1 (110) ш 7.0 (126) ш 6.1 (110)  ш 6.7 (120) ш 7.8 (140) ш 6.7 (120) 
2-hr glucose ш 10.0 (180) ш 11.1 (200) ш 11.1 (200)  ш 10.0 (180) ш 11.1 (200) ш 11.1 (200) 
 
Impaired glucose tolerance 
      
Fasting and < 6.1 (110) < 7.0 (126) < 6.1 (110)  < 6.7 (120) < 7.8 (140) < 6.7 (120) 
2-hr glucose ш 6.7 (120) ш 7.8 (140) ш 7.8 (140)  ш 6.7 (120) ш 7.8 (140) ш 7.8 (140) 
 
Impaired fasting glucose 
      
Fasting and ш 5.6 (100) 
< 6.1 (110) 
ш 6.1 (110) 
< 7.0 (126) 
ш 5.6 (100) 
< 6.1 (110) 
    
(if measured) 
2-hr glucose 
< 6.7 (120) < 7.8 (140) < 7.8 (140)     
 
1.2 Pathogenesis 
In the pathogenesis of type 2 diabetes, two key features play a role, namely insulin 
resistance and beta-cell failure. Insulin resistance is characterized by the diminished 
ability of insulin to stimulate glucose uptake. Beta-cell failure is characterized by the 
inability to adequately produce sufficient amounts of the insulin. In the development 
of type 2 diabetes, which takes several decades, impairments in both features are 
believed to result in a transition from normal glycemia to hyperglycemia and hyperin-
sulinemia (10). Mild hyperglycemia can be classified as IFG when present in the fasted 
state and as IGT when present in the postprandial state (11). Subsequent deterioration 
of insulin resistance and beta-cell failure will lead to overt type 2 diabetes mellitus 
(figure 1.1) (11, 12). Insulin resistance and beta-cell failure are both under the influ-
ence of genetic variation and other factors, such as dietary intake, physical activity, 
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obesity. The relative contribution of these factors is strongly influenced by the patient 
population, e.g. ethnicity and age. With increasing age the risk for developing type 2 
diabetes also increases. 
 
 
Figure 1.1 Progression from normal glucose tolerance to impaired glucose tolerance and type 2 diabetes
mellitus (adapted from Saad et al. A two-step model for development of non-insulin-dependent diabetes. 
American Journal of Medicine. 1991;90(2):229-35). The progression can be effected by older age, genes and 
lifestyle, while changes towards a healthy lifestyle can delay or (partly) reverse the process. 
 
1.3  Impaired glucose tolerance 
The global prevalence of IGT is expected to increase from 314 million people in 2003 to 
472 million in 2025, accounting for approximately 9% of the adult worldwide popula-
tion (2). Depending on the characteristics of the population, e.g. age, BMI and ethnicity, 
the prevalence may range between 2% in rural areas and 20% in high-risk populations 
(13). 
 IGT is a strong predictor for the development of type 2 diabetes mellitus. In the 
Dutch Hoorn study, IGT, IFG and IGT/IFG combined predict the development of type 2 
diabetes over 6 years with 9.1% progression for IFG, 32.5% progression for IGT and 
64.5% for combined IGT/IFG (14). Besides the risk for development of type 2 diabetes, 
a graded positive relationship is also observed between postprandial glucose levels 
and cardiovascular mortality (8). 
1.4 Risk factors for diabetes progression 
Risk factors for the progression towards type 2 diabetes include lifestyle components 
such as body weight, dietary composition, and physical activity. Obesity is the most 
modifiable risk factor and BMI and body weight gain are strongly associated with 
diabetes risk (15). In addition to over-all obesity, body fat distribution and especially 
increased intra-abdominal fat mass is a predictor of type 2 diabetes (16, 17). Specifi-
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cally an increased visceral fat depot, as shown by using magnetic resonance imaging 
and computed tomography, has been shown to be related to the presence of insulin 
resistance (18-21). Besides obesity, total fat intake and saturated fat intake are impor-
tant risk factors for the development of type 2 diabetes. The energy-density of fat 
favors increased food intake and obesity. In the San Louis Valley Diabetes Study, a 40g 
higher fat intake corresponded with a 6-fold increase in diabetes risk in IGT subjects 
after adjustment for obesity and markers of glucose metabolism (i.e. fasting glucose 
and insulin) (22). Also, the kind of dietary fats seem to influence postprandial glucose 
metabolism and insulin resistance. The KANWU study reported an improved insulin 
sensitivity when replacing saturated fatty acids in the diet with mono-unsaturated fat 
in healthy volunteers during a period of 3 months, when a habitual diet low in fat was 
consumed. (23). In a recent study in subjects with normal glucose and triglyceride 
levels, beta cell function and insulin sensitivity progressively improved in the post-
prandial state as the proportion of mono unsaturated fatty acids as compared to 
saturated fatty acids in dietary fats increased (24). Also, a low glycemic-index diet and 
low glycemic load in type 2 diabetes patients during 6 months seems to moderately 
reduce body weight and HbA1c levels and increase high-density lipoprotein-cholesterol 
(HDL-cholesterol) (25). Besides the diet also other lifestyle factors influence diabetes 
risk. A recent systematic review and meta-analysis has shown that active smoking is 
associated with an increased risk for type 2 diabetes, with a greater risk for heavy 
smokers compared to light smokers (26). The causality and mechanism still need to be 
unraveled. Also lack of physical activity influences diabetes progression. Increasing 
physical activity has shown to decrease diabetes risk. For example, in IGT men from 
the Diabetes Prevention Study (DPS), individuals with the highest increase in their level 
of moderate-to-vigorous physical activity were 63-65% less likely to develop type 2 
diabetes during the 4.1 year follow-up compared to individuals with the lowest in-
crease in physical activity (27). 
2. Prevention of Type 2 Diabetes 
Over the past decades, several lifestyle intervention studies have been performed 
trying to reveal if, how and to what extent these programs could postpone or prevent 
deterioration of glucose tolerance and progression towards type 2 diabetes mellitus. 
These lifestyle intervention studies are composed of dietary intervention, exercise 
intervention, or the combination of diet and exercise. 
2.1 The SLIM study: design, purpose and previous results 
The SLIM study was designed to study the effect of a lifestyle intervention according to 
general public health recommendations regarding dietary intake and composition and 
physical activity on Dutch subjects at high risk for developing type 2 diabetes mellitus. 
Therefore, 147 subjects were randomized into an intervention and control group with 
stratification for sex and 2-hr glucose levels. Details of the design and screening has 
been described previously (28). A previous publication of this study show that the 
largest decrease in body weight and 2-hr glucose levels was observed after 1 year of 
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lifestyle intervention (29). Is was also shown that after 2 years, adherence to the diet 
and exercise recommendations gave the largest improvement in body weight, waist 
circumference, fasting insulin and 2-hr glucose levels, compared to adherence to the 
diet or exercise recommendations alone (29). This thesis describes the effects of the 
SLIM lifestyle intervention after 3-6 years as well as additional analyses on metabolic 
factors possibly associated with glucose tolerance, insulin resistance or the develop-
ment of type 2 diabetes. 
2.2  Dietary intervention 
Several dietary components are related to body weight, insulin resistance and the 
development of type 2 diabetes (for more detail, see chapter 2). In normalweight and 
overweight subjects, ad libitum reduced-fat diet without energy restriction resulted in 
a moderate body weight reduction between 3-5 kilograms (30, 31). Besides reducing 
body weight and sustaining a body weight reduction, a high-fiber, low-fat diet also 
reduces the development of type 2 diabetes (32). In addition, the type of fatty acid 
may modify insulin sensitivity (23) and diabetes risk, e.g. by positive effects on skeletal 
muscle insulin sensitivity (33-35). In this thesis, we examined if dietary advice as part of 
a lifestyle intervention according to general public health recommendations has an 
effect on the dietary composition, glucose tolerance, insulin resistance and diabetes 
risk, and whether these changes are prolonged during a period of 3-6 years. 
2.3 Exercise intervention within a lifestyle intervention 
A recent meta-analysis has shown that lifestyle interventions aimed at increasing 
exercise combined with diet are able to decrease the incidence of type 2 diabetes 
mellitus in high risk groups (36) (for more detail, see chapter 2). Vigorous physical 
activities seem to give the largest reduction in diabetes risk, whereas also small but 
sustained increases in physical activity seem beneficial in the long-term (27, 37). There 
seems to be a dose-response relationship between physical activity and fitness (38), 
exemplifying that even a little exercise is good for health but that increasing exercise 
may even be better. Besides reducing diabetes risk and increasing fitness, physical 
activity may also prevent weight regain after weight loss. Currently, approximately 420 
minutes of moderate intensity exercise (30 minutes a day) is recommended to prevent 
weight gain in overweight subjects (39). In this thesis, we examined if exercise recom-
mendations and a physical activity program consisting of combined aerobic and resis-
tance training, as part of a lifestyle intervention according to general public health 
recommendations, had an effect on maximal aerobic capacity, glucose tolerance, 
insulin resistance and diabetes risk and whether these changes are prolonged during a 
period of 3-6 years. 
2.4  Diet and exercise intervention 
Several combined diet and exercise lifestyle interventions have shown to reduce 
diabetes risk by ~40-60% during 3-6 years in European (40-42) and non-European IGT 
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people (43, 44) (for more detail, see chapter 2). Recently, the first studies have been 
published showing a significant diabetes reduction of 43% following 3-14 years cessa-
tion of the lifestyle intervention (45, 46). The effect of combined diet and exercise 
lifestyle interventions on 2-hr glucose levels has been less consistent (47, 48) (for more 
detail, see chapter 2). 
 Although combined diet and exercise lifestyle interventions have proven to be 
effective in reducing diabetes risk, it is not know if these lifestyle interventions can be 
effectively implemented in the general population. Currently, different approaches for 
lifestyle implementation are evaluated (49), which is a complex process that involves 
multiple factors that have to be aligned to achieve success. In chapter 2, more details 
regarding implementation are stated. 
 In this thesis, we assessed which factors are related to adherence to the diet and 
exercise recommendations and which factors are indicative for dropout to the lifestyle 
intervention program. Identification of these factors is the first step that can lead to 
increased effectiveness and efficacy of lifestyle interventions and can help to clarify 
difficulties that may interfere with successful implementation in the general popula-
tion. In the next paragraph, metabolic mechanisms of importance in the etiology of 
diabetes, and thus possibly responsible for the lifestyle intervention effect, will be 
covered. 
3. Metabolic disturbances associated with the development of type 2 
diabetes 
3.1 Ectopic fat accumulation 
In the etiology of type 2 diabetes mellitus, several major organs and their interactions 
play a role like adipose tissue, liver, skeletal muscle and pancreas. Adipose tissue is the 
major organ for triglyceride storage. Normally, adipose tissue functions as a lipid 
buffering depot, taking up dietary fatty acids in the postprandial state, to release them 
later on when there is an increased need for fat as a fuel. In insulin resistance, this 
buffering capacity is disturbed leading to an excess of lipids (free fatty acids (FFA) and 
triglycerides) in the circulation. This increased lipid overflow to non-adipose tissue 
organs may result in ectopic fat deposition in tissues like liver, pancreas and skeletal 
muscle (33-35, 50-52) (figure 1.2). Elevated levels of FFA can cause peripheral insulin 
resistance (53, 54) and acute lowering of FFA by the antilipolytic drug acipimox en-
hances insulin action on glucose uptake in the periphery (55). Fat storage in the liver in 
the form of triacylglycerol (TAG), e.g. in non-alcoholic fatty liver disease (NAFLD), has 
been associated with all features of the metabolic syndrome including hepatic insulin 
resistance, type 2 diabetes and elevated triglyceride levels (56, 57). Hepatic insulin 
resistance results in a reduced inhibition of hepatic glucose production during fasting 
contributing to hyperglycemia. The increased TAG storage in liver seems to be largely 
due to increased delivery of free fatty acids from adipose tissue to the liver (58).  
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Figure 1.2 The normal function of adipose tissue is to buffer the daily influx of dietary fat. When the buffer-
ing capacity for lipid storage in adipose tissue is decreased, as in obesity (when the fat cells are overloaded), 
other tissues like skeletal muscle, pancreas and liver are exposed to an excessive influx of fatty acids and 
TAG. TAG storage in these tissues may result in conditions related to insulin resistance, such as glucose 
intolerance, hyperinsulinemia and hyperlipidemia (adapted from Frayn, KN. Adipose tissue and the insulin
resistance syndrome. The Proceedings of the Nutrition Society. 2001; 60(3): 375-80 and Goossens, G. PhD 
thesis: The renin-angiotensin system in obesity, metabolic and hemodynamic effects. ISBN-13: 978-905278-
542-4) 
 
 
In skeletal muscle, accumulation of lipids as intramyocellular lipid (IMCL) has been 
strongly linked with skeletal muscle insulin resistance in both lean and obese subjects 
(59-62). In particular lipid intermediates like diacylglycerol (DAG) and ceramides, may 
interfere with insulin signaling or induce inflammatory pathways thereby reducing 
insulin action (63-66). 
 Also, the insulin resistant muscle may be characterized by a reduced fat oxidation 
(67-69) or an inability to adjust fat oxidation to different metabolic conditions (meta-
bolic inflexibility, (70)). Mitochondrial dysfunction has been proposed to contribute to 
a reduced or insufficient capacity to oxidize fatty acids and to skeletal muscle insulin 
resistance, (71, 72), while evidence is increasing that this relationship is not as straight-
forward as originally thought (73). Previous studies have suggested that one of the 
underlying mechanisms by which physical activity may contribute to type 2 diabetes 
prevention is via improved capacity to oxidize fatty acids (74-76). 
3.2 Adipose tissue as endocrine organ 
During recent years it has become increasingly clear that adipose tissue is not only a 
lipid buffering depot, but also produces many peptides and hormones, which may act 
locally (autocrine and/or paracrine) or may be secreted in the circulation to act as 
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endocrine factors. These adipo(cyto)kines may provide a link between obesity and 
insulin resistance and related metabolic complications (figure 1.3). As adiposity in-
creases adipocytes become hypertrophied and the ability of adipose tissue to function 
as an endocrine organ and secrete multiple biologically active proteins is affected (77). 
 Among others, adipose tissue secretes adiponectin, leptin and resistin. Several 
prospective studies have shown that low adiponectin levels are predictive of the 
development of insulin resistance and type 2 diabetes mellitus (78-82). Adiponectin 
has been shown to inhibit TNF-ɲ (83) and activate AMP-activated protein kinase 
(AMPK) and, in turn, modulate inflammatory signals (84). High-molecular weight 
(HMW) adiponectin has been proposed to be the biologically active form of the hor-
mone (85), although although HMW adiponectin and total adiponectin had similar 
ability to predict the presence of insulin resistance (86).  
 
 
 
Figure 1.3 Adipocytes secrete a variety of substances which can have autocrine/paracrine and endocrine
functions. Some of these factors may be associated with disturbances in obesity, glucose intolerance and
insulin resistance (adapted from Goossens, Physiology and Behavior, 2008). 
 
 
Leptin was originally thought to be a hormone whose primary role was to inhibit 
obesity by reducing food intake (87, 88). This idea was driven by the observation that 
rodents and humans lacking leptin or functional leptin receptors develop hyperphagia 
and obesity (87). The hypothesis was questioned when it was observed that obesity is 
typically associated with high leptin levels (89, 90) and fasting (or weight loss) induces 
a rapid fall in leptin levels, e.g. in obese subjects (91). A fall in leptin levels induces 
changes in energy balance and hormone levels (88, 89). Recently is was shown that in 
6 obese subjects, restoration of leptin levels to the original levels before body weight 
loss, causes maintenance of weight loss and reversal of changes in brain control of 
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food intake (91), indicating a potential of leptin to induce and sustain body weight loss 
(92). 
 With regard to resistin, conflicting data have been provided that do (93) and do 
not (94, 95) find an association with insulin resistance. For the complement system, 
data are more conclusive about a linear correlation with insulin resistance, in particular 
complement factor 3 (C3) and complement factor 4 (C4) (96, 97). Besides the liver, 
adipose tissue may be a source of C3 production, through activated macrophages (98) 
and adipocytes (99), thereby contributing to the development of type 2 diabetes. C-
reactive protein (CRP), which is also produced by the liver, has also shown to be a 
predictor of future risk of type 2 diabetes (100-102). Lifestyle interventions have 
shown to be able to reduce CRP levels (103, 104). 
 In recent years, the metabolic role of IL-6 regained interest with the new concept 
of skeletal muscle producing cytokines (myokines), e.g. IL-6, during physical activity 
(105). IL-6 seems to be paradoxically related to both an enhanced and reduced insulin 
action. On one hand, IL-6 is markedly produced and released in the post-exercise 
period (106) when insulin action is enhanced but (107-109), on the other hand, IL-6 has 
been associated with obesity (110), diabetes and atherosclerotic vascular disease (111). 
It seems that chronic elevation of IL-6 is not desirable (110), while short elevations of 
IL-6 do not seem to be harmful. 
 A discussion on the mechanisms for the increased inflammatory state in obesity, 
insulin resistance (112, 113), and type 2 diabetes (101, 114-116), would go beyond the 
scope of this introduction. In this respect, it has been demonstrated that hypertro-
phied adipocytes secrete macrophage chemoattractants, including monocyte 
chemoattractant protein-1 (MCP-1). MCP-1 recruits macrophage infiltration which, in 
turn, leads to a pro-inflammatory state in which macrophages secrete, among others, 
large amounts of tumour necrosis factor-ɲ (TNF-ɲ) (77, 117, 118). The pro-
inflammatory state may in turn increase lipolysis, e.g. by interfering with the insulin 
signaling, and decrease triglyceride synthesis within the adipocyte by downregulation 
of peroxisome proliferator-activated receptor-ɶ (PPAR-ɶ), and thereby increase lipid 
overflow to other organs (77). 
 Furthermore, although recent progress has been made in the understanding by 
which mechanisms biologically active proteins act on adipose tissue and skeletal 
muscle, a lot of questions remain to be answered to reveal the complex process of the 
pathogenesis of type 2 diabetes, thereby creating exciting opportunities in science. 
3.3 Iron metabolism 
The iron metabolism has been associated with insulin resistance and the development 
of type 2 diabetes (119). Until recently, however, it was not clear whether elevated 
iron stores predicted the risk of development of insulin resistance and type 2 diabetes. 
Proof of concept was provided by a large prospective study in healthy women that 
showed that higher iron stores (reflected by ferritin concentrations and the ratio of 
transferrin receptors to ferritin) were associated with an increased risk of type 2 
diabetes, independently of known diabetes risk factors (120). Epidemiological studies 
have further demonstrated that both ferritin and transferrin predict the development 
of type 2 diabetes (121-123). The mechanism by which ferritin and transferrin may 
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contribute to insulin resistance is still unclear. Transferrin has been shown to be a 
determinant of lipolytic activity in human adipocytes (124), and adipose tissue lipolysis 
has been recognized as a major determinant of insulin resistance (125). Also, ferritin 
has been suggested to affect insulin action (126) or catalyze hydroxyl radicals (124, 
127). Ferritin may stimulate lipolysis and subsequent lipid overflow towards liver and 
skeletal muscle, and the development of insulin resistance, thereby affecting the 
pathogenesis of type 2 diabetes. 
4. Outline of the thesis 
The leading thread through this thesis is the Study on Lifestyle intervention and Im-
paired glucose tolerance Maastricht (the SLIM-study) and each chapter will address a 
different question with respect to this study. In chapter 2 an overview is given about 
lifestyle intervention studies in the prevention of type 2 diabetes with respect to the 
main outcome and determinants of outcome and adherence, recent cost-effectiveness 
analyses and future implementation strategies. After 1 and 2 years, results of the SLIM 
study have shown that most improvement in glucose tolerance is achieved after 1 year 
of intervention and that adherence to the diet and exercise recommendations gives 
the largest improvement in body weight, waist circumference, fasting insulin and 2-hr 
glucose levels, compared to adherence to the diet or exercise recommendations alone 
(29). Chapter 3 addresses the 3-yr effects of on glucose tolerance, insulin resistance 
and the effect on metabolic cardiovascular risk factors, i.e. factors associated with the 
Metabolic Syndrome. Long-term effects of a lifestyle intervention (mean 4.2 years) as 
well as determinants of the main outcome and characteristics of dropout are evalu-
ated in chapter 4. Non-adherence to lifestyle interventions is a widespread problem 
(128) in need of clarification so that the success of lifestyle interventions involves the 
majority of the target group. Therefore, the study in chapter 5 aims to assess adher-
ence to the physical activity and nutrition advices and to determine personal and 
environmental factors that may have affected adherence. In the chapters thereafter, 
factors are examined, which may be associated with the success of the lifestyle inter-
vention. This may reveal predictors of intervention outcome and/or clues underlying 
the mechanism of the pathogenesis of type 2 diabetes mellitus. The 1-year and 3-year 
lifestyle-associated changes in inflammatory and immune markers with insulin resis-
tance and glucose tolerance are discussed in chapter 6 and 7. Increasing adipose tissue 
(adiposity), as observed in obesity, is the main risk factor for type 2 diabetes. As adi-
posity increases, the ability of adipose tissue to function as endocrine organ and 
secrete multiple biologically active proteins, also called adipokines, is affected. In 
chapter 8, the relationship between the iron metabolism and insulin resistance after 1 
year of lifestyle intervention is discussed. In chapter 9, the results and conclusions of 
the previous chapters are integrated and discussed in a broader perspective and 
implications for future research are given. 
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Abstract 
Lifestyle interventions are reported to reduce the risk of type 2 diabetes in high-risk 
individuals after mid- and long-term follow-up. Information on determinants of inter-
vention outcome and adherence and the mechanisms underlying diabetes progression 
are valuable for a more targeted implementation. Weight loss seems a major determi-
nant of diabetes risk reduction, whereas physical activity, dietary composition may also 
independently contribute. Also, body composition and genetic variation may affect the 
response to intervention. Lifestyle interventions are cost-effective and should be 
optimized to increase adherence and compliance, especially for the high-risk group 
with a low socio-economic status, so that public health policy can introduce targeted 
implementation programs nationwide. The aim of this review is to summarize the mid- 
and long-term effects of lifestyle interventions on impaired glucose tolerance and type 
2 diabetes mellitus and to provide determinants of intervention outcome and adher-
ence which can be used for future implementation of lifestyle interventions. 
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Introduction 
The World Health Organization predicts a global increase in diabetes prevalence of 
39% between 2000 and 2030, increasing absolute numbers to 366 million people (1). 
Impaired glucose tolerance (IGT), impaired fasting glucose (IFG) and IGT/IFG combined 
predict the development of type 2 diabetes over 6 years with 9.1% progression for IFG, 
32.5% progression for IGT and 64.5% for combined IGT/IFG (2). IGT is characterized by 
insulin resistance and reduced ɴ-cell glucose sensitivity (3-5), which may develop over 
many years. Lifestyle intervention may improve the metabolic profile and reverse the 
progression towards diabetes (figure 2.1) (5). 
 In this manuscript, we summarize the mid- and long-term effects of lifestyle 
interventions in subjects with IGT to lifestyle intervention outcome, i.e. changes in 
glucose tolerance or diabetes incidence. To develop implementation strategies it is 
important to know which factors determine the effectiveness and adherence to the 
intervention. Therefore, we provide information on lifestyle factors, i.e. (central) 
obesity, physical activity, dietary patterns (2, 6-9), on metabolic factors and genetic 
variation. Implementation of lifestyle interventions in general health care services will 
only start after lifestyle interventions have shown to be cost-effective. Therefore, this 
subject is discussed in a separate section. To conclude, this manuscript provides 
conclusive paragraphs regarding the long-term effects of lifestyle interventions and the 
major determinants of intervention outcome and adherence. In addition this manu-
script discusses the cost-effectiveness of lifestyle interventions and concludes with a 
summary on these paragraphs and additional implementation strategies for the future, 
which also include social-economic, social and psychological factors. 
 
 
Figure 2.1 Transition from normal glucose tolerance to diabetes mellitus type 2: three step model (adapted
from Saad et al. (1999) (5)). The development of normal glucose tolerance to impaired glucose tolerance and
type 2 diabetes mellitus can be affected by age, genes and lifestyle. It is (partly) reversible by healthy
changes in lifestyle. 
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Lifestyle interventions: effect on diabetes incidence and 2-hour glucose 
concentrations 
In table 2.1 and 2.2 a summary is given of lifestyle intervention studies to prevent type 
2 diabetes in IGT subjects. Only studies were included, that investigated the effect of 
exercise and/or dietary intake on 2-hour glucose concentration as an intermediate 
endpoint (table 2.1) or diabetes incidence as primary endpoint and that lasted more 
than 1 year (table 2.2). 
Glucose tolerance 
There is evidence that lifestyle intervention leads to an improvement in glucose toler-
ance, measured as the 2-hr plasma glucose concentration after a 75-g glucose load. 
Lifestyle interventions generally aim to achieve a body weight loss of at least 5 percent, 
through a healthy diet and energy restriction and to increase physical activity of 
moderate intensity to at least 30 minutes a day (table 2.3). The healthy diet most often 
refers to a total fat intake of less than 30 percent of energy consumed (E%), a satu-
rated fat intake of less than 10 E% and an increase in fiber intake to at least 15 g per 
1000 kcal. In the Diabetes Prevention Study (DPS), 2-hour glucose levels tended to 
decrease more in the intervention as compared to the control group after 3 years of 
lifestyle intervention (10). In New Zealand, a 1-year lifestyle intervention directed at 
reducing fat intake, by education of IGT participants on dietary fat intake, showed a 
lower increase in 2-hour glucose levels in the intervention group after a follow-up of 5 
years (11) (p < 0.01, table 2.1). Three smaller diet and exercise intervention studies, 
one in Swedish participants, one in Japanese Americans and one in British subjects 
with IGT, demonstrated a reduced body weight (12-14) and an improved insulin sensi-
tivity, but no significant differences in 2-hour glucose changes after 2 years (13, 14). In 
Japanese Americans, central adiposity measured with computed tomography was 
reduced and the incremental area under the curve for glucose during an oral glucose 
tolerance test (OGTT) was improved after 6 months in the diet plus endurance training 
group versus the diet plus stretching (control) group (13). The Dutch Study on Lifestyle 
intervention and Impaired glucose tolerance Maastricht (SLIM) evaluated a combined 
diet-and-exercise lifestyle intervention in IGT subjects. After 3 years, the postprandial 
glucose concentration was 0.8 mmol/l lower in the lifestyle group compared to the 
control group, representing a substantial diabetes risk reduction (15). 
 Most, but not all studies show a beneficial effect of lifestyle intervention on 
glucose tolerance. Sample size and a short follow-up of 1-2 years may explain part of 
the variation in effect size. Differences in baseline characteristics between intervention 
and control group, like waist circumference (13), fasting glucose and insulin levels (12) 
and percentage of subjects engaging physical activity at least once a week (14) may 
have influenced the effect of lifestyle interventions on 2-hr glucose levels. Interesting 
is that a lack of significant effect on 2-hr glucose is not necessarily related to a lack of 
effect on diabetes risk reduction. In the DPS, the reduction in 2-hr glucose levels was 
not significant (10) (0.4 mM difference between intervention and control), but risk 
reduction was 58% (table 2.2). Part of the risk reduction may be mediated via other 
pathways than 2-hr-glucose, e.g. via sub-clinical inflammatory factors (16) or preserva-
tion of ɴ-cell function (4). 
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Diabetes incidence 
The Malmö-study (17) and the Chinese Da Qing IGT and Diabetes study (18) were two 
of the first studies to show a reduced type 2 diabetes risk of more than 50% and 42%, 
respectively, by a diet and exercise program during a follow-up of 6 years. More 
recently, both the Finnish Diabetes Prevention Study (DPS) (19) and the Diabetes 
Prevention Program (DPP) in the USA (20) confirmed the beneficial effect of lifestyle 
and showed a diabetes risk reduction of 58% in IGT subjects that received a lifestyle 
intervention consisting of dietary and exercise advice during a follow-up of 3.2 and 2.8 
years, respectively. Interestingly, in an additional follow-up, the DPS showed that even 
after 3 years cessation of a 4-year lifestyle program (total follow-up 7 years), diabetes 
risk was still reduced with 43% (21). The Chinese Da Qing IGT and Diabetes study found 
the same diabetes risk reduction after a 14-year follow-up of a 6-year lifestyle inter-
vention (22). A 4-year randomized controlled trial in Japan reduced diabetes risk with 
67.4% by a combined dietary and exercise advice to IGT men (23) and the Indian 
Diabetes Prevention Program (IDPP-1) reduced diabetes risk by 28.5% in the diet and 
exercise intervention after 3 years (24). Thus, lifestyle changes in IGT subjects reduce 
or delay the development of type 2 diabetes. The risk reduction of studies that follow 
the lifestyle criteria listed in table 2.3 (the DPP (20), DPS (19) and SLIM (15)) is ap-
proximately 58% after 3 years follow-up. Although all studies show a beneficial lifestyle 
effect, the risk reduction ranges from 28% to 67%. Differences in risk reductions may 
be due to different population characteristics, ethnicity, duration of the lifestyle 
intervention and follow-up, and the lifestyle goals accomplished. 
 A recent systematic review and meta-analysis shows that lifestyle interventions 
seem at least as effective as pharmacological interventions, e.g. with orlistat, a drug 
which reduces intestinal fat absorption (25). In the DPP, metformin, a drug which 
suppresses hepatic glucose production, was less effective to reduce type 2 diabetes 
risk (−31%) than lifestyle intervention (20). 
 In general, lifestyle changes in subjects with IGT considerably reduce or delay the 
development of type 2 diabetes and is at least equally effective as pharmacological 
interventions. 
 
Table 2.3 Common features of lifestyle interventions. 
Body weight loss ш 5 % 
 
Dietary guidelines 
 
Carbohydrates  ± 55 E% 
Total Fat < 30 E% 
 - Saturated Fat ч 10 E% 
 - Cholesterol < 33mg/MJ 
Proteins 10-15 E% 
Fiber  3 g/MJ a day 
 
Exercise guidelines 30 minutes of moderate physical activity 
 a day for at least 5 days a week 
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Determinants of intervention outcome and adherence 
The progression towards type 2 diabetes can be influenced by lifestyle components 
such as body weight loss, dietary composition, and physical activity. These factors may 
all contribute to the improved glucose metabolism and the response and adherence to 
the lifestyle intervention. 
Body weight and diabetes risk 
Body mass index (BMI) and body weight gain are strongly associated with diabetes risk 
(26). Weight gain of 11-20 kg in 14 years of follow-up increased age-adjusted relative 
diabetes risk 5.4-fold in female nurses who had normal weight at age 18 (BMI 22-25 
kg/m2) relative to nurses with normal weight at age 18 y who had no weight gain or 
loss of more than 5 kg. In addition to over-all obesity, body fat distribution and espe-
cially increased intra-abdominal fat is a predictor of type 2 diabetes (27, 28). The BMI 
of middle-aged women at midlife strongly predicts 3-year incidence rates of type 2 
diabetes (29), whereas short-term weight changes during this period did not signifi-
cantly affect the onset of type 2 diabetes (29). 
The effect of changes in body weight on diabetes risk 
In the lifestyle intervention group of the DPP, weight loss was the dominant predictor 
of reduced diabetes risk with a 16% reduction for every kilogram weight loss during 
the 3.2 year follow-up (30). Thereafter, in the 4-year follow-up, insulin sensitivity in the 
entire group (intervention plus control) improved by 64% in the highest tertile of 
weight loss, but deteriorated with 24% in those who gained weight, while insulin 
secretion remained unchanged in IGT subjects who managed to loose weight (31). 
Overall, weight loss is a major contributor in the prevention of type 2 diabetes mellitus. 
 Besides weight loss, changes in body fat distribution may influence diabetes risk. 
It has been shown that a relatively minor loss of body weight (-3%) which was accom-
panied by a major reduction in visceral fat mass (-12%) and liver fat content (-33%) was 
associated with improved insulin sensitivity (32, 33). However, to bring the visceral 
depot to normal levels, subjects with upper body obesity, those with a larger visceral 
depot compared to subjects with lower body obesity, may need to loose larger 
amounts of body weight compared to subjects with lower body obesity (34). The loss 
of visceral fat seems to be predominantly determined by the initial amount of fat in 
the visceral fat depot (35, 36). Subjects with high visceral adipose tissue and liver fat or 
high BMI may more easily loose body weight and visceral fat, while this does not imply 
metabolic benefits (32). Even after weight loss, fat deposition in these subjects is 
above average, which may not make a metabolic difference, because an improvement 
in insulin sensitivity may require a reduction in ectopic fat deposition below a specific 
threshold (32). Overall, with regard to body fat distribution, lifestyle interventions have 
lead to a reduced diabetes risk, in parallel with reductions in preferentially visceral fat 
but also subcutaneous fat and total body fat (13, 37). It is still unclear to what extent 
body fat distribution adds to the metabolic benefits of lifestyle interventions. There-
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fore, no clear suggestions can be made at this point regarding body fat distribution as 
determinant of intervention outcome. 
 The relationship between increased adiposity and insulin resistance and diabetes 
may, on one hand be explained by an increased lipid overflow in the circulation. 
Normally, adipose tissue functions as a ‘metabolic buffer’ trapping dietary fatty acids, 
whilst in insulin resistant conditions this buffering action is impaired resulting in 
exposure of non-adipose tissues like muscle and liver to excessive fluxes of lipids. 
Accumulation of lipids in these tissues plays a critical role in the etiology of insulin 
resistance and type 2 diabetes mellitus (38-43). On the other hand, the relationship 
between adiposity and insulin resistance may be explained by an alteration in the 
production of inflammatory factors. Inflammatory factors, which can be produced by 
adipose tissue but also numerous other cell types, may have autocrine effects (i.e. 
effects on gene expression, lipid and glucose metabolism) (44) or may be secreted as 
endocrine factors influencing energy and substrate metabolism and insulin sensitivity 
in other tissues like skeletal muscle and liver (45). For example, baseline adiponectin 
levels, an adipose-derived adipokine, seems a strong predictor of incident diabetes in 
the DPP (46). Considerable weight loss seems to restore high adiponectin levels (47, 
48), but lifestyle interventions according to general guidelines do not seem to have a 
relevant effect on adiponectin in either diabetic patients (49), IGT subjects (50) or 
obese subjects (51). Leptin, another adipokine, seems also related to improvements in 
insulin sensitivity, independent of changes in body composition (50). 
The effect of changes in physical activity on diabetes risk 
To design optimal guidelines for physical activity as part of lifestyle programs, it is 
important to define the independent effect of physical activity on the risk of type 2 
diabetes. Post-hoc analysis of 487 IGT men and women in the DPS on whom data of 
leisure-time physical activity were available revealed that individuals with the highest 
increase in their level of moderate-to-vigorous physical activity were 63-65% less likely 
to develop type 2 diabetes during the 4.1 year follow-up compared to individuals with 
the lowest increase in physical activity (52). Similarly, in the DPP, indexes that reflect 
autonomic function and fitness improved (i.e., heart rate decreased and heart rate 
variability increased) during a 3.2 year intervention and were inversely related to 
diabetes risk, independent of weight change (53). In the Chinese Da Qing IGT and 
Diabetes Study (18), diet and exercise were equally effective as exercise alone to 
prevent the progression of IGT to type 2 diabetes. Results from the Dutch SLIM study 
(54) and the Oslo Diet and Exercise study (55) showed most effect in improving glucose 
tolerance and preventing type 2 diabetes by the combination of diet and exercise. 
These post-hoc analyses show that exercise contributes to improve glucose metabo-
lism, independent of weight loss (52) and therefore seems to have an additive effect 
on diabetes prevention. Besides reducing diabetes risk, increasing exercise training 
results in an improved fitness in a dose dependent manner (56), which may positively 
influence daily-life activities. Physical activity is also an important predictor of weight 
maintenance after weight loss (57). To conclude, physical activity is besides body 
weight loss an independent contributor to improve glucose metabolism. There are 
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indications that especially moderate-to-vigorous physical activity help prevent type 2 
diabetes. 
 One of the underlying mechanisms by which physical activity may contribute to 
type 2 diabetes prevention is via improved capacity to oxidize fatty acids (58-60). Free 
fatty acid (FFA) oxidation is reduced in subjects with type 2 diabetes mellitus and 
impaired glucose tolerance (IGT) and it has been shown that a combined diet and 
physical activity intervention program can prevent further deterioration of impaired 
fatty acid oxidation during exercise in subjects with IGT (61). An improved utilization of 
fatty acids for energy may reduce the accumulation of lipids and lipotoxic intermedi-
ates in skeletal muscle and thereby improve insulin sensitivity (62-64). Additionally, it 
has also been suggested that training can bring about improvements in the regulation 
of hepatic glucose output (65, 66). 
 With respect to duration and intensity, the guidelines of the International Diabe-
tes Federation (IDF) and the American College of Sports Medicine prescribe at least 30 
minutes of moderate-intensity physical activity on most, preferably all days of the 
week (6, 67). However, in formerly obese or overweight subjects 60-90 minutes/day or 
45-60 minutes/day of moderate intensity physical activity are recommended, respec-
tively, to prevent further weight gain (68). To date, a recent review indicated that 30 
min/day of moderate- or high-level physical activity is an effective and safe way to 
prevent type 2 diabetes in all populations (69). There is enough evidence to justify that 
physical activity has an additive effect when combined with a dietary intervention and 
should be included in lifestyle programs, despite the uncertainty about the exact 
duration and intensity to effectively prevent diabetes (70). 
 With respect to the kind of physical activity, a recent trial showed most improve-
ment in hemoglobin A1c levels of patients with type 2 diabetes when the physical 
activity consisted of combined aerobic and resistance training (71). Recent guidelines 
on physical activity and public health in older adults from the American College of 
Sports Medicine and American Heart Association also recommend muscle strengthen-
ing and balance exercise as an integrated part of physical activity intervention in older 
adults (72, 73). 
 Lifestyle interventions face the challenge of increasing adherence and compliance 
to the program and it seems that men and women with a low initial BMI may be more 
likely to meet activity goals (74). However, reaching the recommended physical activity 
level for the majority of people at risk for diabetes may be quite a challenge, since the 
majority (61%) of US patients with diabetes or at highest risk for diabetes do not 
engage in regular physical activity (75). On the other hand, in the Nurses’ Health Study 
it was shown that even among women who did not perform vigorous physical activity, 
diabetes risk was reduced with 26% after 8 years of follow-up for those who had 
walked most relative to those who walked least (76). This seems to indicate that even 
small but sustained increases in physical activity are beneficial in the long-term; exem-
plifying that physical activity should be included in lifestyle programs. Since there is a 
high heterogeneity in high-risk subjects, i.e. with regard to co-morbidity and muscle 
strength, as is the case for diabetic patients, the exercise intervention should become 
more individualized to optimize its therapeutic value (73). A personalized activity plan 
may be one of the ways to achieve the physical activity recommendations (72). 
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The effect of changes in dietary composition on diabetes risk 
Dietary factors related to the development of type 2 diabetes include, besides energy 
intake restriction, total fat intake, fat quality, fiber, glycemic index/glycemic load, 
alcohol consumption and coffee consumption (7). A western diet, emphasizing red 
meat, French fries and high fat dairy products has been associated with increased 
diabetes risk (77, 78), while a ‘prudent’ diet, emphasizing fruits, vegetables, fish and 
whole grains has been associated with a reduced diabetes risk (79-82). The Women’s 
Health study, a large prospective study, showed a relative risk of 1.28 for women in the 
highest quintile of red meat use, versus the lowest quintile (83). Short-term dietary 
changes towards high-carbohydrate and low glycemic index seem to improve ɴ-cell 
function in IGT subjects (84). Dietary fibers can reduce the rate of glucose absorption 
in the intestine, thereby lowering postprandial glycemic and insulinemic responses (85). 
Also the total fat intake is an important risk factor for the development of type 2 
diabetes as its energy-density favors increased food intake and obesity. In the San 
Louis Valley Diabetes Study, a 40g higher fat intake corresponded with a 6-fold in-
crease in diabetes risk in IGT subjects after adjustment for obesity and markers of 
glucose metabolism (i.e. fasting glucose and insulin) (9). An ad libitum reduced-fat diet 
without energy restriction has been shown to produce a moderate weight reduction 
between 3-5 kilograms (86, 87). In agreement with these findings, results from the DPS 
in 500 IGT subjects (intervention plus control group) during a 4.1 year follow-up sug-
gest that a high-fiber, low-fat diet predict sustained weight loss and reduces the 
development of type 2 diabetes, even after adjustment for other risk factors such as 
physical activity (88). In addition, the quality of dietary fat modifies diabetes risk. In 
particular, an excess of saturated fat may have detrimental effects on skeletal muscle 
insulin sensitivity (38-40). Insulin sensitivity improved when saturated fatty acids in the 
diet were replaced either by mono-unsaturated fat (89) or poly-unsaturated fat (90). 
Unsaturated fatty acids may influence diabetes risk by increasing the fluidity of mem-
branes, thereby facilitating membrane signaling, including insulin signaling (91) and/or 
by influencing the regulation of genes involved in the breakdown and oxidation of fatty 
acids (92). The relation between insulin sensitivity and n-3 poly-unsaturated fatty acids 
(PUFAs) is less clear, but most studies using a euglycemic hyperinsulinemic clamp have 
found no effect of n-3 PUFAs on insulin sensitivity in healthy or diabetic subjects (89, 
91, 93). Recent interest has developed for specific fatty acids, and for enzymes that 
alter the saturation of ingested fatty acids, the so-called desaturase enzymes (94). In 
the SLIM study, lifestyle-induced changes in insulin sensitivity were partly related to 
changes in fatty acid profile of serum cholesteryl esters, and in particular to changes in 
desaturase activities (95). 
 To conclude, multiple components of a healthy diet, e.g. high fiber and a low 
saturated fat intake, reduce diabetes risk, and contribute to sustained weight loss and 
should therefore be included in long-term lifestyle interventions. Composition of the 
diet plays a key role in diabetes prevention in the first place to sustain weight loss in 
the long-term and in the second place to initiate weight loss and diabetes risk reduc-
tion. 
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Genetic susceptibility 
Genetic variability may partly explain why there are non-responders to lifestyle treat-
ment despite compliance and adherence to the lifestyle intervention program. In the 
DPS a large number of genes have been examined for their effect on diabetes inci-
dence and intervention success (for review of genes investigated in the DPS, see (96)). 
An interaction with intervention outcome has been found for the TT genotype of SNP 
rs12255372 in the TCF7L2 gene which was associated with 2.85-fold increased risk of 
incident type 2 diabetes in the control subjects of the DPS, but not in the intervention 
subjects (97). The TCF7L2 gene is presumed to play a role in the first-phase insulin 
release (97). A similar pattern was found for a single nucleotide polymorphism (SNP), 
the X/Ala genotype of the PPARɶ-2 Pro12Ala SNP, which was associated with increased 
diabetes risk in the control group, whereas there was no newly diagnosed diabetes in 
the Ala/Ala genotype subjects of the intervention group (98). One explanation is that 
subjects with the Ala12 allele are more responsive to weight reduction and physical 
activity than subjects with the Pro/Pro genotype, and thus suffer more from bad 
lifestyle habits but profit more from the lifestyle intervention as well. 
 A large study that investigates the interaction between exercise training and 
genes, is the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) Family 
Study (99). Multiple genes related to the response of an exercise program were identi-
fied, including several Quantitative Trait Loci (QTL) on chromosome 1p, 3q, 6p, 7q, 10p, 
12q and 19q in white participants (100, 101), the -514 C>T SNP in the Hepatic Lipase 
gene (LIPC) in both white and black individuals (101) and the rs2180062 and rs9018 of 
the Four and a Half LIM domains 1 (FHL1) gene (102). 
 The Tübinger Lifestyle Intervention Program (TULIP) (103) followed the lifestyle 
protocol from the Finnish DPS study (weight loss, increase physical activity and healthy 
diet) (19). They showed that the minor G allele of SNP rs2267668 in PPARD and the 
minor serine-encoding allele of the common Gly482Ser SNP in PPARGC1A were inde-
pendently associated with less increase in individual anaerobic threshold (104), indicat-
ing that these alleles impair the effectiveness of aerobic training. In addition, low 
skeletal muscle mitochondrial function in vitro was detected in young carriers of the G 
allele of the rs2267668 SNP of PPARD. They also showed that variation in the adi-
ponectin receptor 1 (ADIPOR1) gene predicted the improvement of insulin sensitivity 
and the reduction of liver fat after lifestyle intervention (105). The adiponectin recep-
tor 1 may have a putative role in the development of body size, as has been suggested 
by the Finnish DPS (106). 
 To conclude, genetic variation can play a role in the response to a lifestyle inter-
vention. Some SNP’s may increase the vulnerability for lifestyle factors. This means 
that these individuals run an increased risk for developing type 2 diabetes with adverse 
lifestyle behavior, and at the same time may benefit more from lifestyle intervention. 
Other SNP’s increase diabetes risk independent of lifestyle factors. Studies involving 
interactions between genes and lifestyle intervention response are still limited and 
need confirmation in large cohorts. When more conclusive evidence is provided, the 
effectiveness of tailored lifestyle programs should be tested in subgroups with geno-
types that are associated with adequate and impaired metabolic response to a lifestyle 
intervention (96). 
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Costs and cost-effectiveness 
The potential benefits of lifestyle intervention are substantial, but so are the costs for 
implementing such programs. In return, the potential for cost savings from the preven-
tion or delay of type 2 diabetes and its complications is also considerable. Although 
several studies have shown effectiveness over longer periods, up to 6 years, it is 
important for policy makers and health care providers to predict its effectiveness in 10, 
20 or 30 years time. To assist policy makers, researchers have developed computer 
models that simulate the progression of diabetes, expenditures on diabetes care, and 
effects of interventions. Two principal types of diabetes models exist. The Markov 
model simulates transitions from one disease state to another (e.g. from IGT to type 2 
diabetes) as chance events. A second novel type of model, named Archimedes, inte-
grates detailed biological and administrative information in complex differential 
equations to simulate pathophysiological processes (e.g. postprandial glucose disposal) 
that change over time and can lead to disease (107). 
 The results of the DPP and DPS have been extensively used for cost-effectiveness 
analyses using both models, resulting in different outcomes. The outcome depends on 
many factors, such as the assumptions for the natural progression of glycemia and the 
effectiveness of the lifestyle intervention, the time horizon that is used (30 years or 
until death after diagnosis), characteristics of included patients (age, degree of obesity, 
ethnicity, gender), and the costs of the lifestyle program, which depends on the ap-
proach (group or individual counseling) and country where the implementation will 
take place (108). 
 The DPP developed an analysis based on the Markov model, lifetime horizon and 
a societal perspective. The cost was $8800 per quality-adjusted life-years (QALY) for 
the lifestyle intervention and $29.900 for metformin that would be saved (109), which 
fall both within a range generally accepted as being cost-effective (110). When using 
the Archimedes model with time horizons of 10, 20 and 30 years and a societal per-
spective, the cost per QALY of beginning the intensive lifestyle intervention in subjects 
with IGT was $62.600, and $35.400 for metformin over 30 years, when compared with 
no intervention (111). The cost per QALY for an intensive lifestyle intervention started 
after the onset of diabetes was $24.500 (111). The Archimedes model adopted more 
conservative assumptions for the development of diabetes and its complications, 
which may have reduced cost-effectiveness. Both studies underline that lifestyle 
intervention will substantially reduce the proportion of patients at risk to develop 
diabetes, it will postpone the onset of diabetes from 7 or 8 to 14 or 18 years, and it will 
lead to fewer complications, longer life, and improved quality of life. 
 When the DPS results were applied to a Swedish setting, the cost-effectiveness 
analysis based on the Markov model predicted that the program would be cost-saving 
from the healthcare payers’ perspective (112). In the Netherlands, two different 
approaches for health care interventions were evaluated: a community based ap-
proach targeted at the general population with a high number needed to treat (300-
1500 individuals) but low costs per individual (113), and a health care intervention 
approach aimed at high risk individuals with a low number needed-to-treat (7-30 
individuals) but relative high costs per individual (54). Both approaches were evaluated 
using a Markov-type, multistage transition model, which describes the development 
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over time of demography, risk factor prevalence, disease incidence, and mortality in 
the Dutch population (114). Both approaches were cost-effective in the range of 
€5600- €9900 (114). 
 To design cost-effective lifestyle interventions, the effectiveness of lifestyle 
intervention for different subgroups may need to be taken into account. The results 
from the DPP show no differences in progression towards type 2 diabetes between 
ethnic groups, once they are identified as impaired glucose tolerant (115). Age may be 
important: metformin was only cost-effective in IGT subjects under the age of 65, but 
lifestyle intervention was effective in all age groups (109). Metformin had a better 
impact on costs in younger and more obese subjects, whereas lifestyle intervention 
was more effective in subjects with a BMI below 30 kg/m2 (108). Further identification 
of factors that modify intervention outcome may increase the efficacy of tailored 
advice, improving cost-effectiveness. 
 In general, the implementation of lifestyle intervention as a therapy to prevent 
and postpone type 2 diabetes and its complications looks promising and cost-
effectiveness seems acceptable. In particular differences in the effectiveness of life-
style intervention between groups and countries, and approach for implementation 
(group or individual counseling), will be of influence on the cost-effectiveness. In 
Finland, a large implementation trial to evaluate different approaches for lifestyle 
intervention in the health care system started recently (116). It will provide valuable 
information about the barriers, strategies and costs of lifestyle implementation in a 
real-life setting. 
Implementation strategies 
Lifestyle interventions are cost-effective in reducing the risk for type 2 diabetes on the 
long-term. The next question is how to implement a lifestyle intervention in the gen-
eral public health setting in a way that is most successful. The high-risk approach has 
the advantage over a community-based strategy that tailored advice can increase 
personal risk awareness of diabetes as well as the magnitude and durability of behav-
ioral changes, whereas a community-based strategy will prompt the individual to a 
lesser extent to undertake action. 
 Recently, the IDF has proposed a simple three-step plan for the prevention of 
type 2 diabetes in high-risk individuals: first, identification of those who may be at 
increased risk, second, measurement of risk and third, intervention to prevent the 
development of type 2 diabetes (6). For identification the IDF recommends brief 
questionnaires with criteria of obesity, family history, age, cardiovascular history, 
gestational history and drug history to assess the level of risk. These questionnaires are 
simple, practical, non-invasive and inexpensive. In Finland, a type 2 diabetes risk 
assessment form has already been developed which assesses diabetes risk based on 
age, BMI, waist, physical activity, fruit and vegetable intake, blood pressure medication, 
previous high blood glucose (i.e. during pregnancy or illness) and family history of type 
2 diabetes, the so-called FINDRISC score (117). A recent post-hoc analysis of the DPS 
results shows that the FINDRISC may be useful in identifying high-risk groups most 
likely to benefit from intensive lifestyle intervention to prevent type 2 diabetes (118). 
Thesis C Roumen V12.pdf   41 14-9-2009   11:11:09
Chapter 2 
 42 
For measurement of risk the IDF recommends the measurement of venous fasting 
plasma glucose levels. If plasma glucose levels are above 6.1 mmol/l, a 2-hour OGTT is 
recommended to detect cases of IGT and undiagnosed diabetes. For intervention the 
IDF recommends gradual weight loss, change in dietary composition and increasing 
physical activity to 30 minutes moderate intensity physical activity per day, on most 
days of the week (6). Similar recommendations are made in recent reviews evaluating 
diet, glucose tolerance and type 2 diabetes (119, 120). Furthermore, although smoking 
is not usually included as part of a lifestyle intervention program, it is an important 
lifestyle-related risk factor for diabetes. Since quitting smoking may lead to weight gain 
(121), special attention is necessary with regard to weight control (122). Lifestyle 
intervention programs can be suitable for this. 
 However, merely providing the method of implementation will not be sufficient 
for successful implementation of lifestyle interventions. For achieving and sustaining 
lifestyle changes throughout the lifespan, intervention mapping can be used as a tool 
for the development of health promotion interventions (123). However, efforts from 
the individual, the practitioner, the community and policy makers fulfill a key role in 
giving high-risk individuals tailored advice and encouragement to decrease their 
diabetes risk. 
 To increase sustainable lifestyle changes, first, the individual should be aware of 
his/her increased risk for type 2 diabetes and his/her lifestyle. This can be achieved by 
e.g. the general practitioner who asks individuals at risk if they have family or friends 
who suffer from the disease. In a recent cross-sectional study, African Americans with 
a family history of diabetes were more aware of diabetes risk factors and were more 
likely to engage in certain health behaviors than were subjects without a family history 
of the disease (124). 
 Second, motivational interviewing by nurse practitioners can be applied to assist 
individuals to achieve a positive attitude towards changes in diet, physical activity or 
the social aspects associated with it. The intentional behavior stage of an individual, as 
identified by the transtheoretical model of behavior change, is of influence on the 
preparedness for lifestyle changes (for review with regard to exercise see (125)). In 
subjects who have developed type 2 diabetes, being in the action stage was associated 
with healthier eating, compared to those in a pre-action stage (126). In the action 
stage people are active as in undertaking action for less than 6 months and in the pre-
action stages (precontemplation, contemplation and preparation), individuals are not 
active and have no intention to become active or, in the latter two cases, have the 
intention to become active within 6 months or 1 month, respectively (127). Knowing 
the behavioral stage of the individual gives the advantage of formulating specific 
advice. Altogether, tailored information and advice may increase the intention to 
adopt a certain lifestyle aspect (125, 128). 
 Third, general practitioners should be aware and convinced of the clinical signifi-
cance of IGT and reducing type 2 diabetes incidence by targeting lifestyle interventions 
at patients at risk (129). Practitioners or dieticians should inform subjects about read-
ing food labels and understanding portion size (130). Therefore, it is desired that 
practitioners have skills that include assessment of dietary history and physical activity 
counseling, or refer patients to professionals who have those skills, such as dieticians 
and physiotherapists. A Finnish study evaluating lifestyle counseling in primary care 
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has recently shown a lack of communication skills of nurses and physicians counseling 
subjects with diabetes and IGT with regard to diet and physical activity (131). Improv-
ing communication skills, e.g. by teaching the motivational interviewing approach to 
health care professionals, may therefore improve intervention outcome. 
 To conclude, high-risk screening and tailored advice seem to have potential for 
success. In addition, it is acknowledged that community-based strategies involving the 
food industry and government policies may be necessary as an integral component of 
diabetes prevention to create an environment supportive of an active and healthy 
lifestyle (6). 
Conclusion 
The studies mentioned in this review clearly illustrate that improvements in lifestyle 
can have a large beneficial impact on diabetes risk. Very promising are the new data on 
long-term effects of lifestyle programs, showing a sustained diabetes risk reduction, 
even after counseling was stopped (21, 23). Lifestyle intervention can additionally have 
a positive impact on cardiovascular risk profile (132) and features of the metabolic 
syndrome (133). Therefore, we conclude that lifestyle interventions can reduce the 
diabetes risk substantially in subjects with impaired glucose tolerance, especially when 
existing of a combined diet and exercise program. We underscore the importance of 
cost-effective changes in lifestyle that are sustainable over a long period. 
 With regard to determinants of intervention outcome, weight loss seems the 
most important factor for reducing diabetes risk. At the same time, physical activity 
has shown to be an important contributor, independent of obesity, as well. Relatively 
small changes in physical activity that are prolonged over several years already seem 
to contribute to a diabetes risk reduction, although moderate-to-vigorous physical 
activity seems to have a larger effect. Changes in dietary composition are in the first 
place important to sustain achieved weight loss in the long-term and in the second 
place to initiate weight loss and reduce diabetes risk. Body composition and genetic 
variation seem to modulate the effect of lifestyle intervention on metabolic benefits. 
However, on both subjects no conclusive data are yet available for evidence-based 
recommendations. More large studies are necessary to elucidate the major modula-
tors and the way they interact with lifestyle effect.   
 With respect to determinants of adherence, this paper shows that lifestyle inter-
vention outcome is not just the result of the individuals’ motivation, but the result of a 
variety of metabolic, genetic and socio-economic factors, i.e. low social economic class 
(134-136). Increasing self-efficacy, motivational readiness, social activities (137) and 
decreasing perceived stress (126), exemplifying the importance of prevention and 
giving tailored personal advice may be a first step in increasing adherence. As an 
alternative for non-effective lifestyle intervention, subscription of medication or 
change of policy to adjust the environment to a more favorable one may be necessary. 
Furthermore, concise and conclusive reporting on risk genotypes and reasons for non-
adherence in future publications is essential, so that 1) lifestyle interventions can be 
adjusted for those less likely to adhere and benefit from it or so that 2) the environ-
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ment can be adjusted to increase adherence and compliance, especially for the low 
social-economic classes or 3) preferentially both. 
 To conclude, lifestyle intervention programs are feasible and cost-effective for the 
long-term and will probably be the most important tool to alleviate the burden of 
diabetes and related complications in the future, and to sustain healthy ageing. Thus, 
the question is no longer whether lifestyle interventions might be effective, but under 
which circumstances they will be most effective. 
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Abstract 
Objective  
To evaluate the effect of a 3-year diet- and exercise lifestyle intervention, based on 
general public health recommendations, on glucose tolerance, insulin resistance and 
metabolic cardiovascular risk factors in Dutch subjects with impaired glucose tolerance 
(IGT). 
Method 
Subjects 147 IGT subjects (75 male, 72 female) were randomized to the intervention 
group (INT) or control group (CON). 106 subjects (52 INT, 54 CON) completed 3 years 
of intervention. Annually, glucose, insulin and free fatty acid (FFA) concentrations were 
determined during fasting and after an oral glucose tolerance test and measurements 
of body weight, serum lipids, blood pressure and maximal aerobic capacity. 
Results     
According to our completers analysis, the lifestyle intervention improved body weight 
(INT: -1.08 ± 4.30 kg; CON: +0.16 ± 4.91 kg, p=0.01), HOMA index for insulin resistance 
and 2-hour FFA. 2-Hour glucose concentrations improved in INT, most pronounced 
after 1 year with a regain to baseline values after 3 years, from 8.59 ± 1.55 mM to 8.55 
± 0.34 mM, but deteriorated in CON: from 8.46 ± 1.84 mM to 9.35 ± 2.50 mM (p=0.02). 
For INT, diabetes incidence was reduced by 58% (p=0.025). 
Conclusion 
Our lifestyle intervention showed a sustained beneficial effect on 2-hr glucose concen-
trations, insulin resistance and 2-hr FFA, even after 3 years. Our lifestyle intervention is 
efficacious, but for implementation more information is warranted on determinants of 
adherence. 
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Introduction 
Impaired glucose tolerance (IGT) is an obligatory transition state between normal 
glucose tolerance and type 2 diabetes, and from a health perspective IGT subjects are 
an important high-risk target group for the prevention of type 2 diabetes and related 
complications. 
 We demonstrated previously in the SLIM Study (Study on Lifestyle intervention 
and IGT Maastricht) (1), that a combined diet- and exercise lifestyle intervention can 
improve the postprandial glucose metabolism and insulin resistance in IGT subjects 
with a relatively high level of physical activity and low prevalence of obesity. The 
Diabetes Prevention Study (DPS) showed a tendency towards an improved glucose 
tolerance during a 3-yr lifestyle intervention program (0.4 mM difference in 2-hr 
glucose) (2). Also, the DPS as well as the Diabetes Prevention Program (DPP) showed 
that changes in lifestyle can prevent the onset of type 2 diabetes in IGT subjects by 
58% over a 3-yr period (3-4). Although the SLIM study is relatively small compared to 
the DPS and DPP, its advantage is that we performed a detailed phenotyping of HOMA-
IR, 2-hr glucose, 2-hr insulin, 2-hr FFA concentrations and performed a test for maximal 
aerobic capacity (VO2 max) at baseline and follow-up. We have performed mechanistic 
studies to underscore our intervention results (5-6). Additionally, we have a well-
controlled exercise program in which subjects participated at an intensity of at least 
70% of their maximal peak oxygen consumption (VO2max).  
 Elevated 2-hr glucose concentrations are an important risk factor for the devel-
opment of type 2 diabetes, but also for cardiovascular disease (CVD) (7). Prolonged 
postprandial glucose excursions can be considered a risk marker of insulin resistance 
and dyslipidemia that collectively impact on CVD risk (8). In IGT subjects, disturbances 
in fatty acid utilization are already present (5) and increased plasma free fatty acids 
(FFA) have been associated with type 2 diabetes, insulin resistance and CVD risk (9). 
Moreover, IGT has been related to the Metabolic Syndrome (MetS), which is a cluster-
ing of pathologies associated with insulin resistance, type 2 diabetes and CVD risk (10-
12). 
 The SLIM project offers the opportunity to address the impact of lifestyle changes 
on glucose tolerance and maximal aerobic capacity, as an objective measure for 
physical fitness. Furthermore, we provide specific data regarding lifestyle efficacy and 
effectiveness. Our aim was to investigate the impact of a 3-year lifestyle intervention 
on glucose homeostasis after an oral glucose tolerance test (OGTT) in IGT subjects. In 
addition, we assessed the changes in metabolic CVD risk factors and evaluated the 
impact of the lifestyle intervention on the incidence of type 2 diabetes. 
Patients and methods 
The SLIM project (Study on Lifestyle Intervention and Impaired Glucose Tolerance 
Maastricht) is a randomized controlled trial, designed to study whether a 6-yr com-
bined dietary and physical activity intervention program can improve glucose tolerance 
in IGT subjects (13). In addition, changes in body composition, body fat distribution, 
fasting and 2-hr insulin and plasma glucose concentrations, FFA levels, serum lipids, 
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blood pressure and maximal aerobic capacity are determined. This report concerns the 
results after 3 years of intervention. 
Study design and subjects 
The study design has been described in detail previously (13). Briefly, subjects with an 
increased risk for glucose intolerance were selected from a cohort in the area of 
Maastricht, and invited to undergo a capillary standard OGTT. Those subjects with a 2-
hr blood glucose concentration > 7.8 mM were invited for a second venous OGTT. For 
inclusion, mean 2-hr glucose concentration of both OGTTs had to be between 7.8 and 
12.5 mM and fasting glucose concentration < 7.8 mM. Data obtained during the sec-
ond (venous) OGTT were used as baseline values. Exclusion criteria were known 
diabetes, glucose concentrations outside the inclusion criteria, chronic illness, medica-
tion known to interfere with glucose tolerance, participation in a vigorous exercise 
and/or diet program. 
 Screening and inclusion of subjects for the SLIM study occurred between March 
1999 and May 2000 and in 2002. In total, 147 subjects were included in our study. All 
analyses in this paper were adjusted for the screening period. Subjects were random-
ized with stratification for sex and mean 2-hr plasma glucose concentration to the 
intervention group (INT: 74 subjects; 38 male, 36 female) or the control group (CON: 
73 subjects; 37 male, 36 female). It was calculated, according to the preliminary results 
after 1 year of the Finnish DPS (14), that 50-60 subjects per group would be sufficient 
to detect a 1.0 mmol/l difference in 2-hr glucose concentration between groups. Data 
analyses of the 3-year results include those subjects still participating in the study 
(completers, n=106: 52 INT subjects and 54 CON subjects). 41 Subjects (22 INT, 19 
CON) were unable to adhere for 3 years of study of whom 28 subjects, (14 INT and 14 
CON) completed the first year. From all dropouts, 32 subjects discontinued the study 
(16 INT, 16 CON ) due to medical reasons in 10 cases, lack of time in 7 cases, lack of 
motivation in 7 cases, dissatisfaction in 3 cases, no response in 1 case, no transporta-
tion in 1 case, unknown in 2 cases and death in 1 case. 9 Subjects did not attend all 
annual measurements. 
Lifestyle Intervention 
The intervention program consisted of a dietary and physical activity part. Dietary 
recommendations were based on the Dutch guidelines for a healthy diet (Dutch Nutri-
tion Council). A skilled dietician gave personal dietary advice during a one-hour coun-
seling session every 3 months, after consideration of a 3-day food record. In addition, 
subjects received individual advice on how to increase their level of physical activity to 
at least 30 minutes a day for at least 5 days a week. A body weight loss of 5-7% was the 
objective. Dietary intake and physical activity were documented in 3-day records and 
new goals were set and documented for future reference. Furthermore, subjects were 
encouraged to participate in a combined aerobic- and resistance exercise program in 
which subjects participated at an intensity of at least 70% of their maximal peak 
oxygen consumption (VO2max). Three times a year subjects were asked to participate 
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in the exercise program using a heartbeat watch to validate the exercise intensity. 
Control subjects were only briefly informed about the beneficial effects of a healthy 
diet and physical activity, whereas no individual advice was provided. 
Measurements 
Body weight was measured with an electronical scale to the nearest 0.1 kg. Waist was 
measured to the nearest 0.5 cm, with the subject in standing position at the level 
midway between the lowest rib and the iliacal crest. Body fat percentage was deter-
mined by using a bio impedance (Hydra S ecf/icf, rev1.0d, Xitron technologies). 
 A 3-day weighed food record (two weekdays and 1 weekend day) was kept before 
the annual visit. Nutrient intake was calculated using the Dutch food table (NEVO 
version 1996). An incremental exhaustive exercise test was performed on an electroni-
cally braked bicycle ergometer to determine maximal peak oxygen consumption 
(VO2max). 
 Changes in glucose tolerance were studied using an OGTT. Plasma glucose, FFA 
and serum lipids were measured in the fasting state and after 2 hours, with a standard 
enzymatic technique, automated on a Cobas Fara centrifugal analyzer. Plasma insulin 
concentration was measured with a Radio Immuno Assay (Cat. #HI-14K, Linco Re-
search) that shows no cross-reactivity with pro-insulin. HBA1c was determined in a 
fasting serum sample with high-performance liquid chromatography. The HOMA-IR 
index for insulin resistance was calculated as described by Matthews et al., (1985) (15). 
Low-density lipoprotein (LDL) cholesterol was calculated according to the formula of 
Friedewald (16). Blood pressure was measured with a Maxi Stabil 3 pressostabil 
(CE0047, Speidel en Keller) in duplo with the subject in supine position, after 10 min-
utes of rest. 
 The MetS was defined according to the NCEP criteria (17) as having 3 or more of 
the following conditions: waist circumference greater than 102 cm in men and greater 
than 88 cm in women; fasting serum triglyceride levels of at least 1.7 mM (ш150mg/dl); 
high-density lipoprotein (HDL) cholesterol level less than 1.03 mM (<40mg/dl) in men 
and less than 1.30 mM (<50mg/dl) in women; blood pressure of 130/85 mm Hg or 
greater; and fasting glucose levels of at least 6.2 mM (110mg/l). Subjects using anti-
hypertensive drugs or lipid lowering medication were classified positive for the respec-
tive criterion. The incidence of type 2 diabetes was determined by one OGTT according 
to WHO criteria of 1999 (18). 
Statistical analysis 
Data analysis was conducted using SPSS for Macintosh (version 10.0) on subjects who 
completed 3 years of lifestyle intervention (n=106, completers analysis). In addition, 
we analyzed all available data of all 147 subjects, including those who dropped out 
before the 3-yr examination, to indicate intention-to-treat. Insulin, serum lipids and 
FFA concentrations were not normally distributed and were ln-transformed. Data are 
presented as mean ± SD. Differences between groups were tested with a Student’s t 
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test for independent samples or by a χ2 test when applicable. Changes over time 
between groups were assessed using ANOVA for repeated measures for the  
completers analysis and with MIXED linear models for the intention-to-treat analysis. A 
p-value of less than 0.05 was considered statistically significant. All tests were two-
sided. 
Statement of ethics 
We certify that all applicable institutional and governmental regulations concerning 
the ethical use of human volunteers were followed during this research. The Medical 
Ethical Review Committee of Maastricht University approved the study protocol and all 
subjects gave their written informed consent before the start of the study. 
Results 
Table 3.1 shows the baseline characteristics of the subjects who completed the 3-yr 
period. Age was higher in CON compared to INT (p=0.001), whereas no differences 
were seen in other baseline characteristics. Within each study group, men had a 
significantly higher weight, waist-to-hip ratio and maximal aerobic capacity and a lower 
fat percentage and HDL cholesterol levels, compared to women (pall <0.05). 
 After 1 year, INT subjects had a mean weight change of –2.77 ± 3.69 kg versus -
0.62 ± 3.92 kg in CON subjects (p=0.003, time x group interaction) (table 3.2). After 3 
years, the weight change between groups became smaller but remained statistically 
significant different (p=0.01, time x group interaction). Moreover, after 3 years, the 
increase over time in body fat percentage and body fat mass was smaller in INT com-
pared to CON, (p=0.006 and p=0.016, respectively, time x group interaction). Further-
more, INT subjects improved their maximal aerobic capacity (VO2 max), while that of 
CON aggravated (p=0.02) (table 3.2). Intention-to-treat analysis did not change these 
results (table 3.2). Exercise intensity was regularly monitored during the exercise 
program by means of heart rate recording. After 3 years, the mean heart frequency 
during the exercise program was 76% of the maximal heart frequency, indicating the 
moderate to high intensity. Intervention subjects who participated in the exercise 
program during at least the second and third year (n=17) increased their maximal 
aerobic capacity and tended to increase more compared to those who did not partici-
pate in the exercise program (n=25), +0.17 l/min versus -0.03 l/min, respectively 
(p=0.08). The intervention group increased in the number of days that they were at 
least 30 minutes physically active in doing bicycling, gardening or doing sports with 
0.89±2.75 days while those of the control group decreased with -0.55±3.31 days, 
p=0.046. In the total study population, an increase in the number of days at least 30 
minutes physically active in doing bicycling, gardening or doing sports was significantly 
associated with an increase in aerobic capacity (correlation coefficient R=0.34, p=0.01). 
In line with these results, fat intake decreased significantly more in INT vs. CON (p 
interaction<0.001) and carbohydrate intake increased more in INT compared to CON (p 
interaction=0.001). Fiber intake increased more in INT compared to CON (p interac-
tion=0.05). 
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Table 3.1 Baseline characteristics of the subjects participating in the 3-yr SLIM lifestyle intervention study. 
    Intervention group Control group 
n (male/female)  52 (28/24) 54 (30/24) 
Age (years) 54.2 ± 5.8 58.4 ± 6.8* 
Weight  (kg) 87.5 ± 13.7 83.0 ± 11.7 
BMI  (kg/m2 ) 29.6 ± 3.8 29.2 ± 3.3 
Waist  (cm) 103.2 ± 10.6 102.4 ± 9.2 
Body fat percentage (%) 38.4 ± 6.3 37.5 ± 6.4 
Body fat mass (kg) 33.4 ± 7.2 31.0 ± 6.6 
Body fat free mass (kg) 54.1 ± 10.4 51.9 ± 9.4 
VO2 max  (l/min) 2.22 ± 0.61 2.13 ± 0.55 
Fasting glucose  (mmol/l) 5.97 ± 0.87 5.90 ± 0.70 
2-hr Glucose  (mmol/l) 8.59 ± 1.55 8.46 ± 1.84 
HBA1c  (%) 5.6 ± 0.5 5.8 ± 0.5 
Fasting insulin  (mU/l) 18.0 ± 6.3 17.1 ± 6.9 
2-hr Insulin  (mU/l) 103.3 ± 73.0 96.4 ± 89.9 
HOMA-IR  4.82 ± 2.04 4.55 ± 2.05 
Triglycerides (mmol/l) 1.56 ± 1.33 1.49 ± 0.88 
Total Cholesterol (mmol/l) 5.17 ± 0.78 5.25 ± 0.84 
HDL Cholesterol (mmol/l) 1.14 ± 0.30 1.11 ± 0.27 
LDL Cholesterol (mmol/l) 3.40 ±0.78 3.47 ± 0.71 
FFA (µmol/l) 589 ± 231 551 ± 172 
2-hr FFA (µmol/l) 115 ± 79 102 ± 42 
Diastolic blood pressure (mm Hg) 90 ± 9 88 ± 7 
Systolic blood pressure (mm Hg) 142 ± 16 145 ± 14 
Data are Mean ± SD, n= 106. * p= 0.001 (Student’s t-test). 
 
2-Hour plasma glucose levels decreased in INT from 8.59 ± 0.24 mM at baseline to 7.96 
± 0.29 mM after 1 year and returned to 8.55 ± 0.34 mM after 3 years (figure 3.1, open 
circles). In CON an increase was seen from 8.46 ± 0.23 mM at baseline to 8.83 ± 0.29 
mM after 1 year and to 9.35 ± 0.33 mM after 3 years (p=0.023 time x group interac-
tion) (figure 3.1, black squares). In the intention-to-treat analysis, there remained a 
tendency towards a difference between groups (p=0.086). The difference between 
groups was 0.87 mM after 1 year and remained relatively constant throughout the 
study (p interaction=0.014). 
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Figure 3.1 2-hr Plasma glucose levels for the intervention group (open circles) and control group (black
squares) at baseline and after 1, 2 and 3 years of follow-up. Data are mean ± SEM, n= 106: 52 INT, 54 CON. 
P= 0.023* for the difference between the groups over time (GLM ANOVA for repeated measures). 
 
Multiple linear regression analysis revealed that a decrease in body weight was corre-
lated with a decrease in 2-hr glucose levels (ɴ= 0.257 kg, p=0.020), and a decrease in 2-
hr glucose levels was correlated with an improvement in VO2max (ɴ= -0.220 l/min, 
p=0.048), although not independent of bodyweight loss (ɴ= -0.174 kg, p=0.117). No 
differences were observed in fasting plasma glucose and HBA1c in the completers 
analysis, whereas the change in fasting glucose did become significantly different 
between groups in the intention-to-treat analysis (p=0.04, table 3.2). 
 Insulin resistance, as indicated by the HOMA index for insulin resistance (HOMA-
IR), decreased in the INT after 3 years (-0.19: -1.11; 1.12), while there was an increase 
in CON (+0.37: -0.97; 1.52); p interaction=0.04). Fasting insulin decreased in both 
groups and 2-hr insulin levels tended to increase more in CON compared to INT (p 
interaction=0.07). Using intention-to-treat analysis, differences between groups in 
insulin levels and HOMA-IR were reduced. Multiple linear regression analysis revealed 
that the change in body weight was significantly correlated with the change in HOMA-
IR (ɴ= 0.470 kg, p<0.001), whereas the change in VO2 max was not predictive (ɴ= -
0.073 l/min, p=0.513). 2-Hr FFA levels decreased more in INT, compared to CON (p 
interaction=0.04), whereas the 3-yr decrease in fasting FFA level was not different 
between groups (table 3.2). 
 Triglyceride levels were decreased after 2 years in INT versus an increase in CON, 
but these differences disappeared after 3 years. Total cholesterol, HDL and LDL con-
centrations did not change over time, and did not differ between groups (pall >0.05). 
Both in INT and CON a decline in time was observed in diastolic blood pressure 
(p<0.001) and systolic blood pressure (p=0.001), which was not different between 
groups (p=0.14 and p=0.92, respectively). Results on serum lipids and blood pressure 
were similar for the intention-to-treat analysis and after taking lipid lowering and 
antihypertensive medication into account respectively. 
*
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Within each study group, men and women did not significantly differ in change over 3 
years, except for waist-to-hip ratio and percentage body fat. The waist-to-hip ratio 
increased in women, but remained relatively stable in men (p<0.01 for differences 
between sex in each study group). In both study groups, the percentage body fat 
increased slightly in women, whereas a slight decrease was observed for men (p<0.01 
for differences between sex in each study group). 
 Prevalence of the MetS rose from 61.4% at baseline to 66.0% after 3 years in INT 
(n = 44, 24 male/20 female) and from 58.3% to 68.8% in CON (n = 48, 27 male/21 
female) (p=0.630 for difference between groups). More women (33/41) than men 
(29/51) had the MetS (p=0.02), since more women than men met the criteria for a high 
waist circumference (p=0.004) and a low HDL cholesterol (p<0.001). 
 Although the primary outcome of this study was change in 2-hr plasma glucose 
concentration, we also examined the cumulative diabetes incidence during the study, 
although the results have to be interpreted with caution, since our study was under-
powered for these analyses. In the analysis of the subjects who completed the full 3 
years of the study, the cumulative incidence was 18% (8/44) in the intervention group 
and 38% (18/47) in the control group. The p-value of the log-rank test amounted to 
0.025, and the relative risk was 0.42 (95% CI 0.18-0.96) (figure 3.2). In the intention-to 
treat-analysis the cumulative incidence of diabetes in the intervention group was 18% 
(11/61) compared to 32% (19/60) in the control group. The p-value from the log-rank 
test comparing the survival curves was 0.07, the relative risk amounted to 0.52 (95% CI 
0.25-1.10). Adjustment for age and mean weight did not change the outcome of this 
study. 
 
 
INT 44 44 38 35 
CON 47 38 34 29 
Total subjects at risk for each study group during 3 years of study 
 
Figure 3.2 Proportion of subjects without diabetes during the study. The relative risk of diabetes for 
subjects in the intervention group, as compared with those in the control group, was 0.42 (p=0.025 for the 
comparison between groups). 
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At baseline, metabolic characteristics of dropouts (n=28) were similar between INT and 
CON except for 2-hr insulin levels, which were 81.68 mU/l in INT and 131.96 mU/l in 
CON (p=0.02). The reasons for dropout were similar between INT and CON and no 
differences in dropout were observed between men and women. Dropouts had a 
higher baseline BMI, 2-hr plasma glucose levels and a lower maximal aerobic capacity 
than subjects who completed all 3 years of study (pall <0.05 for difference between 
dropouts and completers). As specific dropout can affect the result of our analysis, we 
performed an intention-to-treat analysis (n=147; table 3.2). This analysis affected 2-hr 
glucose, insulin and HOMA-IR (p>0.05 for differences between INT and CON), while no 
significant changes were observed in BMI, waist, body fat mass and distribution, HBA1c 
VO2 max, serum lipids, blood pressure and dietary intake. 
 
 
Table 3.3 Changes in energy intake, based on 3-day food records, after 1, 2 and 3 years compared to 
baseline.  
  Baseline ѐ Year 1 ѐ Year 2 ѐ Year 3 ѐ Year 3 
95% CI interval 
P 
Energy              
(MJ/day) INT 8.8 ± 2.2 -0.7 ± 1.7 -0.9 ± 2.1 -1.1 ± 1.9 (-1.6; -0.5) 0.231 
 CON 8.7 ± 2.2 -0.2 ± 2.0 -0.3 ± 1.8 -0.3 ± 1.8 (-0.8; 0.2)  
Total fat              
(E%) INT 36.2 ± 6.7 -4.8 ± 6.3 -4.3 ± 7.6 -4.7 ± 5.9 (-6.4; -3.0) <0.001 
 CON 35.0 ± 6.8 -0.2 ± 7.1 0.2 ± 7.0 -0.5 ± 5.8 (-2.1; 1.1)  
Saturated fat              
(E%) INT 13.6 ± 2.9 -2.4 ± 2.9 -2.3 ± 3.7 -2.9 ± 3.2 (-3.8; -2.0) <0.001 
 CON 13.6 ± 3.5 -0.2 ± 3.2 0.1 ± 3.1 -0.7 ± 3.1 (-1.6; 0.1)  
Carbohydrates              
(E%) INT 41.0 ± 7.4 4.5 ± 5.5 5.3 ± 6.9 4.8 ± 5.6 (3.3; 6.4) 0.001 
 CON 43.4 ± 7.3 0.3 ± 6.7 0.3 ± 7.0 1.2 ± 5.4 (-0.3; 2.8)  
Fiber              
(g/MJ) INT 2.7 ± 0.8 0.5 ± 0.7 0.4 ± 0.8 0.5 ± 0.6 (0.3; 0.7) 0.050 
 CON 2.7 ± 0.9 0.1 ± 0.8 0.2 ± 0.8 0.2 ± 0.8 (0.0; 0.5)  
Alcohol              
(E%) INT 6.2 ± 7.1 -0.6 ± 5.4 -1.6 ± 4.6 -1.5 ± 3.7 (-2.5; -0.4) 0.304 
 CON 5.6 ± 5.5 -0.0 ± 5.6 -0.4 ± 3.7 -0.1 ± 4.5 (-1.4; 1.2)  
Data are mean ± SD, n= 96: 47 INT, 49 CON. 
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Discussion 
The SLIM study shows that a lifestyle intervention program according to general 
guidelines was effective in improving dietary composition (reduction fat intake), and 
increasing VO2 max, and resulted in a beneficial effect on glucose tolerance and insulin 
sensitivity in a Dutch population at high risk for type 2 diabetes. After 3 years, the 
difference between groups in 2-hr plasma glucose levels remained as high as 0.8 
mmol/l (similar as after 1 year), which was associated with a 58% reduction in the 
incidence of diabetes. In addition, HOMA-IR and 2-hr FFA concentrations improved 
more in the INT group. However, no significant changes were found in components of 
the metabolic syndrome. 
 Our lifestyle intervention showed a modest weight reduction after 1 year of -2.8 
kg, with a gradual regain in the following years, which is consistent with data from the 
Finnish DPS: after a weight reduction of -4.5 kg during the first year, a regain of ap-
proximately 1 kg after 3 years was observed (2). Furthermore, INT subjects improved 
their dietary habits by increasing carbohydrate and fiber intake, decreasing fat intake 
and they improved their VO2 max, indicating that diet and exercise recommendations 
were (at least partly) followed.  
 Despite the relatively small weight changes in our study, substantial improvement 
in 2-hr glucose concentration was observed in the INT, and the difference between 
groups persisted throughout the 3 years of lifestyle intervention. Although our results 
seem less impressive than for example the 1.6 mmol/l reduction in 2-hr glucose by 
rosiglitazone from the DREAM trial (19), a similar lifestyle intervention from the DPS 
has recently shown that beneficial lifestyle changes were sustained during a follow-up 
period for a median of 3 years without individual lifestyle counseling (20), whereas this 
has not been proven yet for a pharmacological intervention. Furthermore, our lifestyle 
intervention reduced average weight with -1.08 kg, whereas the rosiglitazone group in 
the DREAM trial increased in weight by 2.2 kg, which may be considered disadvanta-
geous for diabetes and CVD risk over the long term. 
 In contrast to 2-hr glucose, we did not observe a significant difference in fasting 
glucose concentrations in the completers analysis, which is in agreement with the 
hypothesis that fasting and postchallenge hyperglycemia may represent phenotypes 
with distinct natural histories in the evolution of type 2 diabetes (21). Whereas post-
prandial glucose disposal may be the main defect in IGT, impaired fasting glucose (IFG) 
may only reflect an abnormal glucose setpoint, but not an abnormal postprandial 
glucose response (22). Cumulative diabetes incidence was 38% in CON, but only 18% in 
INT, reflecting 58% less progression towards type 2 diabetes. Intention-to-treat analy-
sis did not appreciably change these results, although the relative risk decreased to 
48% for INT compared to CON (p=0.07). Although our study was not designed to 
investigate diabetes incidence and thus lacked the statistical power, the results are 
comparable to results of the Finnish DPS and American DPP, both showing a 58% 
diabetes risk reduction after approximately 3 years time (3-4). 
 The natural progression towards type 2 diabetes, as is observed in the CON, is 
very high in our IGT group. Our results are in agreement with the Hoorn study (23), 
which showed a progression of 34% in isolated IGT subjects during a follow-up of 6.4 
years. In the study of Meigs and colleagues (21), 21% of the subjects with baseline 
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IFG/IGT progressed towards type 2 diabetes during a 5-year follow-up. Our study 
underscores the importance of lifestyle intervention in subjects with IGT, since they 
are clearly at high risk for developing type 2 diabetes. 
 In addition, HOMA-IR declined in our completers analysis, indicating improvement 
in insulin sensitivity. Furthermore, our intervention not only improved glucose homeo-
stasis and insulin sensitivity but also reduced postprandial circulating FFA. Elevation of 
(postprandial) FFA concentration may induce peripheral (skeletal) muscle and hepatic 
insulin resistance (24). Thus, reduced FFA concentrations may be one of the mecha-
nisms for an improved insulin sensitivity in these subjects. Furthermore, previous 
studies showed that in subgroups of these IGT subjects, skeletal muscle fat oxidation 
capacity and fat oxidation improved after one year of lifestyle intervention, which may 
also be related to an improved insulin sensitivity (25). 
 IGT has been associated with an increased CVD risk (26-27) and although our 
study showed a marked improvement in 2-hr glucose, this was not accompanied by 
changes between groups in NCEP MetS prevalence. An explanation can be the rela-
tively small number of subjects in each study group, combined with only minor 
changes in waist circumference and fasting plasma glucose concentrations and no 
changes in the other MetS criteria. When we applied the MetS criteria of the Interna-
tional Diabetes Federation (IDF) (28) the results were essentially similar. 
 2-Hr glucose concentrations and HOMA-IR seem more sensitive to minor changes 
in weight and lifestyle and these criteria may be required for prediction of CVD risk, 
since type 2 diabetes alone may convey a much greater risk on CVD than the presence 
of MetS (29). Furthermore, the NCEP MetS does not include CVD risk factors such as 
age, physical activity or history of CVD events and does not weigh the severity of each 
criterion, which may be critically important for adequate prediction of CVD risk [29]. 
Also, endothelial dysfunction, possibly induced by oxidative stress and inflammation, 
may be associated with IGT and recent discovered CVD risk markers involved in in-
flammation and coagulation/fibrinolysis like CRP (30), IL-6 and PAI-1 (31) await to be 
determined. 
 After 3 years, 28% of all study subjects (22 out of 74 in INT and 19 out of 73 in 
CON) discontinued their participation, compared to a dropout rate of 8% and 7.5% in 
the DPS and DPP, respectively. Several explanations for the difference in dropout rate 
between the DPS, DPP and SLIM can be given. First, our study population was originally 
recruited from the general population and they may have had less internal motivation 
to participate in the study, as compared to subjects recruited via advertisements or 
high-risk screening, as was done in the DPS (14). The DPP recruited subjects from a 
variety of resources, including informational mailings, advertisements, open screenings 
and referrals from health care professionals (32). Second, no weight loss program was 
offered when subjects did not loose weight which may have led to dissatisfaction for 
participants. Interestingly, our dropout percentage is similar to that observed in the 
DREAM trial (19), with 29.3% (772/2635) dropout in the rosiglitazone group and 25.0% 
(658/2634) in the control group. Our dropouts were in a worse metabolic condition at 
baseline than completers, but the dropout rate was not different between study 
groups. Intention-to-treat analysis revealed that the difference in 2-hr glucose toler-
ance, HOMA-IR and 2-hr FFA was less pronounced, which suggests selective drop-out 
according to subjects in the intervention group with smaller improvements. To in-
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crease effectiveness of our lifestyle intervention in a clinical setting, we underscore the 
importance of more insight in the unknown determinants to participate in a lifestyle-
intervention and to remain adherent. 
 In conclusion, our lifestyle intervention program, aimed at increasing physical 
activity and using a healthy diet, resulted in a sustained beneficial effect on 2-hr 
glucose concentrations, insulin resistance and 2-hr FFA in a population at high risk for 
type 2 diabetes, even after 3 years, which was associated with a reduced risk for 
developing type 2 diabetes. Although there was some selective dropout, intention-to-
treat analysis still showed a similar trend in results with a significant difference in 
fasting glucose and a tendency towards a difference in 2-hr glucose and diabetes 
incidence. No effect was observed on components of the metabolic syndrome or on 
fasting glucose concentrations, suggesting that fasting and postchallenge hyperglyce-
mia may represent phenotypes with distinct natural histories in the evolution of type 2 
diabetes. Our lifestyle intervention is efficacious, but due to the relatively high dropout 
rate of subjects in worse metabolic condition, additional information on determinants 
of adherence and dropout for increased effectiveness and successful implementation 
is needed. 
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Abstract 
Objective  
To evaluate the effect of a 4.1 year (range 3-6 years) lifestyle intervention according to 
general public health recommendations on glucose tolerance and dropout in a Dutch 
population with impaired glucose tolerance (IGT). 
Method  
In the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht 
(SLIM), 147 Caucasian IGT subjects were randomized to an intervention group (n=74, 
38 male, 36 female (INT)) and control group (n=73, 37 male, 36 female (CON)). Annu-
ally, subjects underwent measurements of body weight, anthropometry, glucose 
tolerance (OGTT), insulin resistance (HOMA-IR), maximal aerobic capacity (VO2 max), 
blood lipids and blood pressure. INT received individual advice regarding a healthy diet 
and physical activity. 
Results  
INT decreased their saturated fat intake (p<0.05) and VO2 max (p=0.04), versus CON. 
Body weight did not change between groups. After a decrease, 2-hr glucose levels 
overall increased in INT (+0.11 mmol/l), but significantly less than CON (+1.18 mmol/l; 
p=0.04). Diabetes incidence was lower in INT versus CON (30% versus 56%, p=0.04). 
Change in body weight was associated with change in 2-hr glucose levels (ɴ=0.399 
mmol/l, p=0.02). Dropouts (n=32) had a lower maximal aerobic capacity and social 
economic status and a higher BMI and 2-hr glucose, compared to non-dropouts 
(n=115). 
Conclusion 
Prolonged feasible changes in diet and physical activity prevent deterioration of glu-
cose tolerance and reduce diabetes risk. Body weight changes is the strongest predic-
tor of changes in 2-hr glucose levels. Low social economic status, low maximal aerobic 
capacity and high BMI and 2-hr glucose are indicative of dropout to the program. 
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Introduction 
Type 2 diabetes needs effective prevention measures for curbing the growing burden 
worldwide. Diabetes incidence is 10–20 times greater in those with impaired glucose 
tolerance (IGT) or impaired fasting glucose (IFG) than those with normal glycemia (1). 
Lifestyle interventions in IGT are an efficacious (2, 3) and cost-effective (4) way to 
prevent type 2 diabetes (5, 6), even after active counseling is stopped (7). 
 Lifestyle changes towards general guidelines for diet and physical activity seems 
inversely associated with diabetes risk (8), indicating that the more strict compliance 
to the regime, the better the outcome. The Diabetes Prevention Program (DPP) has 
shown that a lifestyle-induced reduction in body weight was most associated with a 
reduced diabetes risk (9). This study, the Study on Lifestyle intervention and Impaired 
glucose tolerance Maastricht (SLIM), showed that subjects who adhered to both the 
dietary as well as the physical activity recommendations had the greatest one-year 
improvement in bodyweight, waist and fasting insulin (10) and prevented deterioration 
of 2-hr glucose levels after 3 years (3). 
 The dropout rate in lifestyle interventions is an important factor associated with a 
decreased efficacy of the program. Overall, dropout rate varies highly between life-
style interventions with or without medication (5, 6, 11-13), depending on the patient 
population, the medical condition, the form of treatment, but also the complexity of 
the regime and the period of time. The SLIM regime has a complex regime and a long-
term follow-up. Therefore, this study offers the opportunity to increase our knowledge 
on determinants of dropout and intervention outcome (2-hr glucose tolerance) may 
contribute to a more efficient and targeted intervention to prevent and/or treat type 2 
diabetes in the future. 
 The aim of the present SLIM study was to 1) assess the effectiveness of a lifestyle 
intervention on glucose tolerance and related cardiovascular risk factors during a mean 
follow-up of 4.1 years, 2) to examine which lifestyle behaviors changed during the 
course of the intervention, 3) to examine whether change in these lifestyle behaviors 
was associated with change in glucose tolerance and 4) to determine factors associ-
ated with dropout to the program. The present paper extends previously published 3-
year results by providing novel information on determinants of intervention outcome 
and dropout, which can help optimize identification, lifestyle effect and adherence in 
high-risk subjects. 
Methods 
The SLIM study (Study on Lifestyle intervention and Impaired glucose tolerance Maas-
tricht) is a randomized controlled trial, evaluating the effect of a combined dietary and 
physical activity intervention program on glucose tolerance in IGT subjects (10). 
Changes in body composition, fasting and 2-hr insulin and plasma glucose concentra-
tions, serum lipids, blood pressure and maximal aerobic capacity are determined 
annually. The Medical Ethical Review Committee of Maastricht University approved 
the study protocol and all subjects gave their written informed consent before the 
start of the study. 
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Study design and subjects 
The study design has been described in detail previously (10). Briefly, subjects with an 
increased risk for glucose intolerance, e.g. family history of diabetes, age >40 years, 
BMI > 25 kg/m2, were selected from a cohort in the area of Maastricht, and were 
invited to undergo a capillary standard Oral Glucose Tolerance Test (OGTT) (response 
rate 46.2%, see reference (14)) at the University of Maastricht. Those subjects with a 2-
hr blood glucose concentration > 7.8 mmol/l were invited for a second venous OGTT. 
For inclusion, mean 2-hr glucose concentration of both OGTTs had to be between 7.8 
and 12.5 mmol/l and fasting glucose concentration < 7.8 mmol/l. Data obtained during 
the second (venous) OGTT were used as baseline values. Exclusion criteria were known 
diabetes, chronic illness, medication known to interfere with glucose tolerance, par-
ticipation in a vigorous exercise and/or diet program. The incidence of type 2 diabetes 
was determined according to WHO criteria of 1999 (15). 
 Screening and inclusion started in 1999. Originally, the study follow-up was 3 
years, but this was extended to 6 years in 2002. In 2002, a second screening period 
was performed, and an additional 33 subjects were included in the study. In total, the 
study population consists of 147 subjects. It was calculated, according to the prelimi-
nary results after 1 year of the Finnish DPS (16), that 50-60 subjects per group would 
be sufficient to detect a 1.0 mmol/l difference in 2-hr glucose concentration between 
groups. The study was completed in June 2006 (see figure 4.1). Subjects were random-
ized, with stratification for sex and mean 2-hr plasma glucose concentration, to either 
the intervention group (INT: 74 subjects; 38 male, 36 female) or the control group 
(CON: 73 subjects; 37 male, 36 female). At the end of the intervention, 58 INT (78%) 
and 57 CON (78%) completed at least 3 years of lifestyle intervention, of whom 6 INT 
and 3 CON did not attend all measurements. This means that the participants in the 
INT group attended the quarterly meetings with the dietician in addition to the annual 
meetings and that the participants in the CON group attended the annual meetings. In 
total 32 subjects (16 INT, 16 CON) discontinued study participation and were classified 
as dropout. Reason for discontinuation did not differ between study groups (p=0.85). 
The SLIM flow-chart is presented in figure 4.1. 
Lifestyle Intervention 
The intervention program consisted of a dietary and physical activity part. Dietary 
recommendations were based on the Dutch guidelines for a healthy diet (Dutch Nutri-
tion Council). A skilled dietician gave personal dietary advice during a one-hour coun-
seling session every 3 months, based on a 3-day food record. A 3-day weighed food 
record (two weekdays and 1 weekend day) was kept before the annual visit. Nutrient 
intake was calculated using the Dutch food table (NEVO version 1996). After considera-
tion of a 3-day physical activity record, subjects received personalized advice by the 
researcher and/or dietician on how to increase their level of physical activity to at least 
30 minutes a day for at least 5 days a week. Subjects were encouraged to participate in 
a free, supervised combined aerobic- and resistance exercise program, especially 
designed for this study, which was offered at 3 different days and time points every 
week until the end of the study. Intensity of the program was evaluated three times a 
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year, by wearing a heart rate monitor during the training sessions. The intensity of the 
program was at least 70% of the maximal peak oxygen consumption (VO2max). Control 
subjects received no individual advice, only annual general information about the 
beneficial effects of a healthy diet and physical activity.  
Measurements 
In both groups, several measurements were performed annually including an OGTT, 
insulin levels, VO2max, body weight, waist circumference, body fat percentage, blood 
pressure, HBA1c, cholesterol and HDL. Body weight was measured with an electronical 
scale to the nearest 0.1 kg. Waist was measured to the nearest 0.5 cm, with the sub-
ject in standing position at the level midway between the lowest rib and the iliacal 
crest. Body fat percentage was determined by skinfold measurements (17). Blood 
pressure was measured in duplo with a Maxi Stabil 3 pressostabil (CE0047; Speidel en 
Keller, Jungingen, Germany) with the subject in supine position, after 10 minutes of 
rest. The mean of both measurements was used in the analyses. On a separate occa-
sion, an incremental exhaustive exercise test was performed on an electronically 
braked bicycle ergo meter to determine maximal peak oxygen consumption (VO2max). 
Changes in glucose tolerance were studied using an OGTT. Blood samples were drawn 
after an overnight fast and again 2 hours after an oral glucose load (75 gram glucose). 
Plasma glucose was measured, with a standard enzymatic technique, automated on a 
Cobas Fara centrifugal analyzer. Plasma insulin concentration was measured with a 
Radio Immuno Assay (catalogue no. HI-14K; Linco Research, St Charles, MO, USA) that 
shows no cross-reactivity with pro-insulin. The HOMA-IR index for insulin resistance 
was calculated as described by Matthews et al., (1985)(18). Glycated hemoglobin 
(HBA1c) was determined in a fasting serum sample with high-performance liquid 
chromatography (reference values for our laboratory 4.4-6.2%). Total cholesterol, HDL 
cholesterol, and triglycerides levels were measured, with a standard enzymatic tech-
nique, automated on a Cobas Fara centrifugal analyzer. Low-density lipoprotein (LDL) 
cholesterol was calculated according to the formula of Friedewald (19). In a question-
naire, subjects were asked to fill in their highest educational background. At baseline 
and annually until year 3, physical activity was measured with the Short QUestionnaire 
to ASsess Health-enhancing physical activity (SQUASH) in all participants, which proved 
to be fairly reliable and reasonably valid (20). This Dutch questionnaire contains 10 
questions about the number of days spent per week, the average time spent per day 
and intensity regarding four activity categories: commuting activities, leisure time 
activities, household activities and activities at work and school. The questionnaire 
categorizes all activities into light, moderate and vigorous intensity activities, based on 
MET (metabolic equivalent) values defined by Ainsworth’s compendium of physical 
activities (21) and the respondents’ age. 
Statistical analysis 
Data analysis was conducted using SPSS for Windows (version 14.1). Insulin and serum 
lipid concentrations were not normally distributed and were ln-transformed. Data are 
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presented as mean ± SD in the tables and text, and as mean ± SEM in the figures to 
improve graphical presentation. Differences between groups at baseline were tested 
with a Student’s t test for independent samples or a chi-square test. Changes over time 
between groups were assessed using mixed model analysis on intention to treat, which 
included all available observations, including those from later dropouts. P-values of 
interaction between group and time were used to indicate differences between the 
groups as a result of the lifestyle intervention. Survival analysis was used to determine 
the hazard ratio for diabetes development and to produce a Kaplan-Meier graph. 
Stepwise backward linear regression analysis was used to determine which parameters 
were associated with changes in glucose tolerance. A p-value of less than 0.05 was 
considered statistically significant. All tests were two-sided. 
Results 
Effectiveness of the lifestyle intervention 
At baseline, no differences between the randomized groups were seen apart from age, 
which was higher in the control subjects (58.8 ± 8.4 years) compared to the interven-
tion subjects (55.0 ± 6.5 years, p=0.001 for differences between groups; table 4.1). The 
age difference remained similar between groups during the lifestyle intervention 
period. 
 The SLIM intervention had a beneficial effect on 2-hr glucose levels and diabetes 
risk. 2-Hr glucose levels decreased in INT in the first 4 years of the study and increased 
slightly at the end of the study. In CON, 2-hr glucose increased from 8.80±2.09 mmol/l 
to 9.38 ± 2.45 mmol/l, p=0.041 for average difference between groups (figure 4.2D). 
Diabetes incidence was higher in the control group compared to the intervention 
group with a p-value of the log-rank test that amounted to 0.04 and a relative risk of 
0.53 (95% CI 0.29-0.97) (figure 4.3). 
Lifestyle-induced behavior change 
During the lifestyle intervention, intervention subjects decreased their total fat intake 
(p=0.01 time x group interaction, figure 4.2A) and increased their carbohydrate intake 
from 40.9±7.5 E% at baseline to 46.7±5.9 E% at the end of the study (p=0.002), 
whereas the increase was smaller in CON (+1.2 E%). INT decreased their saturated fat 
intake with 2.4%, while a minor decrease of 0.9% was observed for CON (p<0.001). 
Fiber intake increased in INT from 2.7±0.7 mg/MJ to 3.4±1.1 mg/MJ and increased less 
in CON from 2.7±0.9 mg/MJ to 3.3±1.2 mg/MJ (p=0.05 between groups). Changes in 
energy, cholesterol, protein and alcohol intake were similar between study groups 
(p>0.05, data not shown). Data on energy intake from baseline to year 3 have been 
published previously (3). 
 During the lifestyle intervention, body weight decreased in INT after 1 year (-2.47 
kg) and during the first 4 years (-0.32 kg) (table 4.1), but increased to baseline value at 
the end of the study, whereas body weight did not change in CON (p=0.20, figure 4.2B). 
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Maximal aerobic capacity (VO2 max) improved more in INT, compared to CON, p=0.042 
(figure 4.2C). To verify the association between physical activity and aerobic capacity 
we looked at the number of days that subjects were at least 30 minutes physically 
active doing walking, bicycling, gardening or doing sports after 3 years. Statistical 
analyses revealed that the number of active days per week increased significantly in 
the intervention group from 2.9±2.4 days at baseline to 3.8±2.5 days after 3 years 
(change: 0.9±2.8 days), while those of the control group decreased from 3.0±2.6 days 
at baseline to 2.5±2.7 days (change: -0.55±3.31 days (mean±SD)), p=0.05 between 
groups. In the total study population, the increase in number of days was significantly 
associated with an increase in aerobic capacity (Pearson’s correlation coefficient 
R=0.343, p=0.01). No differences between groups or over time were observed in 
fasting glucose, fasting insulin and 2-hr insulin, HOMA-IR, triglycerides, total choles-
terol, HDL and LDL cholesterol, diastolic and systolic blood pressure or medication use 
(p>0.05, table 4.1). 
 
 
 
Figure 4.1 Trial profile of the SLIM intervention study in the Netherlands between the year 2000 and 2006.
Participants who dropped out of the program were treated as censored observations in the intention-to-
treat analyses. 
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Associations between changes in lifestyle behavior and changes in glucose tolerance 
Regression analysis in INT (n=49) revealed that in a model including ѐbody weight, 
ѐmaximal aerobic capacity, ѐtotal fat intake and ѐfiber intake as covariates, only 
ѐbody weight was significantly associated with changes in 2-hr glucose levels (ɴ=0.303 
mmol/l, p=0.04). When replacing ѐbodyweight with ѐwaist circumference, this pa-
rameter was slightly more strongly associated with ѐ2-hr glucose (ɴ=0.316 mmol/l, 
p=0.03). In the control group, suprailiacal skinfold thickness and age at baseline pre-
dicted worsening in 2-hr glucose levels (ɴ=0.19 cm, p=0.05; ɴ=0.23 mmol/l, p=0.01). 
Factors associated with dropout to the program. 
At the end of the study, 115 (58 INT/57 CON) subjects were still participating and 32 
(16 INT/16 CON) had dropped out. At baseline, adherent subjects had a higher VO2 
max (p<0.05), were higher educated and had a lower BMI and 2-hr glucose levels 
compared to dropouts (p<0.01, table 4.2). Results were similar when tested for the 
intervention group and control group separately. 
 
 
 
Figure 4.2 A-D. Changes in lifestyle parameters and 2-hr glucose concentrations, during a combined diet-
and-exercise lifestyle intervention to prevent type 2 diabetes (SLIM study). The study was performed in the
Netherlands between the year 2000 and 2006. Data are presented as mean ± SEM. Total fat intake (A), Body 
weight (B), VO2 max (C), and 2-hr plasma glucose levels (D) for the intervention group (black squares) and
control group (open triangles) at baseline, after 1 year, 2 years and at the end of the lifestyle intervention 
(mean 4.1 years). Dashed lines between year 2 and endpoint represents estimate progression in between. 
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Table 4.2 Baseline characteristics of participants of the SLIM lifestyle intervention, which was held between 
the year 2000 and 2006 in the Netherlands. Participants who completed the full study protocol (completers) 
were compared to those who discontinued participation previous to the end of the study (dropouts).  
  Completers Dropouts P 
N  115 32 - 
INT (male/female)  58 (30/28) 16 (7/9) 0.49 
CON (male/female)  57 (31/26) 16 (6/10) 0.13 
Age (years) 56.2 ± 7.1 58.3 ± 6.7 0.16 
Low Social Economic Status N (% of total) 47 (41%) 23 (72%) <0.01 
Smoking status N (% of total) 15 (13%) 3 (9%) 0.62 
Weight (kg) 85.1 ± 13.0 87.0 ± 11.4 0.46 
BMI (kg/m2) 29.4 ± 3.5 31.3 ± 4.4 <0.01 
Waist (cm) 102.8 ± 10.2 106.6 ± 11.3 0.07 
Body fat percentage (%) 38.1 ± 6.3 40.4 ± 6.4 0.07 
Diastolic blood pressure (mm Hg) 89.3 ± 8.4 88.2 ± 9.6 0.52 
Systolic blood pressure (mm Hg) 142.8 ± 15.7 145.1 ± 16.0 0.47 
VO2 max (l/min) 2.2 ± 0.6 1.9 ± 0.6 0.04 
Fasting glucose (mmol/l) 5.9 ± 0.8 6.1 ± 0.7 0.23 
2-hr Glucose (mmol/l) 8.6 ± 1.7 9.8 ± 2.8 <0.01 
HBA1c (%) 5.9 ± 0.5 6.1 ± 0.5 0.15 
Fasting insulin (mU/l) 17.4 ± 6.6 18.8 ±11.5 0.94 
2-hr Insulin (mU/l) 99.12 ± 78.9 110.6 ± 72.9 0.42 
HOMA-IR  4.6 ± 2.0 5.2 ± 3.8 0.79 
Triglycerides (mmol/l) 1.4 ± 0.7 1.4 ± 0.6 0.91 
Total cholesterol (mmol/l) 5.2 ± 0.8 5.3 ± 1.0 0.73 
HDL cholesterol (mmol/l) 1.1 ± 0.3 1.1 ± 0.3 0.95 
LDL cholesterol (mmol/l) 3.4 ± 0.7 3.5 ± 0.9 0.56 
Total energy intake (MJ/day) 8.8 ± 2.4 8.2 ± 2.1 0.18 
Total fat intake (En%) 35.6 ± 6.7 35.5 ± 6.4 0.94 
Saturated fat intake (En%) 13.6 ± 3.2 13.4 ± 3.2 0.74 
Total carbohydrate intake (En%) 42.2 ± 7.5 43.8 ± 6.0 0.31 
Fiber intake (mg/MJ) 2.7 ± 0.8 2.9 ± 0.9 0.17 
Alcohol consumption (En%) 5.8 ± 6.3 4.2 ± 7.6 0.24 
Data are Mean ± SD. 
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Figure 4.3 Proportion of subjects with diabetes during the SLIM lifestyle intervention in the Netherlands 
between the year 2000 and 2006. Cumulative diabetes incidence in the intervention group and control 
group. The relative risk of diabetes for subjects in the intervention group, as compared with those in the
control group, was 0.53 (P=0.04 for the comparison between the groups). 
Discussion 
The present study demonstrates long-term effectiveness of lifestyle intervention in the 
Dutch setting as well as novel information on factors associated with dropout and 
intervention outcomes. Our findings add to the knowledge about identification, life-
style effect and adherence in certain high-risk subgroups, and optimize implementa-
tion. 
Effectiveness of the SLIM lifestyle intervention 
In our lifestyle intervention the difference in 2-hr plasma glucose levels between 
groups remained as high as 0.72 mmol/l, which was associated with a diabetes risk 
reduction of 47%, despite no significant differences in body weight between groups. 
The diabetes risk reduction is similar to that found in the DPS (6, 7) and DPP (5). The 
control group showed a relatively small increase in 2-hr glucose levels and one may 
argue that the control group would not reflect the actual general population. However, 
at present, self-monitoring, self-tests, multimedia attention and increasing information 
availability and presentation of diabetes and diabetes-related complications may well 
increase awareness of the general population and induce small changes in their dietary 
and physical activity habits. The control group in our study may therefore be reflective 
of the informed general population at present. 
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Lifestyle-induced behavior change 
At the end of the lifestyle intervention, subjects in the intervention group had a sus-
tained higher aerobic capacity compared to the control group, and intervention sub-
jects had increased their total number of physically active days per week. Unfortu-
nately, we were not able to analyze whether attendance to the exercise program 
predicted the outcome of the intervention due to limited power. However, since 
approximately 70% of the intervention subjects also used other exercise facilities or 
physical activities, the total number of physically active days per week may be more 
indicative for the whole intervention group. Physical activity may independently 
reduce diabetes risk (9), also by sustaining weight loss (9). Even small sustained in-
creases in physical activity, as was also observed in this study, seem beneficial in the 
long term. Surprisingly, changes in aerobic capacity were not correlated with changes 
in glucose tolerance, possibly due to lack of statistical power for aerobic capacity (n=48 
for the intervention group). 
 Similar to the DPS, our lifestyle intervention did not have an effect on cholesterol, 
triglyceride levels and blood pressure, or on medication use, which could have masked 
the lifestyle effects (22). A high consumption of carbohydrates results in a rise in 
triglyceride concentrations (23). Body weight loss, mediated by both a low-fat or a 
high-fat diet may reduce triglyceride levels (24). It is possible that in the present 
lifestyle intervention, the increased carbohydrate intake and an increase in maximal 
aerobic capacity leveled out potential effects on plasma triglycerides. 
Associations between changes in lifestyle behavior and changes in glucose tolerance 
In agreement with previous results from the DPP (9), stepwise regression analyses 
revealed that variation in body weight loss and waist circumference was the most 
important determinant of the change glucose tolerance. It can therefore be assumed 
that adherence to a more rigid regime regarding weight loss, compared to what we 
have achieved in our study, may result in even greater improvements in glucose 
tolerance and diabetes risk reduction. 
Factors associated with dropouts to the intervention program 
A limitation in the present study is the seemingly high dropout rate, 21% in total (31 
out of the 147 subjects). This percentage is higher compared to previous reports of the 
DPS (6) and the DPP (5). On the other hand, our dropout percentage is similar to that 
of other lifestyle interventions after 1-2 year follow-up (25, 26) and to that observed in 
the DREAM trial after a follow-up for a median of 3 years (27), with 29.3% (772/2635) 
dropout in the rosiglitazone group and 25.0% (658/2634) in the control group. Two 
explanations for the difference between the DPS, DPP and SLIM can be given. First, our 
participants were originally extracted from the general population and they may have 
had less internal motivation to participate in the study, as compared to subjects 
recruited via advertisements, as was done in the DPS (16). Second, no weight loss 
program was provided which may have led to dissatisfaction for participants. In our 
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study, subjects unable to participate until the end of the study had a lower social 
economic status, a lower VO2 max and a higher BMI and 2-hr glucose levels at baseline, 
than those who completed the study. This clustering of factors is known from previous 
studies, which have found that a low educational background is associated with in-
creased risk for obesity (28) and that a low occupational position in adulthood is 
associated with a higher prevalence of type 2 diabetes in men and women (29). 
 Subjects with a low maximal aerobic capacity were more likely to become a 
dropout. This is similar to a previous report in the U.S. showing that especially high-risk 
subjects do not engage in regular physical activity (30). Therefore, these subjects may 
be especially prone to dropout en stay in their non-active physical behavior. More 
studies are necessary that investigate why certain groups of people drop out and how 
this can be changed. 
Conclusions 
Our results underscore that prolonged feasible changes in diet and physical activity 
prevent deterioration of glucose tolerance and reduce diabetes risk by 47% over a 
mean of 4.1 years. Variation in body weight loss and waist circumference was most 
strongly associated with the improved glucose tolerance, exemplifying the importance 
of body weight and central body fat reduction. A low social economic status and a low 
maximal aerobic capacity are indicative of dropout to the program, suggesting that 
these subjects may need special attention to achieve beneficial changes in their life-
style and metabolic profile. 
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Abstract 
Objective 
To assess adherence to physical activity and nutrition advices in adults with impaired 
glucose tolerance (IGT) participating in a lifestyle intervention study, and to determine 
personal and environmental factors that may have affected adherence. 
Method 
59 participants in the intervention group completed a self-administered questionnaire 
measuring potential personal and environmental determinants, derived from a num-
ber of influential theoretical models, after a follow-up of 2 or 4 years. Measures of 
adherence were derived from food records and the SQUASH (Short QUestionnaire to 
ASsess Health enhancing physical activity) completed during one of the annual meas-
urements of the trial. 
Results 
Adherence to the lifestyle advices of the SLIM intervention ranged from 22 to 70%. 
Participants self-rated their adherence to the physical activity and nutrition advices 
much more positive. Multiple regression analysis revealed that adherence to the 
physical activity advice was only positively associated with level of physical activity at 
baseline. Adherence to the nutrition advices was lower among participants who 
usually do the shopping for their household, participants who feel less susceptible for 
getting diabetes and younger participants. Improvement of dietary and physical activ-
ity behaviors compared to baseline was smallest among those with better baseline 
behaviors. 
Conclusion 
This study once more shows that inadequate adherence is a problem for intervention 
efficacy. Two possible ways to improve adherence in the present diabetes prevention 
intervention are to increase perceived susceptibility to getting diabetes and to de-
crease misconception about own adherence. 
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Introduction 
The pandemic of type 2 diabetes is an enormous public health problem due to the high 
prevalence (1), the diabetes-associated morbidity (2) and premature mortality (3, 4) 
and the financial burden (5, 6). Lifestyle interventions in subjects at high risk for devel-
oping type 2 diabetes, i.e. those with impaired glucose tolerance (IGT), have proven to 
be cost-effective (7) and effective in reducing diabetes risk by affecting the risk factors 
for the development of type 2 diabetes (8-10). Important risk factors for the develop-
ment of type 2 diabetes include a diet low in fiber, high in fat and especially saturated 
fat (11, 12), reduced physical activity, a high body mass index (BMI) (13) and an ab-
dominal fat distribution (14, 15). 
 The Study on Lifestyle intervention and Impaired glucose tolerance Maastricht 
(SLIM) is a 6 y randomized controlled trial to study the effect of a lifestyle intervention 
(healthy nutrition, increased physical activity) in adults with IGT in the age 40-65 years. 
This study has shown to be effective (10, 16, 17) and the results are comparable to 
other intervention trials (18). However, non-adherence to lifestyle interventions is a 
widespread problem (19) in need of clarification so that the success of lifestyle inter-
ventions involve the majority of the target group instead of a selected few. Adherence 
has been defined by WHO as “the extent to which a person’s behavior – taking medi-
cation, following a diet, and/or executing lifestyle changes, corresponds with agreed 
recommendations from a health care provider” (19). Estimates of non-adherence 
range from 0% to 100% , with 50% being an average, depending on the patient popula-
tion, medical condition, form of treatment, and the definition of adherence (20, 21). 
Adherence tends to be low when the regimen is complex, must be followed for a long 
period of time, requires changes in the person’s lifestyle and is designed to prevent 
rather than cure illness (21). The current SLIM regimen has all these characteristics. 
 The aims of the present study were to assess adherence to the physical activity 
and nutrition advices of the SLIM- intervention and to determine personal and envi-
ronmental factors that may have affected adherence. Factors associated with adher-
ence to nutrition and physical activity advices among IGT subjects have not been 
studied yet. For the present study potential influencing factors were derived from 
reviews of earlier studies in related populations and fields, and from a number of 
influential theoretical models that explain behavior and behavioral change (22-24), 
because no single model seems to be universally valid (23, 24) (see table 5.1). Attitudes, 
social influences, perceived behavioral control, barriers, perceived disease susceptibil-
ity and severity, past behavior, family foods rules and responsibilities, intervention 
characteristics, and participant characteristics were included as potential influencing 
factors. More insight in the association between these factors and adherence may help 
to develop targeted lifestyle implementation strategies for the prevention and treat-
ment of diabetes and its related complications (table 5.1). 
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Methods 
SLIM Intervention 
The design of the study has been described before (25). Briefly, skilled dieticians 
conducted every three months one-hour individual counseling sessions with the 
participants regarding their dietary habits and physical activity at the research institute. 
Dietary advice was based on the Dutch guidelines for a healthy diet (26, 27). The 
participants were stimulated to consume less than 30-35% of energy intake as fat, less 
than 10% of energy intake as saturated fat, and at least 3g /MJ of fiber a day. In addi-
tion, a body weight loss of 5-10 kg was aimed at, depending on degree of obesity. 
Dietary advice was based on 3-day food records (2 weekdays, 1 weekend day) that 
participants kept before they visited the dietician. 
 With respect to physical activity, participants were stimulated to be moderate-
intense physically active for at least 30 minutes on at least five days of the week (28, 
29). Individual advice was given (e.g., walking, cycling, swimming) and individual goals 
were set and evaluated during every visit. Furthermore, participants were encouraged 
to participate in a Physical Activity Program (PAP) given 3 times a week, especially 
designed for the study. These free 1-hour PAP sessions consisted of aerobic exercise 
training and resistance training and were given 3 times a week. A skilled trainer super-
vised the exercise sessions. 
Research population and measures 
Participants were included in the SLIM study in either 1999/2000 or 2002. The study 
design has been described in detail previously (10, 30). Subjects with an increased risk 
for glucose intolerance were selected from a cohort in the area of Maastricht, and 
invited to undergo a capillary standard oral glucose tolerance test (OGTT). Those 
subjects with a 2-hr blood glucose concentration > 7.8 mmol/l were invited for a 
second venous OGTT. For inclusion, mean 2-hr glucose concentration of both OGTTs 
had to be between 7.8 and 12.5 mmol/l and fasting glucose concentration < 7.8 mM. 
Exclusion criteria were known diabetes, glucose concentrations outside the inclusion 
criteria, chronic illness, medication known to interfere with glucose tolerance, partici-
pation in a vigorous exercise and/or diet program. 
 Subjects were randomized with stratification for sex and mean 2-hr plasma 
glucose concentration to the intervention group or the control group. All 72 persons 
from the intervention group with a follow-up of four years (inclusion period 1999-
2000) or two years (inclusion period 2002) were asked to participate in the present 
study, including the 23 persons that dropped out of the study meanwhile. For the 
present study, data were derived from the baseline SLIM measurements (time 1: 
baseline) and the annual measurement that took place between September 2003 and 
April 2004 (time 2 in the present study) during which the participants completed an 
adherence questionnaire. 
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Measures derived from the annual measurement 
As a measure of adherence to the nutrition advices the daily energy percentage (E%) of 
total and saturated fat intake, and fiber intake (g) was derived from weighted 3-day 
food records. Nutrient intake was calculated using the Dutch food table (NEVO version 
1996) (31). For each of the three nutrients an adherence score of one point was given 
if intake was in accordance with the dietary advice, i.e. below 35 E% for total fat, 
below 10 E% for saturated fat and more than 3 grams per day for fiber intake. An 
overall adherence score for the nutrition norms was made by summing the scores for 
the three nutrients (range from 0 to 3). Adherence to the physical activity advices was 
assessed with one item from the Short QUestionnaire to ASsess Health enhancing 
physical activity (SQUASH), i.e., on how many days a week are you physically active for 
at least 30 minutes (32). Finally, gender, baseline age, and time since inclusion (4 
versus 2 years) were derived from the baseline measurement. 
Adherence questionnaire 
The adherence questionnaire was handed out during the time 2 annual measurements 
or mailed to the persons who dropped out. The participants were asked to complete 
the questionnaire at home. Participants that returned the questionnaire received a 
small present. 
 The adherence questionnaire included measures of potential influencing factors 
as well as self-rated adherence to the advices. Unless indicated, items were measured 
with bipolar five-point scales, e.g. completely agree to completely disagree, very easy 
to very difficult (scored from –2 to 2). Participants were asked to keep the last six 
months in mind in answering the questions. All measures were used in earlier studies 
and operationalized in accordance with theoretical guidelines (33), but most needed 
some adaptation to the intervention at hand. 
 To assess attitude, seven beliefs towards adherence to the physical activity 
advices were measured (e.g. is important, pleasant, helps to prevent diabetes). Simi-
larly, eleven attitudinal beliefs towards the PAP, six beliefs towards adherence to the 
nutrition advices, and five beliefs towards the counseling sessions with the dietician 
were measured. The items were summed and divided by the number of items to 
obtain four overall attitude scores (Cronbach’s ɲ’s ranged from 0.80 to 0.90). 
 Subjective norms were measured by questioning the perceived opinions of 
household members as well as other family members/friends about whether the study 
participant should adhere to the physical activity/nutrition advices. Furthermore, 
observed physical activity and nutrition behavior of household members and other 
family members/friends as well as their support in adhering to the advices was ques-
tioned. 
 Perceived behavioral control was assessed by asking how easy or difficult it is to 
adhere to the physical activity and nutrition advices, and to participate in the PAP. 
Perceived counseling characteristics was assessed with five items, i.e., the dieticians 
talks with me about the results of adherence, whether my expectations are met, 
reasons for non-adherence, solutions for better adherence, and gives compliments 
about the things I do well (Cronbach’s ɲ = 0.85). 
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For eleven potential barriers it was asked how often the barrier had been a reason for 
not adhering to the physical activity or nutrition advices, e.g., illness of themselves or 
others, new job, holidays (Cronbach’s ɲ respectively 0.75 and 0.83). 
 As potential environmental barriers to participating in the PAP the participants 
were questioned about the distance from their home to the sport facilities, transporta-
tion issues, and convenience of the times. 
 Physical activity history was measured by asking how physically active participants 
were as a child, and as an adult before the start of the project. 
 Three items questioned prevalence (yes or no) of food rules at home, i.e. rules 
about eating times, rules that certain products (such as snacks or candy) should not be 
eaten too often, and rules that certain food products (such as fruit and vegetables) 
should be eaten regularly. To assess responsibilities in the household it was questioned 
who usually does the shopping and the cooking. 
 Diabetes related questions included whether they have family members or friends 
with diabetes, perceived seriousness of diabetes, and perceived susceptibility for 
developing diabetes. 
 As participant characteristics, educational level, household size, and main daily 
activities were measured. 
 Finally, participants were asked how often a week/month they participated in the 
PAP, and two items assessed self-rated adherence, i.e. whether they themselves 
thought they adhered to respectively the physical activity and nutrition advices well. 
Analyses 
The data were analyzed using the SPSS 13.0 (SPSS inc., Chicago, IL, USA). A positive 
score is believed to correspond with good adherence. To identify causes of dropout, 
multiple logistic regression of dropout (yes/no) on gender, time of inclusion and age 
was done. 
 To assess associations between adherence and potential influential factors, first 
univariate regression coefficients between the adherence measures and the potential 
influencing factors were calculated. Only factors with a regression coefficient of a 
significance level of less than 0.1 were included as independent variables in two 
backward multivariate linear regression analyses with respectively adherence to the 
physical activity advices and adherence to the nutrition advices as dependent variable. 
Similar analyses were conducted with relative measures of adherence as independent 
variables, i.e. change in number of days physically active for at least 30 minutes com-
pared to baseline and a change in adherence score for the nutrition advices. 
Results 
Response rates, attrition and participant characteristics 
Fifty-nine participants completed the questionnaire (82% response). The mean age of 
participants at baseline was 44.4 years (range 31-56; SD 5.7) and 54.2% were male. 
Thesis C Roumen V12.pdf   91 14-9-2009   11:11:13
Chapter 5 
 92 
Time since inclusion was two years for 27.1% and four years for 72.9% of the partici-
pants. Almost half (49.0%) had a low educational level (primary or basic vocational 
school), 32.1% a medium (secondary vocational or high school), and 18.9% a high 
educational level (college or university level). Most participants (84.9%) shared a 
household with one or more others. About half (47.5%) had a paid job. 
 The thirteen persons who did not complete the adherence questionnaire were all 
SLIM dropouts. Reasons for the 13 persons to dropout were medical problems, time 
restraints or lack of motivation. Gender, time of inclusion and age were not identified 
as causes of dropout. Dietary intake and physical activity data from the annual meas-
urement at baseline and present were available for respectively 49 and 48 of the 
participants. Item non-response was low (0-6 missing values) for most items. For a few 
items (social influence items towards physical activity, the items about barriers and 
attitudinal beliefs towards participating in the PAP) non-response was higher (maxi-
mum 13 missing values). Scales were calculated accepting missing data for a minority 
of the items in that scale. Missing data were not substituted. 
Adherence 
Table 5.2 shows that two or four years after study inclusion about one third of the 
participants adhered to the norm on physical activity. Compared to baseline, the 
percentage participants that adhered to the norm increased by 6.2%. More than 60% 
self-rated to adhere to the physical activity advices at least most of the time. 
 With regard to the dietary advices, almost 70% of the participants adhered to the 
norm on total fat intake. The norm on fiber intake and saturated fat intake was 
reached by more than half and about one third of the participants, respectively. 
Compared to baseline, percentage adherence to the norm of all three dietary advices 
increased with more than 20%. Twenty-two percent of the participants adhered to all 
three advices, representing an increase of 18%. More than 60% self-rated to adhere to 
all the nutrition advices at least most of the time. Self-reported participation in the 
PAP was 60.3% never, 18.9% once a week, 13.8% twice a week and 6.9% three times a 
week (table 5.2). 
Personal and environmental factors 
Table 5.3 shows that overall participants had positive attitudes, meaning that partici-
pants had a general favorable feeling towards the prescribed advices (indicated as a 
positive value). Participants also had positive scores on perceived subjective norms 
towards the physical activity advices as well as the nutrition advices, and perceived 
characteristics of the counseling sessions. Participants had less positive scores on the 
observed physical activity as well as nutrition behavior of others, perceived support of 
others in adhering to the physical activity and nutrition advices, their exercise history, 
self-efficacy towards adhering to the physical activity and nutrition advices, and barri-
ers to come to PAP. Participants indicated that barriers for adhering to the physical 
activity as well as nutrition advices did not occur very often. 
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Food rules were prevalent in most households. Most participants did not usually do 
the shopping, but about half usually did the cooking. 
 Regarding diabetes-related variables, getting diabetes was perceived to be very 
serious, but own susceptibility was rated lower. Most participants had a friend or 
family member with diabetes (table 5.3). 
 With regard to specific attitudinal beliefs towards adhering to the physical activity 
advices (not in table), participants were most positive about ‘the importance’ and 
‘pleasantness’ and that ‘it helps to feel more fit’, and least positive about adherence to 
the physical activity advices as ‘being a way to reduce medication’. ‘Importance’ and 
that ‘it helps to prevent diabetes’ were perceived to be the most positive aspects of 
adherence to the nutrition advices, while ‘pleasantness’ and ‘results of adhering to the 
nutrition advices in comparison with initial expectations’ were evaluated least positive. 
 With regard to participating in the PAP, the study participants were most positive 
about ‘importance’, ‘PAP being a separate program’ and ‘the supervisors’. The least 
positive scores were given on items questioning whether the PAP is ‘pleasant’, ‘boring’, 
‘childish’, ‘though’, and ‘too long’. 
 With regard to the counseling sessions, the ‘expertise of the dietician’ and the 
‘pleasantness’ were evaluated most positive. Participants were least positive about 
whether the sessions ‘help to adhere to the advices’ and ‘are adapted to their daily 
life’. 
 
 
Table 5.2 Dietary intake and adherence to the nutrition advices (n=49), and adherence to the physical 
activity advices (n=48): mean score (SD) or percentage. 
 Baseline Two/four years  
after inclusion 
Change 
Fat 
E% from fat 
% less than 35 en% from fat 
 
35.89 (6.79) 
46.9 
 
31.88 (5.93) 
69.4 
 
-4.00 (7.28) 
22.5 
Saturated fat 
E% from saturated fat 
% less than 10 en% from saturated fat 
 
13.59 (2.98) 
6.1 
 
11.00 (2.88) 
30.6 
 
-2.60 (3.73) 
24.5 
Fiber 
fiber (grams) 
% at least 3 gram 
 
2.68 (0.77) 
28.6 
 
3.12 (0.82) 
57.1 
 
0.45 (0.87) 
28.5 
Adherence to nutrition advices 
score (range 0-3) 
% all nutrition advices 
% self-rated adherence 
 
0.82 (0.88) 
4.1 
 
1.57 (1.02) 
22.4 
62.7 
 
0.76 (1.18) 
18.3 
 
Adherence to physical activity advices 
number of days physically active 
% at least 5 days 
% self-rated adherence 
 
2.95 (2.35) 
29.2 
 
3.11 (2.68) 
35.4 
61.4 
 
0.17 (2.81) 
6.2 
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Table 5.3 Factors associated with adherence to SLIM advices: mean score (SD) or percentage (n=59). 
Variables Score 
Attitude (scales -2 to 2) 
-physical activity advices 
-nutrition advices 
-PAP 
-counseling sessions 
 
1.02 (0.56) 
0.96 (0.53) 
0.97 (0.57) 
1.09 (0.51) 
Subjective norm household members (–2 to 2) 
-physical activity advices 
-nutrition advices 
 
1.49 (0.73) 
1.45 (0.80) 
Subjective norm other family members and friends (–2 to 2) 
-physical activity advices 
-nutrition advices 
 
1.19 (0.84) 
1.12 (0.83) 
Behavior household members (-2 to 2) 
-Physical activity 
-Nutrition 
 
0.04 (0.85) 
0.89 (0.60) 
Behavior other family members and friends (-2 to 2) 
-physical activity 
-nutrition 
 
0.04 (0.77) 
0.21 (0.65) 
Support household members (–2 to 2) 
-physical activity advices 
-nutrition advices 
 
0.63 (0.91) 
0.61 (0.92) 
Support other family and friends (-2 to 2) 
-physical activity advices 
-nutrition advices 
 
0.09 (0.89) 
-0.07 (0.74) 
Perceived behavioral control (-2 to 2) 
-physical activity advices 
-PAP 
-nutrition advices 
 
0.31 (1.03) 
0.29 (1.06) 
0.04 (0.89) 
Counseling characteristics (scale -2 to 2) 1.21 (0.62) 
Past exercise (-2 to 2) 
-as a child 
-as an adult 
 
-0.28 (1.08) 
-0.30 (0.94) 
Occurrence of barriers for adhering to advices (scales 1-5) 
-physical activity advices 
-nutrition advices 
 
4.08 (0.53) 
4.19 (0.61) 
Barriers for participating in PAP 
-Distance (mean km) 
-A lot of time for transportation (-2 to 2) 
-Problems with transportation (-2 to 2) 
-Convenience of times (-2 to 2) 
 
10.85 (20.20) 
0.38 (1.12) 
0.78 (1.12) 
0.18 (1.25) 
Food rules (% yes) 
-when to eat 
-products that should be eaten met mate 
-product that should be eaten regularly 
 
63.8 
50.0 
67.2 
Household responsibilities (% yes) 
-Usually do the shopping 
-Usually do the cooking 
 
28.0 
52.8 
Diabetes related variables 
-Family or friends with diabetes (% yes) 
-Seriousness of getting diabetes (0-3) 
-Susceptibility for getting diabetes (-2 to 2) 
 
72.9 
2.41 (0.62) 
0.38 (0.78) 
A positive score indicates a score positive to adherence. 
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Factors associated with adherence to the physical activity and nutrition advices 
Table 5.4 shows that only adherence to the physical activity advices at baseline was 
positively associated with present adherence to the physical activity advices. Number 
of active days at baseline was negatively associated with change in the number of days 
that participants were physically active for at least 30 min compared to baseline. This 
means that participants who were most active at baseline showed the least increase in 
number of days physically active. 
 Usually do the shopping and susceptibility for getting diabetes were negatively 
associated with adherence to the nutrition advices. Age was positively associated with 
adherence to the nutrition advices. Usually do the shopping and baseline adherence 
were negatively associated with change in the adherence score for the nutrition 
advices compared to baseline (table 5.4). 
 
 
Table 5.4 Multivariate associations between adherence and personal and environmental factors. 
 Standardized ɴ P 
Adherence to physical activity advices 
Adherence at baseline 
Change in adherence 
Number of active days at baseline 
 
0.40 
-0.45 
 
0.01 
0.00 
Adherence to nutrition advices 
Usually do the shopping 
Susceptibility for getting diabetes 
Age 
Change in adherence 
Usually do the shopping 
Adherence at baseline 
 
-0.31 
-0.49 
0.38 
-0.33 
-0.47 
 
0.03 
0.00 
0.01 
0.01 
0.00 
Discussion 
Adherence to the lifestyle advices of the SLIM intervention ranged from 22 to 70%, 
which is in line with the international literature where estimates of non-adherence 
have often been found to be quite suboptimal, especially for lifestyle interventions (20, 
21). 
 Adherence to the physical activity advice (being moderately active at least 30 
minutes on at least five days a week) was only positively associated with the number 
of active days at baseline. This is in line with the results of some earlier studies (34). 
However, increase in number of active days was negatively associated with number of 
active days at baseline. This might be due to the statistical analyses in which the 
change of a variable is strongly inversely associated with the baseline value (regression 
to the mean). Another explanation is a ceiling effect or because of social comparison, 
i.e. those who are already quite active see that they are more active than other par-
ticipants, and therefore already quite satisfied with their present behavior. This finding 
means that treatment efficacy of the physical activity part of the intervention is less in 
participants with a relatively high initial level of physical activity. 
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Adherence to the nutrition advices was lower among participants who usually do the 
shopping for their household, participants who feel less susceptible for getting diabe-
tes and younger participants. Participants who usually do the shopping also improved 
less compared to baseline than other participants. There were no differences between 
men and women with regard the people who usually do the shopping. Similar to the 
physical activity advices, improvement of dietary habits compared to baseline was 
smallest among those with better baseline dietary habits. These results indicate that it 
is important that the dieticians discuss susceptibility with participants and aim to 
achieve realistic perceptions of the risk of getting diabetes among all participants. This 
potential fear arousing information should however be balanced with information and 
strategies to help coping and increase perceived effectiveness of the behavioral 
changes (35). 
 Age is not a behavioral determinant that can be changed, but it needs to be 
realized that adherence to the dietary advices seems to be especially difficult for 
younger participants. This also applies to those who are responsible for the household 
shopping. Further research should give insight into why these subgroups have lower 
adherence rates. Those who do the shopping might for instance face more treats. 
 An interesting finding is that participants self-rated their adherence to the physi-
cal activity advice as well as the nutrition advices much more positive than the more 
objective measure. Misconceptions of own dietary intake and exercise behavior have 
been found before in earlier studies, and are a barrier towards desirable behavioral 
changes (36-38). Aside from reasons of giving socially desirable answers, a possible 
cause for misconceptions about own dietary intake is that the dietary advice was quite 
complicated, and people might have needed more personal feedback on whether they 
achieved the recommendations. It is, however, considered less obvious that people 
grossly misinterpret the advice to be active at least 30 minutes a day for at least five 
days a week. Another explanation for misconception might be that people do not 
compare their behavior with an objective norm, but with other people who are doing 
worse (39). People need to be made aware of this tendency. 
 Several factors that were found to be associated with adherence to nutrition and 
physical activity advices in earlier studies (see table 5.1) were not found to be signifi-
cant in this study. This might be due to some methodological problems of our study. 
Due to the small sample size, only a few independent variables could be included in 
the multivariate tests. We dealt with this by conducting univariate analyses first. 
Subsequently only a few variables with the highest univariate associations were in-
cluded in the multivariate test. Nonetheless, the analyses did not have much power. 
Another issue is that the sample consisted of two subsamples, i.e., participants who 
were included two years ago and participants who were included four years ago. The 
small sample size did not allow subgroup analyses. However, we included time of 
inclusion as potential determinant in the univariate analyses, but no significant asso-
ciations were found (data not shown). 
 We consider the broad conceptual framework including both personal and envi-
ronmental factors to be a strong point of the study. Many earlier adherence studies 
tended to be patient blaming by a strong focus on patient-related factors. There has 
been a relative neglect of environmental factors (19). However, we also had to select 
out of the many factors that have been suggested in the literature as possible predic-
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tors of adherence. We selected concepts from the most influential theories and mod-
els. Reviews of studies into factors associated with adherence to nutrition and physical 
activity advices in related field and populations were studied for empirical evidence. 
Our approach is in line with recommendations in the field of health promotion to 
combine insights from different theories (24, 40). However, using concepts from 
different theories also has a drawback, because the relations between the concepts 
are no longer taken into account, and no distinction is made between more distal or 
more proximal determinants. It is because of this that our study cannot provide an 
explanation why younger participants and participants who are responsible for the 
household shopping are less adherent. 
 The descriptive data of the potential influential factors revealed several opportu-
nities for improvement of the intervention, for instance with regard to support from 
family and friends, perceived behavioral control, and certain beliefs about conse-
quences of adherence. However, aside from the susceptibility and misconception issue, 
we did not find evidence in the present study that improvements in the SLIM interven-
tion, such as achievement of more social support or more positive attitudinal beliefs 
would also improve adherence. 
Implications 
This study once more shows that inadequate adherence is a problem for intervention 
efficacy. Two possible ways to improve adherence in the present diabetes prevention 
intervention are to increase perceived susceptibility to getting diabetes and to de-
crease misconception about own adherence. 
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Abstract 
Objective 
To evaluate whether changes in glucose tolerance and insulin resistance are related to 
changes in inflammation and immune markers in Dutch subjects with impaired glucose 
tolerance (IGT). 
Method 
In the Study of Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM), 
147 IGT subjects were randomized to a lifestyle intervention, directed towards diet 
and physical activity, or a control group. From 104 subjects at baseline and after 1y, 
glucose tolerance, body weight, anthropometric measurements, maximal aerobic 
capacity, C-reactive protein (CRP), interleukin-6 (IL-6), complement factor 3 (C3) and 4 
(C4), and plasminogen activator inhibitor-1 (PAI-1) concentrations were determined. 
Insulin resistance was estimated using the homeostasis model assessment for insulin 
resistance (HOMA-IR).  
Results 
ѐ2-hr Glucose was positively related with ѐCRP, ѐIL-6, ѐC3, ѐC4, independent of ѐbody 
weight, ѐsaturated fat intake, ѐmaximal aerobic capacity, age, medication use, smok-
ing status. The relation between ѐIL-6 and 2-hr glucose was independent of the other 
markers. ѐHOMA-IR was related to ѐPAI-1 and ѐC3, but this relation disappeared after 
correction for ѐbody weight. 
Conclusion 
The 1-year lifestyle intervention effectively reduced body weight and 2-hr glucose 
levels, but did not change CRP, IL-6, C3 and C4 levels. These latter inflammation factors 
were related to reductions in 2-hr glucose levels, not affected by lifestyle changes. 
Change in IL-6 was the only marker related with the change in 2-hr glucose, independ-
ent of the other markers, supporting the concept that IL-6 may be considered as a 
‘nontraditional’ risk marker in the etiology of glucose intolerance. 
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Introduction 
With global rates of type 2 diabetes mellitus rising, it has become essential to under-
stand its etiology in order to obtain clues for a more effective prevention or treatment. 
Lifestyle interventions have already proven to be effective in the prevention of type 2 
diabetes in subjects with impaired glucose tolerance (IGT) (1). The Study on Lifestyle 
intervention and Impaired glucose tolerance Maastricht (SLIM) has shown that 
changes in nutritional intake and physical activity according to general guidelines 
results in a sustained improvement in 2-hr glucose values in subjects at high risk for 
type 2 diabetes (2, 3). Furthermore, sustained lifestyle changes and a reduction in 
diabetes incidence are observed after a lifestyle intervention, even after discontinua-
tion of active counseling (4). Information on the underlying mechanisms, responsible 
for the positive lifestyle effect and on determinants of intervention success may 
provide information for a more personalized intervention and a more targeted imple-
mentation into the health care system. 
 There is increasing evidence that markers of low-grade inflammation and fibri-
nolysis, i.e. interleukin-6 (IL-6), C-reactive protein (CRP) and plasminogen activator 
inhibitor 1 (PAI-1), are related to the insulin resistant state (5) and predict the devel-
opment of type 2 diabetes (6-9). Increased IL-6 levels seem to predict future risk of 
type 2 diabetes, although CRP may be a stronger predictor than IL-6 (7, 10, 11). Also, 
high PAI-1 levels are associated with diabetes incidence, which is mediated by body 
weight and insulin resistance (12). In addition, the complement system may be in-
volved in the development of type 2 diabetes, since complement factor 3 (C3) was 
associated with diabetes development in middle-aged men (13). Additionally, C3 and 
complement factor 4 (C4) are expressed in adipose tissue with a high expression in 
intra-abdominal adipose tissue of obese men, suggesting that (visceral) adipose tissue 
may mediate the relationship between C3 and diabetes risk (14). 
 Until now, several studies have shown that lifestyle interventions can reduce CRP 
(15, 16), IL-6 (15, 17) and PAI-1 levels (18, 19). To the best of our knowledge, only 
mechanistic and population-based cohort studies have provided evidence for a rela-
tionship between elevated levels of C3 and diabetes development, whereas the effect 
of lifestyle interventions on C3 are still unknown. The aim of this study was to evaluate 
the 1-yr effect of a lifestyle intervention based on general public health recommenda-
tion towards a healthy diet and physical activity level and to evaluate if the individual 
outcome of the intervention may be partly reflected in the plasma profile of immu-
nological and inflammatory markers. Therefore, the present study investigated the 
effect of the lifestyle intervention on CRP, IL-6, C3, C4 and PAI-1 and investigated to 
what extent these markers are related to observed changes in glucose tolerance and 
insulin resistance. 
Methods 
The SLIM study (Study on Lifestyle Intervention and Impaired Glucose Tolerance 
Maastricht) is a randomized controlled trial, designed to study whether a 6-yr com-
bined dietary and physical activity intervention program can improve glucose tolerance 
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in IGT subjects. This paper will present data from the 104 subjects who completed the 
1-year intervention and on whom complete data of inflammation markers was avail-
able. In addition, changes in body composition, fasting and 2-hr insulin and plasma 
glucose concentrations, free fatty acid levels and maximal aerobic capacity were 
determined. The Medical Ethical Review Committee of Maastricht University approved 
the study protocol and all subjects gave their written informed consent before the 
start of the study. 
Study design and subjects 
The study design has been described in detail previously (20). Briefly, subjects with an 
increased risk for glucose intolerance, e.g. family history of diabetes, age >40 years, 
BMI > 25 kg/m2, were selected from a cohort in the area of Maastricht, and invited to 
undergo a capillary standard Oral Glucose Tolerance Test (OGTT) (response rate 46.2%, 
see reference (20)). Those subjects with a 2-hr blood glucose concentration > 7.8 mM 
were told their status and invited for a second venous OGTT after and overnight fast. 
For inclusion, mean 2-hr glucose concentration of both OGTTs had to be between 7.8 
and 12.5 mM and fasting glucose concentration < 7.8 mM. Data obtained during the 
second (venous) OGTT were used as baseline values. Exclusion criteria were known 
diabetes, glucose concentrations outside the inclusion criteria, chronic illness known to 
interfere with glucose tolerance or that makes participation of a lifestyle intervention 
and/or 5-year survival improbable, medication known to interfere with glucose toler-
ance, and participation in a vigorous exercise and/or diet program. The study popula-
tion consisted of 147 subjects. Subjects were randomized with stratification for sex and 
mean 2-hr plasma glucose concentration to the intervention group (INT: 74 subjects; 
38 male, 36 female) or the control group (CON: 73 subjects; 37 male, 36 female). It was 
calculated, according to the preliminary results after 1 year of the Finnish DPS (21), 
that 50-60 subjects per group would be sufficient to detect a 1.0 mmol/l difference in 
2-hr glucose concentration between groups. Data analyses of these 1-year results 
include 104 subjects: 51 INT subjects and 53 CON subjects on whom complete data 
were available. Data of 43 subjects were not included in the analyses due to incom-
plete data for regression analysis (n=27) and dropout (n=16, 10 INT: 3M/7F, 6 CON: 
5M/1F). The latter subjects did not complete the first year due to lack of time in 6 
cases, medical reasons in 5 cases, lack of motivation in 2 cases, dissatisfaction in 2 
cases and lack of mobility in 1 case. Between excluded and included subjects, i.e. 
between dropouts and completers, there were no differences in age, BMI, 2-hr glucose 
levels, homeostasis model assessment for insulin resistance (HOMA-IR, calculation 
based on fasting glucose and insulin levels), saturated fat intake, CRP, IL-6, C3, C4 and 
PAI-1. Dropouts had a lower maximal aerobic capacity at baseline compared to com-
pleters (p=0.01). 
Lifestyle Intervention 
The intervention program consisted of a dietary and physical activity part. Dietary 
recommendations were based on the Dutch guidelines for a healthy diet (Dutch Nutri-
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tion Council) and consisted of a carbohydrate intake of at least 55 energy% (E%), a 
total fat intake of 30-35 E%, with a saturated fat intake below 10 E%. A skilled dietician 
gave personal dietary advice during a one-hour counseling session every 3 months, 
after consideration of a 3-day food record (two weekdays, one weekend day). In 
addition, subjects received individual advice on how to increase their level of physical 
activity to at least 30 minutes a day for at least 5 days a week (22). Furthermore, 
subjects were encouraged to participate in a free, supervised combined aerobic- and 
resistance exercise program, especially designed for this study. Three times a year 
subjects were asked to participate in the exercise program using heart rate monitoring 
and continuous registration to validate the exercise intensity, which was approxi-
mately 70% of their maximal peak oxygen consumption (VO2max). Control subjects 
were only briefly informed about the beneficial effects of a healthy diet and physical 
activity, whereas no individual advice was provided. 
Measurements and Biochemical analyses 
Body weight was measured with an electronical scale to the nearest 0.1 kg. Waist was 
measured to the nearest 0.5 cm, with the subject in standing position at the level 
midway between the lowest rib and the iliacal crest. Blood pressure was measured 
with a Maxi Stabil 3 pressostabil (CE0047, Speidel en Keller, Jungingen, Germany) in 
duplo with the subject in supine position, after 10 minutes of rest. The 3-day food 
records were analyzed for nutrient intake using the Dutch food table (NEVO version 
1996). An incremental exhaustive exercise test was performed on an electronically 
braked bicycle ergometer to determine maximal peak oxygen consumption (VO2max). 
Changes in glucose tolerance were studied using an OGTT, as explained above. Plasma 
glucose and free fatty acids (FFA) were measured in the fasting state and after 2 hours, 
using a standard enzymatic technique, automated on a Cobas Fara centrifugal analyzer 
(intra assay coefficient variation for glucose was 1.50%, the inter-assay coefficient 
variation was 3.66%). Plasma insulin concentration was measured with a Radio Im-
muno Assay (Cat. #HI-14K, Linco Research, St. Charles, MO, USA) that shows no cross-
reactivity with pro-insulin. The HOMA-IR index for insulin resistance was calculated as 
described by Matthews et al.(23). Glycated haemoglobin (HBA1c) was determined in a 
fasting serum sample with high-performance liquid chromatography (reference values 
for our laboratory 4.4-6.2%). hsCRP, C3 and C4 were measured in duplicate in fasting 
serum using an autoanalyser (Hitachi 912, Roche Diagnostics, Almere, The Nether-
lands). IL-6 was measured in duplicate in fasting EDTA plasma with a high-sensitive 
ELISA assay (R&D systems, Abingdon, United Kingdom). PAI-1 was measured in dupli-
cate in fasting EDTA plasma with an ELISA assay (Zymutest, Hyphen Biomed, NEUVILLE-
SUR-OISE, France). 
Statistical analysis 
SPSS for Windows (version 14.1) was used for statistical analysis. Insulin, FFA concen-
trations and CRP, IL-6, C3, C4 were not normally distributed and were therefore ln-
transformed. Data are presented as mean ± SD; non-linear variables are expressed as 
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median (25th-75th percentile). Differences between groups were tested with a Stu-
dent’s t test for independent samples or by a χ2 test when applicable. ANOVA was 
used to assess the effect of group, time and group x time interaction. Adjustment for 
dichotomous variables in the linear regression analyses was done using dummy vari-
ables. Adjustment for lifestyle changes in the multiple linear regression analyses was 
done by inclusion of three different variables representing changes in body weight, 
dietary pattern and physical fitness. A p-value of less than 0.05 was considered statisti-
cally significant. All tests were two-sided. 
Results 
General lifestyle effects 
At baseline, no differences were seen in subject’ characteristics apart from age, which 
was higher in the control group compared to the intervention group (p=0.02) (table 
6.1). After 1 year, body weight decreased in intervention subjects from 87.7 kg to 84.1 
kg, whereas a smaller decrease was observed in the control subjects (p=0.004, time x 
group interaction, table 6.1). 2-Hour plasma glucose levels decreased in the interven-
tion group from 8.9 ± 2.2 mM at baseline to 8.4 ± 1.7 mM after 1 year. In the control 
group an increase was seen from 8.1 ± 2.1 mM at baseline to 8.8 ± 2.3 mM after 1 year 
(p= 0.006 time x group interaction). 2-hr Insulin levels showed a significant reduction in 
the intervention group compared to the control group (p=0.004). No differences 
between groups were observed in fasting plasma glucose, HBA1c, fasting insulin and 
HOMA-IR (table 6.1). No subjects developed type 2 diabetes (fasting glucose > 7.0 
mmol/l and/or 2-hr glucose > 11.1 mmol/l) during the first year of study. 
 In line with the reduction in body weight, total fat intake and saturated fat intake 
decreased significantly more in the intervention subjects and carbohydrate intake and 
fiber intake increased more in the intervention subjects, compared to the control 
subjects (pall<0.01, table 6.2). 
 Changes in CRP, IL-6, C3, C4 and PAI-1 did not differ between study groups 
(pall>0.05, table 6.1). 
Inflammation and immune markers and glucose tolerance 
We evaluated if the individual outcome of the intervention, i.e. changes in 2-hr glucose 
levels and changes in HOMA-IR, are reflected in the plasma profile of immunological 
and inflammatory markers. Since the randomization, i.e. lifestyle intervention or 
control, did not affect the levels of CRP, IL-6, C3 and C4 and PAI-1, study groups were 
combined (total group, n=104). In the total group, 1-year changes in CRP, IL-6, C3 
(pall<0.01) and to a lesser extend C4 (p<0.05) were significantly positively related with 
changes in 2-hr glucose levels (table 6.3, crude analysis). The associations between ѐIL-
6 and ѐC3 and ѐ2-hr glucose were similar when tested in the intervention group 
separately (data not shown). When these analyses were adjusted for three major 
aspects of the lifestyle intervention, i.e. changes in body weight, saturated fat intake  
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Table 6.1 Participant characteristics at baseline and after 1 year of the Dutch SLIM lifestyle intervention. 
   Intervention group Control group P  
   Baseline After 1 year Baseline After 1 year Group Time Group 
x Time 
Men/women (n)  31/20(51) 31/20 (51) 31/22 (53) 31/22 (53) 0.81 - - 
Smokers (%) 14 12 13 23 0.49 0.51 0.02 
Medication use  
for blood pressure 
(%) 27 33 23 25 0.55 0.06 0.35 
Medication use  
for blood lipids 
(%) 6 10 8 11 0.78 0.10 0.99 
Age (years) 55.6 ± 6.0 - 58.7 ± 1.0* - 0.02 - - 
Body weight (kg) 87.7 ± 13.1 85.1 ± 12.7 84.1 ± 13.1 83.5 ±12.1 0.30 0.00 <0.01 
BMI (kg/m2) 29.7 ± 3.5 28.8 ± 3.4 29.5 ± 3.6 29.3 ± 3.2 0.82 <0.01 0.01 
Waist (cm) 103.8 ± 9.9 100.3 ± 10.2 103.3 ± 10.0 101.8 ± 10.2 0.78 <0.02 0.05 
VO2 max (l/min) 2.3 ± 0.6 2.4 ± 0.6 2.1 ± 0.5 2.1 ± 0.6 0.06 0.00 0.02 
Fasting glucose (mmol/l) 6.1 ± 0.9 6.0 ± 0.9 5.8 ± 0.6 5.9 ± 0.6 0.21 0.77 0.06 
2-hr Glucose (mmol/l) 8.9 ± 2.2 8.1 ± 2.1 8.4 ± 1.7 8.8 ± 2.3 0.75 0.34 <0.01 
HBA1c (%) 6.0 ± 0.5 5.8 ± 0.4 5.9 ± 0.5 5.7 ± 0.5 0.35 <0.01 0.24 
Fasting insulin (mU/l) 17.8  
( 11.4; 21.8) 
15.3  
(9.9; 20.8) 
16.7  
(11.4; 22.7) 
16.0  
(10.3; 22.6) 
0.55 0.13 0.12 
2-hr Insulin (mU/l) 88.5  
(60.0; 120.6) 
66.9  
(47.2; 101.4)
82.0  
(61.3; 122.7) 
95.1  
(59.5; 139.7) 
0.09 0.96 <0.01 
HOMA-IR  4.8  
(3.1; 6.0) 
4.0  
(2.6; 5.9) 
4.3  
(2.8; 5.9) 
4.2  
(2.5; 5.8) 
0.80 0.27 0.08 
FFA (µmol/l) 562  
(459; 682) 
435  
(366; 572) 
549  
(421; 663) 
483  
(386; 585) 
0.99 <0.01 0.13 
2-hr FFA (µmol/l) 100  
(79; 126) 
72  
(60; 89) 
100  
(74; 121) 
78  
(60; 108) 
0.65 <0.01 <0.01 
CRP (mg/l) 2.6  
(1.3; 4.9) 
2.5  
(0.8; 4.9) 
3.1  
(1.3; 4.8) 
2.5  
(1.7; 4.8) 
0.13 0.39 0.11 
IL-6 (pg/ml) 1.5  
(1.1; 2.0) 
1.4  
(1.0; 1.9) 
1.6  
(1.2; 2.6) 
1.8  
(1.2; 2.3) 
0.06 0.27 0.34 
C3 (g/l) 1.3  
(1.1; 1.4) 
1.3  
(1.1; 1.4) 
1.3  
(1.1; 1.4) 
1.3  
(1.1; 1.4) 
0.93 0.69 0.21 
C4 (g/l) 0.3  
(0.2; 0.3) 
0.3  
(0.2; 0.3) 
0.3  
(0.3; 0.3) 
0.3  
(0.3; 0.3) 
0.95 0.47 0.21 
PAI-1 (ng/ml) 46.0  
(38.5; 60.3) 
48.4  
(39.3; 57.3) 
46.7  
(33.1; 53.0) 
48.8  
(40.5; 55.0) 
0.55 0.33 0.12 
Data are Mean ± SD, n= 104. Fasting insulin, 2-hr insulin, HOMA-IR, FFAs, CRP, IL-6, C3, C4 and PAI-1 are 
expressed as median (25th percentile; 75th percentile. 
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and maximal aerobic capacity, as well as age, medication use and smoking status, all 
aforementioned associations remained significant (table 6.3, adjusted). Replacement 
of body weight by BMI and inclusion of gender in these models did not affect the 
outcomes significantly. To estimate which of these markers had an independent 
contribution on the change in 2-hr glucose levels, we carried out stepwise linear 
regression analysis in a model that included ѐCRP, ѐIL-6, ѐC3, ѐC4, age, smoking status, 
mean value 2-hr glucose of concentrations, ѐbodyweight, ѐsaturated fat intake and 
ѐVO2max. Of all the inflammation markers, only ѐIL-6 was independently associated 
with ѐ2-hr glucose. Delta IL-6 explained 6.7% of the variation in glucose tolerance. Also 
in the intervention group separately, IL-6 was the only marker significantly associated 
with ѐ2-hr glucose when adjusting for the aforementioned lifestyle changes (p=0.04, 
data not shown). 
 CRP levels above 10 mg/ml may be indicative of infection. To investigate whether 
the association between CRP and 2-hr glucose was not mediated by the acute-phase 
response, 10 subjects (7 INT: 5F/2M, 3 CON: 1F/2M) were excluded with CRP levels 
above 10 mg/ml at baseline or at year 1. Exclusion of these subjects abolished the 
significant correlation between ѐCRP and ѐ2-hr glucose (ɴ=0.131 mmol/l, p=0.19). 
 
Inflammation and immune markers in relation to insulin resistance 
The 1-year changes in PAI-1 and C3 were positively associated with changes in esti-
mated insulin resistance (table 6.3, crude). However, these associations were to a large 
extent explained by ѐbody weight (after adjustment p>0.5). 
 
Table 6.2 Energy intake, based on 3-day food records, of participants of the SLIM lifestyle intervention at 
baseline and after 1 year. 
   Baseline  Year 1 P Group P Time  P Group X Time 
Energy (MJ/day) INT 9.1 ± 2.3  8.1 ± 2.1 0.68 0.01 0.06 
  CON 8.5 ± 2.3  8.4 ± 2.3    
Total fat (E%) INT 35.8 ± 5.4  30.8 ± 6.7 0.10 <0.01 <0.01 
  CON 35.5 ± 7.2  34.5 ± 6.3    
Saturated fat (E%) INT 13.6 ± 2.4  11.3 ± 2.9 0.04 <0.01 <0.01 
  CON 13.8 ± 3.4  13.3 ± 3.5    
Carbohydrates (E%) INT 41.9 ± 7.5  46.9 ± 7.7 0.52 <0.01 <0.01 
  CON 43.0 ± 7.4  44.1 ± 7.6    
Fiber (g/MJ) INT 2.7 ± 0.8  3.2 ± 1.0 0.08 <0.01 <0.01 
  CON 2.7 ± 1.0  2.7 ± 0.8    
Alcohol (E%) INT 6.1 ± 7  4.9 ± 6.2 0.87 0.26 0.36 
  CON 5.4 ± 5.9  5.3 ± 5.6    
Data are mean ± SD. 
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Table 6.3 Linear regression analysis of the 1y changes during the SLIM lifestyle intervention in 2-hr glucose 
levels on changes in markers of inflammation, fibrinolysis and the immune system crude and after adjust-
ment.  
      Crude Adjusted 
Dependent Independent Standardized ɴ P Adjusted R2 Standardized ɴ P Adjusted R2 
ѐ 2-hr Glucose 
(mmol/l) ѐ CRP (mg/l) 0.28 <0.001 0.13 0.25 <0.001 0.22 
 ѐ IL-6 (pg/ml) 0.26 <0.001 0.11 0.32 0.001 0.25 
 ѐ C3 (g/l) 0.37 <0.001 0.17 0.27 0.01 0.22 
 ѐ C4 (g/l) 0.23 0.02 0.10 0.22 0.03 0.20 
 ѐ PAI-1 (ng/ml) 0.06 0.53 0.05 -0.08 0.45 0.17 
         
ѐ HOMA-IR ѐ CRP (mg/l) 0.04 0.73 -0.01 -0.09 0.25 0.47 
 ѐ IL-6 (pg/ml) -0.03 0.78 -0.01 -0.07 0.37 0.46 
 ѐ C3 (g/l) 0.35 0.001 0.11 0.07 0.44 0.47 
 ѐ C4 (g/l) 0.08 0.43 0.01 -0.02 0.81 0.47 
 ѐ PAI-1 (ng/ml) 0.23 0.02 0.05 0.04 0.61 0.48 
Regression model adjusted for age, study group, mean value of the dependent and independent (crude) and 
in addition medication use, smoking status, and the change in body weight, saturated fat intake and maximal 
aerobic capacity (adjusted). 
Discussion 
The lifestyle intervention used in the SLIM study is effective in preventing deterioration 
in glucose tolerance (3), but does not affect CRP, IL-6, C3, C4 or PAI-1 levels. However, 
the first four of these markers are significantly associated with 1-year changes in 2-hr 
glucose levels and these associations are not affected by lifestyle changes, i.e. changes 
in body weight, saturated fat intake and maximal aerobic capacity. IL-6 was the strong-
est marker associated with 2-hr glucose, independent of the other markers studied, 
suggesting that these markers and especially IL-6 may be linked to the etiology of 
glucose intolerance. 
Inflammation and immune markers and glucose tolerance 
The change in IL-6 levels was the only marker related with ѐ2-hr glucose, independent 
of the other markers and lifestyle changes, suggesting that IL-6 has an essential role in 
the changes of glucose tolerance, compared to the other markers investigated. The 
relationship between 2-hr glucose and IL-6 has been established before in cross-
sectional studies (24, 25) and is in agreement with previous findings showing a plasma 
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IL-6 increase in response to acute hyperglycemic spikes (26) and increased IL-6 produc-
tion from muscle in the postprandial phase of IGT men (27). In agreement with our 
results, IGT was recently found to be associated with IL-6 levels in a well-functioning 
older population, independent of obesity, fat distribution and inflammation-related 
conditions (28). 
 The association between IL-6 and 2-hr glucose, independent of the other markers 
investigated, suggests an effect of IL-6 independent of the acute-phase response. IL-6 
may negatively affect insulin sensitivity via a stimulatory action on adipose tissue 
lipolysis (29) or by direct effects on skeletal muscle affecting insulin-stimulated glucose 
disposal (30). However, in the present study we could not demonstrate a relationship 
between IL-6 and markers of insulin metabolism (fasting insulin, HOMA-IR or 2-hr 
insulin). The strong relationship between IL-6 and 2-hr glucose may be explained by an 
inhibitory effect of IL-6 on insulin signaling in the liver (31), i.e. by decreasing insulin-
mediated suppression of endogenous glucose production (EGP) (32), observed in 
animal studies. Human studies to verify this hypothesis are scarce. One study showed 
no effect of IL-6 on EGP (30), but this study was done in healthy individuals and not in 
subjects with a disturbed glucose metabolism. IL-6 may also increase insulin secretion 
promoting hyperinsulinemia, possibly via a Ca2+-dependent mechanism (33), although 
limited in vivo studies are available at present. 
 High CRP levels are indicative of infection. Exclusion of 10 subjects with high CRP 
levels attenuated the relation between 2-hr glucose and CRP. Therefore, we cannot 
exclude involvement of the acute-phase response mediating the association between 
CRP and 2-hr glucose. The 10 subjects were more often current smokers, suggesting 
that they may be especially vulnerable for progression towards type 2 diabetes.  
 The mechanism behind the positive association between IL-6 and C3 and C4 may 
be due to hepatic synthesis of C3 and C4, which is regulated by proinflammatory 
cytokines, such as IL-6 (34). Up to now, there is limited information regarding the 
relationship between inflammation factors and the complement system in the devel-
opment of type 2 diabetes. Recently, CRP, C3 and C4 were all associated with body fat 
in healthy adolescents, while no statement was made concerning the mutual relation-
ships (35). 
 Body weight did not explain the relationship between ѐC3 and ѐ2-hr glucose, 
suggesting that C3 may have effects on the glucose metabolism, not mediated by body 
weight (36). C3 has been shown previously to be related to diabetes development (13), 
independently of the main indexes of abdominal and general obesity and has shown to 
be strongly related to 2-hr glucose in non-diabetic Pima Indians (37). These data 
suggest a detrimental effect of C3 on the development of type 2 diabetes, while the 
mechanism is still unclear.   
Inflammation and immune markers and insulin resistance 
Changes in PAI-1 were associated with HOMA-IR, which was largely explained by 
changes in body weight. In the Diabetes Prevention Program a similar association was 
found with tissue plasminogen activator (tPA), which is used to estimate the level of 
antifibrinolytic activity, and HOMA-IR, independent of measures of demographics, 
adiposity, insulin and glucose (38). Also, Festa et al. (2006) found the relation of PAI-1 
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to incident diabetes to be independent of insulin resistance and/or bodyweight (12). 
Lifestyle interventions have shown to be able to reduce PAI-1 levels (18, 19), but more 
mechanistic studies are necessary to clarify the role of adipose tissue in the relation-
ship between PAI-1 and insulin resistance. 
 Body weight also explained the positive relation between changes in C3 and 
ѐHOMA-IR, suggesting that adipose tissue may mediate this relationship. These data 
suggest that besides the liver, adipose tissue may be a proinflammatory source of C3 
production which seems consistent with findings of a high C3 expression in (omental) 
adipose tissue (14). 
 Our study has several limitations that need to be addressed. First, the sample size 
was relatively small. However, the original power calculation suggest that these num-
bers are sufficient to detect a 1.0 mmol/l difference in glucose tolerance. Also, our 
study shows strong associations (p<0.001), despite the relatively low sample size. In 
addition, characterization of immunological and inflammatory markers was more 
comprehensive than in previous studies. Second, associations were performed com-
bining the two study groups together, whereas the control group was not given per-
sonalized lifestyle advice. However, as can be observed in the one-year decrease in 
body weight, subjects in the control group had their own ‘mini intervention’. Several 
reasons may have attributed to the change in body weight e.g. increasing awareness of 
the advantages of a healthy lifestyle. In addition, regression analyses were adjusted for 
study group and the main results regarding IL-6 and C3 were similar in the intervention 
group separately as well. 
 In summary, the changes in 2-hr glucose observed in our lifestyle intervention 
study were associated with changes in IL-6, C3 and C4, independent of study group, 
age, medication use, smoking status and lifestyle changes. Change in IL-6 was the only 
marker related with the change in 2-hr glucose independently of the other markers, 
suggesting that IL-6 is an independent mediator of glucose tolerance and may be 
considered as a ‘nontraditional’ risk marker in the etiology of type 2 diabetes mellitus. 
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Abstract 
Objective 
To investigate the effect of lifestyle intervention according to general recommenda-
tions on circulating adiponectin, resistin, leptin, plasminogen-activator inhibitor-1 (PAI-
1), C-reactive protein (CRP), Complement factor 3 (C3) and Interleukin-6 (IL-6) in 
subjects at risk for diabetes as well as the potential of these inflammation factors as 
biomarkers of changes in glucose metabolism and insulin resistance. 
Method 
In the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht 
(SLIM), 147 subjects with impaired glucose tolerance were randomized to either a 
combined diet-and-exercise intervention or a control program. At baseline and after 1, 
2 and 3 years, an oral glucose tolerance test, an exercise test, and anthropometric 
measurements were performed. After 3 years, complete data of 102 subjects (50 
intervention and 52 control) were obtained. 
Results 
Over the 3 years, leptin levels increased less in the intervention group, compared to 
the control group (pall<0.05). High baseline leptin levels were predictive of improve-
ments in glucose tolerance, partly independent of body fat mass, suggesting a role of 
leptin mediating glucose tolerance. Independent of changes in body weight, saturated 
fat intake and maximal aerobic capacity, 3-yr changes in PAI-1 levels were significantly 
positively associated with changes in HOMA-IR. 
Conclusion 
The 3-yr SLIM lifestyle intervention blunts the increase in leptin levels in the interven-
tion group compared to the control group. Baseline leptin levels are reflective of 
baseline body weight and are indicative of beneficial lifestyle-induced changes in 2-hr 
glucose levels. 
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Introduction 
There is increasing evidence for a relationship between inflammatory factors and the 
progression towards type 2 diabetes (1-3). C-reactive protein (CRP) and IL-6 concentra-
tions are increased in obesity and have been reported to be significantly elevated in 
impaired glucose tolerance subjects (IGT) compared with normoglycemic subjects, as 
shown in the KORA Survey 2000 (4). In the DPS lifestyle intervention study, CRP was 
the best predictor for progression towards type 2 diabetes in the control group after a 
mean of 3.9 years (1). Plasminogen activator inhibitor 1 (PAI-1), a factor known to be 
involved in blood clotting, has also been able to predict the development of type 2 
diabetes, an effect independent of body weight (5). Also, baseline complement factor 
3 (C3), mainly produced by the liver, has recently been shown to be predictive of 
diabetes development after 6.1 years in non-diabetic healthy men (6). 
 Adipo(cyto)kines, endocrine factors that are produced by adipose tissue, may also 
be associated with the development of type 2 diabetes. Among others, adipose tissue 
secretes adiponectin, leptin and resistin. Based on animal and in vitro data, resistin 
was originally thought to be a hormone linking obesity with insulin resistance, possibly 
by having antagonistic effects compared to those of insulin (7). However, recent 
human studies provide conflicting data showing no association between resistin and 
insulin resistance (8; 9). Adiponectin is solely produced by adipose tissue and hypoadi-
ponectinemia is associated with Impaired Glucose Tolerance (IGT) in non-diabetic men 
(10) and has shown to be predictive of diabetes development in Pima Indians (2) as 
well as in a Caucasian IGT population (3). In these studies, the relationship between 
low adiponectin levels and progression towards type 2 diabetes was not completely 
explained by fat mass, suggesting adiponectin as a marker for metabolic status, e.g. 
adipocyte dysfunction. Both adiponectin and leptin are suggested to be associated 
with diabetes development and cardiovascular disease via pathways involving fat 
metabolism, inflammation and vascular function (10; 11). 
 Lifestyle interventions have been shown to reduce CRP, IL-6 (12), PAI-1 (13) after 
1 year as well as leptin after periods of 1-2 years (14), together with improvements in 
glucose tolerance and insulin sensitivity. Currently, limited lifestyle intervention stud-
ies have reported a potential effect on adipokines and inflammation factors that 
extends periods of 1-2 years. Furthermore, besides the effect of lifestyle intervention 
on adipokines and inflammation factors, more information is also warranted on the 
relationship between inflammation factors and lifestyle intervention outcome. The 
objective of this study was to investigate the effect of a 3-yr lifestyle intervention on 
adipokines and inflammation markers in subjects with impaired glucose tolerance. In 
addition, we established the potential of inflammatory factors as biomarkers for 
lifestyle induced improvements in glucose metabolism and insulin resistance. 
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Methods 
Screening 
The Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM) 
is a randomized controlled trial, designed to study whether a 6-yr combined dietary 
and physical activity intervention program can improve glucose tolerance in subjects 
with impaired glucose tolerance (IGT). Study design, inclusion and exclusion criteria, 
and the diet and exercise program of SLIM have previously been described in detail 
(15; 16). Briefly, subjects with an increased risk for glucose intolerance, e.g. family 
history of diabetes, age >40 years, BMI > 25 kg/m2, were selected from a cohort in the 
area of Maastricht, the Netherlands and invited to undergo a capillary standard oral 
glucose tolerance test (OGTT), response rate 46.2%, see reference (15). Those subjects 
with a 2-h blood glucose concentration > 7.8 mmol/l were invited for a second venous 
OGTT. For inclusion, mean 2-h glucose concentration of both OGTTs had to be be-
tween 7.8 and 12.5 mmol/l and fasting glucose concentration < 7.0 mmol/l. Data 
obtained during the second (venous) OGTT were used as baseline values. Exclusion 
criteria were known diabetes, chronic illness, medication known to interfere with 
glucose tolerance and participation in a vigorous exercise and/or diet program. 
Inclusion 
Screening and inclusion of subjects for the SLIM study occurred between March 1999 
and May 2000 and in 2002. A total of 147 subjects were included in our study. Subjects 
were randomized with stratification for sex and mean 2-hr plasma glucose concentra-
tion to the intervention group (INT: 74 subjects; 38 male, 36 female) or the control 
group (CON: 73 subjects; 37 male, 36 female). From the preliminary 1-yr results of the 
Finnish DPS (17), we calculated that 50–60 subjects per group would be sufficient to 
detect a 1.0 mmol/l difference in 2-h glucose concentration between groups. Of the 
147 subjects enrolled, 106 completed the first 3 years. For regression analysis, four 
subjects were excluded because of missing values for adipokine or inflammation 
factors (data analyses in n =102: 50 INT subjects and 52 CON subjects). Reasons for 
dropout have been reported previously (18). The study protocol was approved by the 
local medical ethical committee of the Maastricht University. All subjects gave written 
informed consent. 
Intervention  
The intervention program consisted of a dietary and physical activity part. Dietary 
recommendations were based on the Dutch guidelines for a healthy diet (Dutch Nutri-
tion Council) and consisted of a carbohydrate intake of at least 55 energy% (E%), a 
total fat intake of 30-35 E%, with a saturated fat intake below 10 E%. A skilled dietician 
gave personal dietary advice during a one-hour counseling session every 3 months, 
after consideration of a 3-day food record (two weekdays, one weekend day). In 
addition, subjects received individual advice on how to increase their level of physical 
Thesis C Roumen V12.pdf   118 14-9-2009   11:11:15
Adipokines, inflammatory factors and 3-yr lifestyle intervention 
 119 
activity to at least 30 minutes a day for at least 5 days a week (19). Furthermore, 
subjects were encouraged to participate in a free, supervised combined aerobic- and 
resistance exercise program, especially designed for this study, which was offered to 
them 4 times a week Participation in the exercise program was monitored and 17 
subjects participated at least once a week during the second and third year. Intensity 
of the exercise program was determined using heart rate monitoring which was ap-
proximately 70% of their maximal peak oxygen consumption (VO2max). Control sub-
jects were only briefly informed about the beneficial effects of a healthy diet and 
physical activity, whereas no individual advice was given. 
Measurements 
In both groups, several measurements were performed annually including an OGTT as 
a measurement of glucose tolerance, insulin levels, VO2max, body weight, waist cir-
cumference, body fat percentage, blood pressure, HBA1c, cholesterol and HDL. Body 
weight was measured with an electronical scale to the nearest 0.1 kg. Waist was 
measured to the nearest 0.5 cm, with the subject in standing position at the level 
midway between the lowest rib and the iliacal crest. Blood pressure was measured 
with a Maxi Stabil 3 sphygmomanometer (CE0047, Speidel en Keller, Jungingen, Ger-
many) in duplo with the subject in supine position, after 10 minutes of rest. The 3-day 
food records were analyzed for nutrient intake using the Dutch food table (NEVO 
version 1996). An incremental exhaustive exercise test was performed on an electroni-
cally braked bicycle ergometer to determine maximal peak oxygen consumption 
(VO2max). The HOMA-IR index for insulin resistance was calculated as described by 
Matthews et al.(20). The incidence of DM2 was determined according to WHO criteria 
of 1999 (21). Low-density lipoprotein (LDL) cholesterol was calculated according to the 
Friedewald formula (22). 
 During the OGTT, plasma glucose, free fatty acids (FFA) and insulin were meas-
ured in the fasting state and after 2 hours, using a standard enzymatic technique, 
automated on a Cobas Fara centrifugal analyzer (intra assay coefficient variation for 
glucose was 1.50%, the inter-assay coefficient variation was 3.66%). Plasma insulin 
concentration was measured with a Radio Immuno Assay (Cat. #HI-14K, Linco Research, 
St. Charles, MO, USA) that shows no cross-reactivity with pro-insulin. Glycated haemo-
globin (HBA1c) was determined in a fasting serum sample with high-performance liquid 
chromatography (reference values for our laboratory 4.4-6.2%). In addition, adipokines 
and inflammation markers are determined. Stored plasma samples were analyzed for 
levels of fasting plasma adiponectin (total adiponectin: full length and globular, coeffi-
cient of variation (CV) 5.8%), resistin (homodimeric, CV 3.7%), leptin (CV 3.7%), PAI-1 
(CV 2.3%) with enzyme-linked immunosorbent assays (Biovendor, Heidelberg, Ger-
many). Samples were analyzed with paired samples from each subject run in the same 
batch. hsCRP, C3 and C4 were measured in duplicate in fasting serum using an 
autoanalyser (Hitachi 912, Roche Diagnostics, Almere, The Netherlands). IL-6 was 
measured in duplicate in fasting EDTA plasma with a high-sensitive ELISA assay (R&D 
systems, Abingdon, United Kingdom). 
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Statistics 
Data analysis was conducted using SPSS for Windows (version 14.1). Data are pre-
sented as mean ± SD or, if not normally distributed (insulin, leptin, adiponectin, resistin, 
CRP, IL-6), as median (25th-75th percentile). Repeated-measures ANOVA were used for 
differences between groups over time. A two-tailed P value of 0.05 was considered 
statistically significant. Multiple linear regression models in the total group (interven-
tion + control) were used to assess whether baseline or 3-yr change of inflammatory 
markers were predictive of the change in 2-hr glucose levels and HOMA-IR index. The 
models used for multiple linear regression analyses are based on the standard model 
(model 1) which is adjusted for inclusion time, study group, age, medication use and 
smoking status and in addition for mean of the dependent and independent variables 
when investigating the changes in inflammatory markers. Lifestyle variables, like body 
weight, maximal aerobic fitness and saturated fat intake were added sequentially to 
each model to assess to what extent the associations were an indirect effect of lifestyle 
factors. 
Results 
Baseline characteristics 
At baseline, inflammation markers were not different between study groups. During 
the 3-yr lifestyle intervention, the intervention group decreased in body weight (-1.1 
kg) and in HOMA-IR (-0.2), whilst the control group increased in these parameters 
(p<0.05, table 7.1). VO2max improved in the intervention group (+0.2 l/min) compared 
to a stable VO2max in the control group (p=0.02). In the intervention group, 2-hr glucose 
levels returned to baseline values whereas 2-hr glucose levels in the control group 
deteriorated (p=0.02). In the intervention group, saturated fat intake decreased more 
compared to the control group (p<0.01). 
Leptin 
Table 7.1 shows that during the 3-yr lifestyle intervention leptin levels increased more 
in the control group (+4.4 ng/ml, 95% CI: 2.3 to 6.6) compared to the intervention 
group (+1.0 ng/ml, 95% CI -0.8 to 2.8; p<0.01). In the total group (intervention and 
control group together), baseline leptin levels were related to changes in 2-hr glucose 
levels, even after adjustment for baseline body weight (table 7.2, model 2). Baseline 
leptin levels were not related to changes in HOMA-IR, when adjusted for baseline body 
weight, VO2max and saturated fat intake (table 7.2, model 3). In the standard model, 
ѐleptin was related to ѐHOMA-IR, but this relationship was abolished when adjusted 
for ѐbody weight (p=0.10, table 7.3, model 2). 
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Table 7.1 Levels of inflammation factors at baseline and after 3 years of follow-up in the SLIM study, 
according to study group. Data are mean±SD or median (25th-75th percentile) 
    Baseline Year 3       
   Intervention Control Intervention Control Group Time Group X 
 Time  
n (male/female) 102 50 (26/24) 52 (27/25) 50 (26/24) 52 (27/25) - - - 
Body weight (kg) 87.5 ± 13.7 82.9 ± 11.7 86.4 ± 13.7 83.1 ± 11.1 0.23 <0.01 0.01 
VO2max (l/min) 2.2 ± 0.6 2.1 ± 0.5 2.4 ± 0.6 2.1 ± 0.7 0.02 <0.01 0.02 
Saturated fat intake (E%) 13.6 ± 2.9 13.6 ± 3.5 10.7 ± 3.0 12.9 ± 3.2 <0.01 <0.01 <0.01 
2-hr glucose  (mmol/l) 8.6 ± 1.6 8.5 ± 1.8 8.5 ± 2.3 9.3 ± 2.5 0.09 0.09 0.02 
HOMA-IR  4.8 ± 2.0 4.6 ± 2.1 4.6 ± 2.1 5.0 ± 2.1 0.81 <0.01 0.04 
Leptin (ng/ml) 19.2  
(15.7-22.7)
16.2  
(13.1-19.4)
20.2  
(16.3-24.2) 
20.7  
(17.0-24.5) 
0.57 <0.01 <0.01 
C3 (g/l) 1.3±0.2 1.3±0.2 1.5±0.3 1.5±0.3 0.78 <0.01 0.92 
PAI-1 (ng/ml) 49.2±16.9 44.0±13.3 29.4±9.7 30.4±9.6 0.94 <0.01 0.43 
Resistin (ng/ml) 3.6  
(3.1-4.0) 
3.6  
(3.2-4.0) 
2.8  
(2.5-3.1) 
2.7  
(2.5-2.9) 
0.76 <0.01 0.58 
CRP (mg/l) 3.9  
(2.9-4.9) 
4.1  
(2.2-6.1) 
3.5 
(2.6-4.5) 
3.9  
(1.9-6.0) 
0.71 0.27 0.77 
IL-6 (pg/ml) 2.2  
(1.0-3.4) 
2.3  
(1.6-3.0) 
2.2  
(1.0-3.4) 
2.8  
(1.6-4.1) 
0.18 0.11 0.95 
Adiponectin (ug/ml) 13.4  
(11.5-15.2)
14.2  
(12.4-15.9)
9.1  
(8.0-10.2) 
8.9  
(8.0-9.8) 
0.27 <0.01 0.66 
C3 
The lifestyle intervention did not affect C3 levels (table 7.1). In the total group, base-
line C3 levels were not associated with changes in 2-hr glucose levels or HOMA-IR 
(table 7.2). ѐC3 and ѐHOMA-IR were positively related in the standard model but this 
relationship disappeared after adjustment for body weight (table 7.3, model 2). The 
positive relation between ѐC3 and 2-hr glucose concentration in the standard model 
became non-significant after additional adjustment for changes in body weight, satu-
rated fat intake and VO2max (p=0.07, table 7.3, model 3). 
PAI-1 
The lifestyle intervention did not affect PAI-1 levels. Baseline PAI-1 was not associated 
with change in HOMA-IR or 2-h glucose (table 7.2). In the total group, ѐPAI-1 was 
positively associated with ѐHOMA-IR, even after adjustment for change in body weight, 
VO2 max and saturated fat intake (p=0.02, table 7.3, model 3). 
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Table 7.2 Multivariable associations between baseline levels and changes in HOMA-IR and 2-hr glucose 
levels during the 3-yr SLIM lifestyle intervention. Models are built with increasing complexity.  
  Model 1  Model 2  Model 3 
  Standardized 
ɴ 
P  Standardized 
ɴ 
P  Standardized 
ɴ  
P 
ѐ HOMA-IR Baseline Leptin -0.20 0.13  -0.34 0.03  -0.22 0.25 
N=93 Baseline C3 0.05 0.61  0.04 0.74  -0.07 0.55 
 Baseline PAI-1 -0.04 0.68  -0.06 0.54  -0.17 0.16 
 Baseline Resistin 0.02 0.84  0.02 0.87  0.05 0.68 
 Baseline CRP 0.10 0.33  0.09 0.39  0.09 0.46 
 Baseline IL-6 0.11 0.29  0.11 0.31  0.04 0.75 
 Baseline Adiponectin -0.14 0.26  -0.14 0.25  -0.16 0.20 
          
ѐ 2-hr Glucose Baseline Leptin -0.28 0.03  -0.37 0.02  -0.17 0.38 
N=102 Baseline C3 -0.15 0.13  -0.16 0.15  -0.22 0.06 
 Baseline PAI-1 -0.04 0.67  -0.02 0.83  -0.11 0.32 
 Baseline Resistin 0.15 0.26  0.16 0.25  0.08 0.59 
 Baseline CRP 0.04 0.68  0.05 0.62  0.03 0.79 
 Baseline IL-6 -0.06 0.53  -0.05 0.61  -0.14 0.22 
 Baseline Adiponectin -0.05 0.64  -0.05 0.66  -0.48 0.70 
Model 1: Adjusted for, inclusion time, study group, age, medication use and smoking status. 
Model 2: Model 1 + adjustment for baseline body weight. 
Model 3: Model 1 + adjustment for baseline body weight, maximal aerobic fitness and saturated fat intake 
Resistin 
The lifestyle intervention did not affect resistin levels and baseline resistin levels 
showed no association with ѐHOMA-IR or ѐ2-hr glucose (table 7.2). However, ѐresistin 
was inversely associated with ѐHOMA-IR (table 7.3, model 1). Adjustment for changes 
in body weight did not change this association (table 7.3, model2). The relationship 
became borderline significant (p=0.07) after additional adjustment for changes in 
saturated fat intake and VO2max. 
CRP 
The lifestyle intervention did not affect CRP levels. Also, (the change in) CRP levels did 
not show any relationship with changes in HOMA-IR or 2-hr glucose (table 7.2 and 
table 7.3). 
Thesis C Roumen V12.pdf   122 14-9-2009   11:11:15
Adipokines, inflammatory factors and 3-yr lifestyle intervention 
 123 
IL-6 and Adiponectin 
The lifestyle intervention did not alter the levels of IL-6 and adiponectin. Nor baseline, 
neither change in these adipokines was related to (change in) HOMA-IR or 2-hr glucose 
(table 7.2 and table 7.3). 
 
Table 7.3 Multivariable associations between changes inflammation factors and changes in HOMA-IR and 2-
hr glucose during the 3-yr SLIM lifestyle intervention. Models are built with increasing complexity.  
  Model 1  Model 2  Model 3 
  Standardized 
ɴ 
P  Standardized 
ɴ 
P  Standardized 
ɴ 
P 
ѐ HOMA-IR ѐ Leptin 0.49 <0.01  0.20 0.10  0.07 0.65 
N=93 ѐ C3 0.29 0.01  -0.05 0.65  -0.09 0.49 
 ѐ PAI-1 0.32 0.01  0.24 0.02  0.28 0.02 
 ѐ Resistin -0.37 0.04  -0.38 0.01  -0.36 0.07 
 ѐ CRP 0.11 0.31  -0.03 0.77  -0.04 0.70 
 ѐ IL-6 0.01 0.97  -0.03 0.79  -0.01 0.95 
 ѐ Adiponectin -0.01 0.95  0.01 0.95  -0.02 0.90 
          
          
ѐ 2-hr Glucose ѐ Leptin 0.12 0.23  -0.04 0.77  -0.16 0.35 
N=102 ѐ C3 0.26 <0.01  0.18 0.11  0.24 0.07 
 ѐ PAI-1 0.18 0.08  0.14 0.17  0.05 0.71 
 ѐ Resistin -0.27 0.09  -0.26 0.09  -0.10 0.63 
 ѐ CRP 0.07 0.48  0.20 0.03  0.17 0.14 
 ѐ IL-6 0.11 0.26  0.10 0.30  0.14 0.26 
 ѐ Adiponectin 0.01 0.96  0.00 1.00  -0.19 0.27 
Model 1: Adjusted for mean of the dependent and independent, inclusion time, study group, age, medica-
tion use and smoking status. 
Model 2: Model 1 + adjustment for change in body weight 
Model 3: Model 1 + adjustment for change in body weight, maximal aerobic fitness and saturated fat intake 
Discussion 
After adjustment for baseline body weight, maximal aerobic capacity and saturated fat 
intake, none of the baseline parameters measured were related to changes in esti-
mated insulin resistance. At baseline, high leptin levels were predictive of an improve-
ment of glucose tolerance and this association was independent of baseline body 
weight. The association was also independent of baseline 2-hr glucose levels. It would 
go beyond the scope of this study to discuss the mechanism behind this association. 
Although speculative, high baseline leptin levels in our subjects may reflect leptin 
resistance, similar to insulin resistance, with increasing leptin concentrations target 
cells become resistant to its actions (23). It is also possible that a high secretion of 
leptin per unit fat mass may stimulate fatty acid oxidation and improve the metabolic 
profile (24). 
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During this study, leptin levels increased more in the control compared to the inter-
vention group and there was a significant relationship between change in leptin levels 
and change in HOMA-IR, an effect that disappeared after correction for change in body 
weight. Exercise is also know to reduce circulating leptin levels (25), and the 1-yr 
results of this study (14) have suggested an association between changes in leptin 
levels and HOMA-IR partly independent of changes in body composition, possibly 
reflecting a change in leptin sensitivity. However, it can be speculated that after 3 
years, the impact of body weight changes seem to predominate the possible exercise- 
induced effect on leptin sensitivity. 
 The 3-yr changes in PAI-1 levels were related to changes in HOMA-IR, independ-
ent of changes in body weight, maximal aerobic capacity and saturated fat intake. This 
is in agreement with previous results in non-diabetic healthy subjects who found an 
association between the changes in PAI-1 and the changes in HOMA-IR after a follow-
up of 5.2 years (26). The finding that the relationship between PAI-1 and HOMA-IR 
persisted after correction for changes in body weight indicates that changes in adipo-
cyte function rather than fat mass per se may contribute to the improved metabolic 
profile. Multiple factors seem to influence PAI-1 expression (27) and diabetes inci-
dence, e.g. triglycerides, free fatty acids, glucose and subclinical inflammation, suggest-
ing that changes in PAI-1 may be a marker of the complex mechanism underlying 
obesity and diabetes development. 
 The 3-yr changes in C3 levels were positively associated with changes in 2-hr 
glucose levels, which was for a large part explained by change in body weight. Previous 
studies have shown a relationship between C3 and 2-hr glucose in non-diabetic Pima 
Indians (28) and with diabetes development in men aged 38–50 years (6), independ-
ently of abdominal and general obesity. The attenuation of the relationship between 
changes in C3 and 2-hr glucose may be due to the relatively small sample size. Al-
though C3 is mainly produced in the liver, the finding that body weight attenuated the 
relationship indicates that C3 may also be produced by other tissues like adipose tissue. 
However, an indirect effect of adipose tissue mass (29) (i.e. FFA inducing inflammation 
(30)) on liver C3 production also offers a plausible explanation. Another possible 
explanation may be that C3 levels reflect ASP, the proteolytic fragment of C3, which 
stimulates glucose uptake and lipid storage in adipose tissue (31; 32). A reduced 
uptake of glucose and fatty acids in adipose tissue of IGT subjects could be related to a 
blunted response to activation of the C3-ASP system. 
 Based on animal and in vitro data, resistin was originally thought to be a hormone 
linking obesity with insulin resistance (7). In contrast with other human studies (8; 9) 
we did find a relationship between changes in resistin and changes in insulin resis-
tance , which was independent of changes in body weight. Further studies have to 
elucidate the exact role of resistin in insulin resistance 
 In conclusion, the 3-yr SLIM lifestyle intervention blunts the increase in leptin 
levels, compared to the control group. At baseline, high leptin levels are predictive of 
improvements of glucose tolerance, independent of baseline body weight, suggesting 
a role of leptin mediating glucose tolerance, partly independent of body fat mass. A 
trend was observed for a relationship between 3-year changes in resistin levels and 
changes in HOMA-IR and between changes in C3 levels and changes in 2-hr glucose 
levels. Lifestyle intervention did not affect PAI-1 levels, despite a positive association 
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between the changes in PAI-1 levels and changes in estimated insulin resistance. 
Baseline leptin levels are reflective of baseline body weight and are indicative of 
beneficial lifestyle-induced changes in 2-hr glucose levels.  
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Abstract 
Objective 
To evaluate the effect of a lifestyle intervention on serum transferrin and ferritin levels 
and the relationship between changes in transferrin and ferritin and changes in glu-
cose tolerance and insulin resistance. 
Method 
Randomized controlled lifestyle intervention directed at a healthy diet and increased 
physical activity in subjects with IGT. 
Results 
After 1 year, ferritin levels tended to decrease in the intervention group as compared 
to the control group (p=0.06). Transferrin change was independently related to the 
change in HOMA-IR and ferritin change was related to the change in 2-hr FFA. 
 
Conclusions 
Changes in insulin sensitivity and postprandial lipid metabolism are related to changes 
in iron metabolism. 
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Introduction 
High serum transferrin and ferritin levels have been associated with the onset of 
hyperglycemia, insulin resistance and type 2 diabetes in several studies (1, 2), indicat-
ing that the iron status may play a role in the etiology of type 2 diabetes. The novelty 
of the present study is that it aims to evaluate the effect of lifestyle changes on trans-
ferrin and ferritin levels and the relationship between changes in transferrin and 
ferritin concentration and glucose tolerance and insulin resistance. 
Methods 
The SLIM study (Study on Lifestyle Intervention and Impaired Glucose Tolerance 
Maastricht) is a randomized controlled trial investigating a 6-yr dietary and physical 
activity intervention on glucose tolerance in subjects with impaired glucose tolerance 
(IGT). The local Medical Ethical Review Committee approved the study protocol. The 
study design has been described before (3). Participants gave their informed consent 
before the start of the study. 
Study design and subjects 
The study is described previously (3). For inclusion, mean 2-hr glucose concentration of 
2 oral glucose tolerance tests had to be between 7.8 and 12.5 mmol/l and fasting 
glucose concentration < 7.8 mmol/l. Originally, 147 subjects were randomized to a 
intervention (INT) or control group (CON), with stratification for 2-hr glucose levels and 
sex. The one-year examination included 129 subjects (see table 8.1). 
Lifestyle intervention 
Intervention subjects were individually guided (every 3 months visits) to achieve a 
healthy diet of 55 Energy% carbohydrates, 35 Energy% fat, <10 Energy% saturated fat 
and more than 3 g/MJ fiber each day, and to increase physical activity to at least 30 
minutes a day for at least 5 days a week. Subjects were encouraged to participate in a 
free aerobic- and resistance exercise program. Control subjects received annually 
general information about the beneficial effects of a healthy diet and increased physi-
cal activity. 
Laboratory and clinical measurements 
Body weight was measured with an electronical scale to the nearest 0.1 kg. Waist was 
measured to the nearest 0.5 cm, with the subject in standing position at the level 
midway between the lowest rib and the iliacal crest. Plasma glucose, free fatty acids 
(FFA) were measured after an overnight fast and 2 hours after the use of a 75 gram 
glucose drink (OGTT), with standard enzymatic techniques, automated on a Cobas Fara 
centrifugal analyzer. Plasma insulin concentration was measured before and during the 
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OGTT with a Radio Immuno Assay (Cat. #HI-14K, Linco Research) that shows no cross-
reactivity with pro-insulin. Transferrin, ferritin and high-sensitive C-reactive protein 
(CRP) were measured after an overnight fast in serum using an autoanalyser (Hitachi 
912, Roche Diagnostics, Almere, The Netherlands). The HOMA-IR index for insulin 
resistance was calculated as described by Matthews et al. (1985) (4).  
Statistical analysis 
Insulin, FFA, ferritin, CRP were not normally distributed and were ln-transformed. 
Subjects with CRP (n=12) levels above 10 mg/l were excluded from analysis. Changes 
over time between groups were assessed using ANOVA (SPSS for Windows 14.0). 
Multiple linear regressions were used to evaluate the relationship between the indi-
vidual changes in transferrin and ferritin and the individual changes in glucose levels 
and insulin resistance. 
Results 
Table 8.1 Subjects characteristics at baseline and after 1 year.  
  
Baseline Year 1 Time Group Group 
x Time 
  INT CON INT CON P P P 
 N 64 (35m/29f) 65 (34m/31f) 64 (35m/29f) 65 (34m/31f)    
Body weight (kg) 86.7±1.60 84.1±1.59 84.4±1.53 83.5±1.53 <0.001 0.46 0.01 
BMI (kg/m2) 29.62±0.45 29.60±0.45 28.83±0.44 29.41± 0.44 <0.001 0.66 0.01 
Waist  (cm) 102.95±1.25 103.22±1.24 100.11±1.31 101.60± 1.30 <0.001 0.62 0.15 
Vo2 max (l/min) 2.28±0.08 2.10±0.08 2.38±0.08 2.11±0.08 0.01 0.06 0.03 
Fasting glucose (mmol/l) 6.05±0.10 5.89±0.10 5.95±0.10 5.94±0.10 0.61 0.52 0.12 
2-hr glucose (mmol/l) 8.82±0.25 8.55±0.24 8.2±0.27 8.79±0.27 0.28 0.62 0.01 
Fasting insulin (mU/l) 17.78±1.01 17.45±1.00 16.03±0.99 17.68±0.97 0.26 0.64 0.32 
2-hr insulin (mU/l) 97.79±10.38 100.19±10.47 90.31±9.71 104.45±9.80 0.96 0.48 0.05 
HOMA-IR  4.88±0.32 4.64±0.32 4.32±0.30 4.74±0.30 0.25 0.81 0.22 
Transferrin (g/l) 2.56±0.05 2.44±0.05 2.55±0.05 2.44 ±0.05 0.82 0.08 0.72 
Ferritin (µg/l) 164.10±21.54 188.64±21.20 143.80±18.77 165.22±18.48 <0.001 0.41 0.06 
Fasting FFA (µmol/l) 602.61±25.58 567.00±25.38 476.04±18.08 480.44±17.94 <0.001 0.69 0.12 
2-hr FFA (µmol/l) 114.30±7.68 100.75±7.61 80.57±4.67 86.51±4.63 <0.001 0.90 0.02 
CRP (mg/l) 2.94±0.30 3.02±0.28 2.49±0.31 3.07±0.29 0.04 0.25 0.16 
Data are mean ± SEM. (n=129). P was measured by ANOVA repeated measures. For all skewed variables 
(fasting insulin, 2-hr insulin, HOMA-IR, transferrin, ferritin) statistics were performed on ln-transformed 
values. 
Baseline characteristics 
At baseline, INT subjects were younger than CON subjects (54.9±0.83 yr versus 
58.4±0.87 yr, p=0.004). 18 Subjects (6 male, 12 female; 10 INT, 8 CON) discontinued 
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the study and were excluded. They had a lower VO2 max, higher 2-hr glucose levels 
(pall<0.05) and a higher BMI (p=0.06) at baseline than those who continued participa-
tion. 
Results of 1-yr intervention 
INT subjects decreased more in body weight and BMI versus CON (p<0.05). Mean 2-hr 
glucose, 2-hr insulin, 2-hr FFA decreased more in INT (pall<0.05) and ferritin tended to 
decrease compared to the CON group (table 8.1). VO2 max increased in INT with no 
changes in CON. Change in transferrin level was similar across groups.  
 
 
Table 8.2 Standardized regression coefficients of 1-yr changes in transferrin and ferritin regressed 1-yr 
changes in metabolic parameters.  
Change in Transferrin P Transferrin P Ferritin P Ferritin P 
  Unadjusted  Adjusted  Unadjusted  Adjusted  
Change in BMI (kg/m2) 0.217 0.018 0.221 0.019 0.042 0.638 0.010 0.912 
Change in Waist (cm) 0.118 0.193 0.172 0.064 -0.007 0.937 -0.035 0.705 
Change in Fasting Glucose (mmol/l) 0.146 0.139 0.185 0.064 -0.006 0.954 -0.032 0.744 
Change in 2-hr Glucose (mmol/l) 0.133 0.174 0.132 0.184 0.119 0.210 0.080 0.405 
Change in Fasting Insulin (mU/l) 0.299 0.001 0.292 0.002 0.001 0.987 -0.024 0.799 
Change in 2-hr Insulin (mU/l) 0.188 0.063 0.153 0.148 0.050 0.613 0.016 0.875 
Change in HOMA  0.295 0.002 0.305 0.001 -0.002 0.982 -0.032 0.736 
Change in Fasting FFA (µmol/l) 0.214 0.038 0.199 0.066 0.090 0.366 0.074 0.482 
Change in 2-hr FFA (µmol/l) -0.037 0.725 <0.001 0.998 0.224 0.020 0.225 0.030 
Change in CRP (mg/l) -0.002 0.983 -0.003 0.974 0.174 0.067 0.157 0.105 
Unadjusted: regression analysis adjusted for the baseline value of the dependent and independent variables. 
Adjusted: regression analysis adjusted for age, gender, random assignment and the baseline value of the 
dependent and independent variables. Data are expressed as standardized betas. For all skewed variables 
(fasting insulin, 2-hr insulin, HOMA-IR, fasting FFA, 2-hr FFA, CRP, transferrin, ferritin) statistics were 
performed on ln-transformed values. 
 
Regression analyses 
Changes in transferrin and ferritin were inversely associated (r= -0.49; p<0.01). Change 
in transferrin was higher in men than in women, was positively associated with change 
in BMI, fasting insulin, HOMA-IR and fasting FFA (palll<0.05), and tended to be associ-
ated with change in 2-hr insulin (table 8.2). ѐTransferrin explained 7.5% of the change 
in ѐHOMA-IR (p=0.02). Results were comparable when analysis was performed on INT 
and CON separately (data not shown). After adjustment for age, gender and study 
group, change in transferrin remained independently associated with change in BMI, 
fasting insulin and HOMA-IR. In addition, the association between change in transferrin 
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and change in HOMA-IR was also independent of changes in BMI and fasting FFA 
(ɴ=0.285 g/l, p=0.02). When replacing HOMA-IR with fasting insulin, results were 
essentially similar (ɴ=0.252 mU/l, p=0.04). 
 For serum ferritin, no association with changes in glucose tolerance or insulin 
sensitivity were observed. Change in serum ferritin was significantly positively associ-
ated with change in ѐ2-hr FFA, independent of age, gender, study group and change in 
CRP (ɴ=0.247 µg/l, p=0.02). 
Discussion 
Epidemiological studies have demonstrated that the iron metabolism may be involved 
in the etiology of type 2 diabetes (1, 2, 5). In our observational study, changes in 
transferrin levels were positively associated with changes in estimated insulin resis-
tance in subjects at high risk for developing type 2 diabetes, i.e. those with impaired 
glucose tolerance. Although these data do not imply causality, they are compatible 
with the results of the DESIR study (1), which showed that transferrin predicted 
changes in fasting insulin. The mechanism behind the relationship between transferrin 
and insulin resistance is still unclear. This study and the DESIR findings merit further 
investigation to clarify causality between transferrin, insulin resistance and the devel-
opment of type 2 diabetes. 
 Our intervention program did not affect transferrin, possibly due to the variation 
in response to the lifestyle intervention within study groups. Our intervention program 
tended to reduce ferritin, which has been associated with type 2 diabetes onset (2), 
fasting insulin and fasting glucose (1). In other studies, ferritin and other inflammation 
markers such as C-reactive protein have also been associated with the metabolic 
syndrome (6, 7). In our study, ferritin and 2-hr FFA levels were positively associated, 
independent of CRP as an indicator of the acute phase response, suggesting involve-
ment of the iron status itself in the regulation of 2-hr FFA levels. The mechanism by 
which iron may stimulate lipolysis is unclear, but ferritin may catalyze hydroxyl radicals 
(8) and contribute to insulin resistance. 
 In conclusion, lifestyle-induced changes in transferrin levels were related to 
changes in fasting insulin, whilst change in ferritin was related to change in postpran-
dial fatty acids. These data have shown an association between changes in insulin 
sensitivity and postprandial lipid metabolism with changes in iron metabolism. 
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Over decades type 2 diabetes has changed from a chronic metabolic disease in elderly 
into a major health problem affecting an increasing number of people worldwide (1). 
Diabetes-related complications are considerable and prevention and treatment of 
diabetes are of utmost importance to increase quality of life and reduce the increasing 
health care costs. Pharmacological treatment has shown to be effective in reducing 
diabetes risk, but lifestyle interventions have shown to be even more effective than 
pharmacological treatment (2; 3). Even more, the effect of lifestyle interventions is 
sustained over more than a decade after active counseling is discontinued (4; 5). 
However, non-adherence to lifestyle interventions is a widespread problem (6) and 
tends to be high with increasing time and complexity and when designed to prevent 
rather than cure illness (7). In this thesis, we focused on the potential benefits of a 
combined nutritional and exercise intervention strategy to stimulate a healthy lifestyle 
and, as such, improve glucose tolerance, insulin sensitivity and prevent/postpone the 
development of type 2 diabetes in a group of subjects at risk. In addition, this thesis 
describes potential behavioral as well as metabolic factors related to lifestyle outcome 
and adherence, in light of future implementation strategies. 
9.1 Can lifestyle intervention prevent or postpone the development of 
type 2 diabetes? 
It has been known for several years that lifestyle interventions targeting changes in 
dietary intake and composition and changes in physical activity frequency and intensity 
reduce diabetes risk in IGT subjects (2; 8; 9) (as reviewed in chapter 2). Based on 
estimates from the Diabetes Prevention Program (DPP), lifestyle interventions seem to 
postpone diabetes onset with approximately 11 years, and prevent diabetes onset 
with 20% (10). In recent years, more has become known about long-term effectiveness 
(3-5) and cost-effectiveness (10-12). 
 In chapter 3, we showed that the SLIM lifestyle intervention, following general 
public health guidelines, is effective in reducing body weight (-1.1 kg) and improving 
maximal aerobic capacity (VO2max) (+0.05 l/min) (13). After 3 years, the 0.8 mmol/l 
difference in 2-hr glucose levels between study groups was associated with a 58% 
reduction in diabetes incidence. This is consistent with the diabetes risk reductions 
found in the major lifestyle intervention studies in the USA and Finland, i.e. the DPP (2) 
and DPS (8).The course of body weight and 2-hr glucose levels is similar to that found 
in the Diabetes Prevention Study (DPS). They showed a weight reduction of о4.5 kg and 
a 2-hr glucose reduction of -0.9 mmol/l during the first year and a regain of approxi-
mately 1 kg and 0.4 mmol/l after 3 years, respectively (14). 
 At the end of the SLIM study, after minimal 3 years and maximal 6 years of inter-
vention (mean 4.1 years), a significant beneficial effect remained on VO2max (0.3 l/min 
difference between intervention and control group). 2-hr Glucose (0.7 mmol/l differ-
ence between intervention and control group) improved and dietary composition 
improved (reduced total and saturated fat, increased fiber and carbohydrate intake), 
despite loss of effect on body weight (chapter 4). Including all available observations, 
diabetes risk reduction was 47% for the intervention group relative to the control 
group. Most lifestyle interventions show a beneficial lifestyle effect on diabetes risk, 
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while the effect on 2-hr glucose levels have been far less consistent (chapter 2). Inter-
estingly, in the DPS a borderline effect on 2-hr glucose (-0.1 mmol/l, p=0.07) is still 
associated with a diabetes risk reduction of 58% (14). Part of the risk reduction may be 
mediated via other pathways than 2 hr-glucose, e.g. on fasting glucose levels, via sub-
clinical inflammatory factors (15) or restoration of ɴ-cell function (16). 
 Lifestyle interventions, i.e. SLIM, have shown to be more cost-effective than 
metformin treatment (10; 11) and have shown to be effective resulting in sustained 
beneficial effects on 2-hr glucose levels and diabetes risk. 
9.2 Lifestyle intervention and the metabolic syndrome 
As mentioned above, current evidence clearly indicates the effect of lifestyle interven-
tions in reducing diabetes incidence as clinical endpoint. However, do lifestyle inter-
ventions also reduce metabolic syndrome features? 
 In recent years, the metabolic syndrome has evolved as a term for a clustering of 
metabolic disorders associated with diabetes and cardiovascular risk, including most 
often criteria for hypertension, (abdominal) obesity, a disturbed blood lipid spectrum 
and an impaired glucose metabolism. Several definitions of the metabolic syndrome 
exist (17), and besides the debate regarding whether obesity or insulin resistance plays 
a central role in the in the underlying pathophysiology, the clinical relevance of the 
syndrome has not been established yet. In chapter 3, we did not observe a lifestyle 
intervention-induced effect on the prevalence the metabolic syndrome or the individ-
ual components waist circumference, fasting trigyceride levels, HDL cholesterol levels, 
blood pressure or fasting glucose levels, despite a marked improvement in 2-hr glucose. 
The minor changes in body weight and waist circumference may be responsible for the 
lack of effect on the metabolic syndrome. In the DPP (18) and DPS (19), a lifestyle 
intervention reduced the incidence of metabolic syndrome by 38-41%. In both studies, 
the reduction in metabolic syndrome appeared strongly related to a reduction in waist 
circumference, while in SLIM no significant changes in waist were observed after 3 
years. It seems that sustained body weight loss, and primarily reduced abdominal fat, 
is necessary to reduce the metabolic syndrome. A recent 15-week low-calorie diet 
showed that body weight loss of nearly 10% reduces the metabolic syndrome by 61%, 
in obese, primarily female subjects (20). 
9.3 Dropout and adherence 
Lifestyle interventions face the challenge of keeping participants in the program and 
sustaining adherence to the program, especially when implemented in the health care 
system. Dropout to the SLIM intervention was 28% after 3 years (chapter 3), compared 
to a dropout rate of 8% and 7.5% in the DPS and DPP, respectively. It is not entirely 
clear why the dropout rate in SLIM is higher compared to the DPS and DPP. However, 
subjects in SLIM had less overweight compared to the subjects in the DPS and DPP. 
Therefore, our SLIM subjects may have had more difficulties to loose weight and be 
satisfied about it. In addition, we observed that half of the SLIM participants had a low 
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socio-economic status, which was a strong determinant of dropout (chapter 4). In 
Europe, mortality rates and poorer self-assessments of health, are higher in groups of 
lower socioeconomic status compared to the higher-status counterparts (21). Recent 
Dutch research has also shown that higher educated people not only live longer, but 
also spend a longer period of their lives in good health (22). In the SLIM study, ap-
proximately 50% of the subjects had a low socio-economic status, which is higher than 
the general proportion in Limburg in 2006, ranging from 33-38% (23). Although the 
SLIM population may not be a representative sample of the general population, it may 
well represent the vulnerable group at high risk for diabetes and other metabolic 
disturbances. The high dropout rate in the SLIM study is worrisome and exemplifies 
the difficulty to reach and sustain lifestyle changes in this vulnerable group and, as 
such, increase the quality of life. The dropout rate of SLIM is not specific for lifestyle 
interventions. Also non-lifestyle studies have reported high drop-out rates, i.e. the 
DREAM trial (24), with 29.3% dropout in the rosiglitazone group. 
 In chapter 5, we showed that a low perceived susceptibility to getting diabetes 
and misconception about own adherence are associated with non-adherence in par-
ticipants. Increasing awareness could be a way to improve adherence in participants as 
well as clinicians, since awareness and perception of advantages (25; 26) have been 
shown to play a critical role in adherence of a certain behavior. Perceived susceptibility, 
as well as awareness and motivation have also been found important mediators of 
participation (26). Also, restricting the travel time towards the exercise facility could 
have improved adherence, although our study did not confirm this (27). Both sufficient 
participation and adherence to the lifestyle changes are necessary for cost-effective 
implementation in the general population (28). Increasing awareness and changing 
perceived susceptibility to one that is more likely to be true may reduce refusal and 
dropout to the lifestyle program, although scientific studies are warranted that study 
these approaches. Other factors that were associated with decreased adherence like 
doing the shopping and cooking or being male are more difficult to explain and need 
further investigation. 
9.4 Lifestyle approach versus pharmacological approach 
Not all subjects that initially participate in lifestyle interventions comply with the 
regime, respond metabolically and are able to continue adherence. For subjects that 
are unable to adhere or do not show a beneficial metabolic response, a pharmacologi-
cal approach, with or without lifestyle changes, may be considered. In the prevention 
and treatment of diabetes, pharmacological approaches have also been used and with 
success (3; 24). Unfortunately, the effect by medication is only present when adhering 
to the prescription and is not sustained over several years after discontinuation, as is 
the case for lifestyle interventions (4; 5). 
 In the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication 
(DREAM) trial, subjects with IGT, IFG, or both were randomly assigned to receive 
rosiglitazone or placebo for a median of 3 years (24). Rosiglitazone substantially re-
duced incident type 2 diabetes (hazard ratio 0.36 for isolated IGT) and a larger number 
of subjects receiving rosiglitazone progressed towards normoglycemia (hazard ratio 
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1.7) than did individuals receiving placebo. However, the occurrence of heart failure 
was higher in the rosiglitazone group (hazard ratio 7.0), as tended the overall cardio-
vascular events (p=0.08). In light of prevention of major cardiovascular events, a recent 
study from the USA and Canada showed that compared to standard drug therapy, 
intensive drug therapy to target normal glycated hemoglobin levels for 3.5 years, using 
several medications, increased mortality and did not significantly reduce cardiovascu-
lar events (29). New pharmacological approaches on diabetes incidence and cardiovas-
cular outcome are currently investigated in subjects with IGT, like the effect of valsar-
tan, a selective angiotensin II antagonist acting on the AT1 receptor subtype (30). 
Lifestyle interventions can have multiple beneficial metabolic effects beyond glycemic 
control and should therefore remain the cornerstone in the prevention and treatment 
of type 2 diabetes. Pharmacological treatment targeting glycemic control is a plausible 
treatment for subjects with incident type 2 diabetes when lifestyle interventions have 
not reached a beneficial effect. 
9.5 Factors associated with the lifestyle-induced effect on glucose 
tolerance, insulin resistance and diabetes risk 
The total effect of lifestyle interventions depends on its components namely the 
effects on body weight, body composition, dietary intake and composition and physical 
activity. Genetic susceptibility and gender can mediate the lifestyle-induced effect. 
9.5.1 Body weight 
In the Netherlands, approximately 46% of the Dutch adults were overweight in 2007 
(31), which seems to be the most important risk factor for type 2 diabetes (32-36). In 
the SLIM study, body weight loss and reduced waist circumference were the strongest 
predictors of changes in 2-hr glucose levels, as discussed in chapter 4. Although body 
weight is the strongest predictor of 2-hr glucose in SLIM, at the end of the study a 
beneficial effect on 2-hr glucose levels was sustained, most likely due to sustained 
changes in dietary composition and VO2max. In the SLIM study, 1-year changes in 
insulin sensitivity were partly related to changes in fatty acid profile of serum choles-
teryl esters (which partly reflect dietary fatty acid intake), and in particular to changes 
in desaturase activities (37). This suggests that the shift in fatty acid composition of the 
diet (reduced saturated fat) may have explained part of the positive lifestyle effects. 
 Not all adipose tissue depots seem to have an equal contribution to diabetes risk. 
A study has shown that a minor loss of body weight, accompanied by a major reduc-
tion in visceral and liver fat, was associated with improved insulin sensitivity (38; 39). 
Reductions in visceral fat depot may depend on the initial fat size (40-42). It is still 
unclear if there is an inverse dose-response relationship between a reduction in 
visceral fat and insulin sensitivity, or if the visceral fat depot has to decrease below a 
specific threshold to have a metabolic benefit (38). To date, the results of SLIM once 
more reinforce that reductions in body weight and especially waist circumference are 
most strongly associated with a reduced diabetes risk. Future studies have yet to 
determine to what extent body fat distribution and changes in adipose tissue depots 
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add to the metabolic benefits of traditional lifestyle factors, i.e. body weight reduction, 
improved dietary composition and increased physical activity. 
9.5.2 Dietary composition 
Dietary intake and dietary composition have attributed to the obesity and diabetes 
epidemic. Therefore, it is rational to realign our eating habits with our physiological 
needs (43). The term ’dietary pattern’ comprises multiple components and this section 
will highlight several of them, including fat, fiber, carbohydrate intake, and glycemic 
index. 
 Total fat, and especially saturated fat intake is an important diabetes risk factor 
(44; 45). Reduced-fat diets without energy restriction have been shown to reduce 
weight with 3-5 kilograms (46; 47), sustain weight loss and reduce diabetes incidence 
(45). In chapter 3 and chapter 4, we confirmed that changes in dietary composition 
towards a reduction in total and saturated fat, and an increase in carbohydrate and 
fiber intake, was associated with a beneficial effect on 2-hr glucose levels and a reduc-
tion in diabetes incidence. A reduction in total fat intake may affect diabetes develop-
ment by a decrease in lipid overflow and triglyceride storage in other tissues than 
adipose tissue. Although the type of fatty acids may also play a role in the develop-
ment of type 2 diabetes (37; 48; 49), we did not investigate this in this thesis. 
 Dietary fibers can reduce the rate of glucose absorption in the intestine, thereby 
lowering postprandial glycemic, insulinemic responses (50) and improving insulin 
sensitivity (51). In SLIM, fiber intake increased more in the intervention group, as 
compared to the control group (chapter 3) and a recent meta-analysis once more 
established the importance of dietary fibers in reducing diabetes risk (52). In the DPS 
(45), high fiber was a independent contributor to a reduced diabetes risk. High glyce-
mic-index, low-fiber diets, independently increase the risk of type 2 diabetes and 
cardiovascular disease (53; 54). A reduced glycemic response diet seems to improve ɴ-
cell function in IGT subjects (55). In addition, a recent meta-analysis and review has 
shown that a reduced glycemic response diet in combination with unavailable carbo-
hydrate intake is followed by favorable changes in, among others, insulin sensitivity 
(56). 
 Proteins of high biological value, i.e. whey protein, seem to have a high potential 
of reducing postprandial glucose levels as well as to increase satiety (57). Another 
potential dietary factor is alcohol use. Light to moderate alcohol use (defined as 0.5 to 
1 drink daily for women, and 1 to 2 drinks daily for men) is associated with increased 
insulin sensitivity, lower postprandial glucose levels and better health (58; 59). With 
regard to the relationship between alcohol abuse and diabetes development, little 
information has been published. In SLIM, we did not observe a significant change in 
alcohol use and total protein intake (chapter 3). 
 The SLIM study shows that an intervention consisting of four meetings a year with 
a trained dietician with advice for a healthy diet is effective in changing the dietary 
composition towards reduced fat and increased carbohydrates and fiber intake after 3-
6 years. Although these changes may help to reduce diabetes risk, body weight reduc-
tion seems the most important factor. 
Thesis C Roumen V12.pdf   143 14-9-2009   11:11:16
Chapter 9 
 144 
9.5.3 Physical activity 
In the Netherlands and across most European countries less than half of the popula-
tion is sufficiently active. The Eurobarometer study in 2006 showed that the preva-
lence of sufficient physical activity for health (5 times a week 30 minutes moderately 
active or 3 times a week vigorously active) across the Netherlands was 44%, ranging 
from 40% in women to 48% in men (60). Among European countries, the Netherlands 
had the highest prevalence of people with sufficient physical activity, while in contrast, 
it also inhabited the second-highest prevalence of people who sit at least 6 hours per 
day (60). More studies regarding sedentary time should be performed, but there 
seems to be a positive correlation with waist circumference, independent of moder-
ate-to-vigorous physical activity (61). 
 In SLIM, we showed that the lifestyle intervention was effective in increasing 
VO2max after 3-6 years (chapter 3 and chapter 4) and in the intervention group this 
was accompanied by an increased number of days that subjects were at least 30 min 
physically active (bicycling, gardening or doing sports). In addition, we showed that 
VO2max is higher in subjects that continue participation of the lifestyle intervention 
until the end of the study. 
 Current physical activity recommendations to maintain health and prevent dis-
ease are at least 30 minutes of moderate-intensity physical activity on most, preferably 
all days of the week (62; 63), which seem an effective and safe way to improve insulin 
sensitivity and insulin secretion (64) and prevent type 2 diabetes in all populations (65). 
However, recent studies investigating interval training (with brief high intensities ~95% 
VO2max) suggests that this type of interval training may be more powerful than train-
ing at 70% VO2max in eliciting changes in the metabolic disturbances associated with 
IGT and heart failure patients (66-71). If interval training is at least as effective as 
moderate intensity training, than more exercise options can be provided, i.e. those 
that limit time use (71). The SLIM study lacks the statistical power to draw conclusions 
about the efficacy of exercise or leisure time physical activity in increasing aerobic 
capacity. In conclusion, it seems that high intensity exercise may be more effective for 
beneficial metabolic changes, while leisure-time physical activity may be easier to put 
into practice. In addition, low-intensity physical activity and physical activity during 
leisure time and work should also be encouraged since even moderate levels of usual 
physical activity are associated with significantly reduced 2-hr glucose levels (72) and a 
reduced risk of mortality and cardiovascular disease in men and women (73; 74). 
9.5.4 Genetics 
In the SLIM study, genetic variation has not yet been analyzed while the interaction of 
genes with the environment may play a role in the metabolic response to a lifestyle 
intervention. Several gene-environment interactions have been found, e.g. the X/Ala 
genotype of the PPARɶ-2 Pro12Ala SNP seems associated with bad lifestyle habits, but 
subjects with this genotype may also profit more from the lifestyle intervention (75). 
Also, in the Tübinger Lifestyle Intervention Program (TULIP) (76), which followed the 
DPS lifestyle protocol, showed that the minor G allele of SNP rs2267668 in PPARD and 
the minor serine-encoding allele of the common Gly482Ser SNP in PPARGC1A were 
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independently associated with less increase in individual anaerobic threshold (77), 
indicating that these alleles impair the effectiveness of aerobic training. 
 To conclude, genetic variation can play a role in the response to a lifestyle inter-
vention. Studies involving interactions between genes and lifestyle intervention re-
sponse are still limited and need confirmation in large cohorts. When more conclusive 
evidence is provided, the effectiveness of tailored lifestyle programs should be tested 
in subgroups with genotypes that are associated with adequate and impaired meta-
bolic response to a lifestyle intervention (78). 
9.5.5 Gender 
Across the general population, lifestyle changes may differ between men and women. 
In the SLIM lifestyle intervention group, men had higher fasting glucose, blood pres-
sure, caloric intake, and lower HDL cholesterol levels at baseline, similar to recent 
results from the DPP (79), presumably making their diabetes risk higher. After 1 year in 
SLIM, lifestyle-induced changes in 2-hr glucose were similar across both sexes and after 
3 years similar changes were observed, except for waist–hip ratio and percentage of 
body fat which increased in women but remained relatively stable in men (chapter 3). 
After 1 year in the DPP, men showed a greater decrease in 2-hr glucose levels when 
losing >3% body weight (79), while diabetes incidence was not lower in men, com-
pared to women. The greater decrease in 2-hr glucose levels may not have leveled out 
the contribution of the high fasting glucose levels at baseline in men. Although it is 
plausible that sex differences mediate metabolic and cardiovascular risk, sex per se 
does not seem to be a predictor of coronary heart disease mortality in subjects with 
type 2 diabetes (80). Studies powered to examine sex-specific consequences of differ-
ent prevention strategies would be useful. 
9.6 Adipokines and Inflammation factors 
Work over the past decades has revealed that adipose tissue is metabolically active in 
controlling glucose homeostasis and insulin sensitivity. With increasing adipose tissue 
mass and reduced adipose tissue function, the lipid buffering capacity of adipose tissue 
decreases, resulting in an increased flux of lipids to non-adipose tissues like muscle and 
liver (lipid overflow). Secondly, the function of adipose tissue to secrete multiple 
biologically active proteins may be impaired (81). Adipocyte dysfunction is character-
ized by hypertrophied adipocytes with an altered secretion of adipokines and high 
secretion of monocyte chemoattractant protein-1 (MCP-1) perhaps enhancing macro-
phage infiltration and the pro-inflammatory state (82; 83). Results from chapter 6 and 
7 will be discussed in light of these hypotheses. 
 In the SLIM study, we observed a relation between change in complement factor 
3 (C3) and change in 2-hr glucose, after 1 and borderline after 3 years of intervention, 
independent of changes in body weight (chapter 6 and chapter 7). Our results were 
similar to those found in non-diabetic Pima Indians (84), suggesting a relation between 
C3 and diabetes development at least partly independent of obesity (85; 86). The 
mechanisms underlying these associations are unclear. Acylation stimulating protein 
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(ASP), a peptide hormone which is formed by the protolytic cleavage of C3, may 
stimulate the uptake of glucose and fatty acids in adipose tissue (87). Hypothetically, a 
blunted response to the C3–ASP system could be related to increased levels of C3, 
glucose and lipids (88). C3 is mainly produced in the liver (89) and cytokines may 
stimulate C3 production as well as the production of lipids, thereby reducing insulin 
resistance. In contrast to the relationship with 2-hr glucose, in SLIM, changes in C3 and 
changes in HOMA-IR were explained by changes in body weight (chapter 6 and chapter 
7). Besides the liver, adipose tissue may be a proinflammatory source of C3 production 
(90), by activated macrophages (91) and adipocytes (92). In agreement with another 
study (93), C3 was a stronger inflammatory marker than CRP, both of which may 
reflect the hepatic inflammatory contribution to diabetes development. 
 In the SLIM 1-year results (chapter 6), we observed an independent relationship 
between changes in 2-hr glucose and changes in IL-6. In a prospective study with 3075 
men and women aged 70-79 years, IGT has shown to be associated with IL-6 (94). Also 
in cross-sectional studies IGT has been associated with increased IL-6 levels (95; 96). 
These findings are in agreement with previous results showing an increased IL-6 
production from muscle in the postprandial phase of IGT men (97). The strong rela-
tionship between IL-6 and 2-hr glucose may possibly be explained by an inhibitory 
effect of IL-6 on insulin signaling in the liver (98), i.e. by decreasing insulin-mediated 
suppression of endogenous glucose production (EGP) (99), as observed in animal 
studies. Human studies to verify this hypothesis are scarce. One study showed no 
effect of IL-6 on EGP (100), but this study was done in healthy individuals and not in 
subjects with a disturbed glucose metabolism. Surprisingly, after 3 years, IL-6 was no 
longer associated with 2-hr glucose levels (chapter 7). The mechanism explaining this 
result is not clear, IL-6 may only have a short-term effect on 2-hr glucose levels. On the 
long term, IL-6 does not seem to play an important role. IL-6 seems to play a physio-
logical role when increased during relatively short periods, while it seems to have a 
pathological role when elevated chronically. The rapid rate at which IL-6 is cleared 
after infusion (101; 102) or exercise (103) suggests that chronic elevation of IL-6 is not 
desirable (104). 
 Lifestyle interventions may have beneficial effects on inflammation factors (105; 
106), although we were unable to confirm this directly in the SLIM study. We did 
observe that beneficial changes in glucose tolerance in the intervention and control 
group together were associated with changes in CRP, IL-6 and C3 after 1 year and 
borderline with C3 after 3 years. This suggests that beneficial changes in glucose 
tolerance may be partly explained through changes in these inflammatory markers.  
However, the magnitude of these factors in contributing to the etiology of type 2 
diabetes and vascular abnormalities remains to be determined. 
 In the SLIM study, leptin levels increased significantly less in the intervention 
group compared to the control group (chapter 7). Changes in leptin were associated 
with changes in HOMA-IR after 1 year (107) and after 3 years (chapter 7). Changes in 
body weight appeared the primary factor explaining this relationship. Similarly, in 
previous studies in men but in not women, baseline leptin levels were related to 
incident diabetes (108;109), independent of markers of body fat. The higher levels of 
leptin observed in women, compared to men, may be an explanation, suggesting a 
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non-linear relationship in women between leptin levels and insulin resistance/ diabe-
tes development.  
 After 3 years of lifestyle intervention, changes in PAI-1 were associated with 
changes in HOMA-IR, independent of changes in body weight, saturated fat intake and 
VO2max (chapter 7). After 1 year however, body weight loss abolished the relationship 
between changes in PAI-1 and changes in HOMA-IR, similar with previous findings 
(106; 110; 111) (chapter 6). The results after 3 years are similar to those found in the 
DPP (112). Multiple factors seem to influence PAI-1 expression (113) and diabetes 
incidence, e.g. triglycerides, free fatty acids, glucose and subclinical inflammation, 
suggesting that in accordance with our findings, changes in adipocyte function rather 
than fat mass per se may contribute to the improved metabolic profile. The beneficial 
changes in adipocyte function may become apparent when they are not overshad-
owed anymore by beneficial changes in adipocyte mass. Also, genetic variation in PAI-1 
may influence diabetes incidence, since genetically obese and diabetic (ob/ob) mice 
lacking the PAI-1 gene have reduced adiposity and amelioration of the diabetic pheno-
type (114). Changes in PAI-1 may be a marker of the complex mechanism underlying 
obesity and diabetes development. 
 In this lifestyle intervention study, the 1-year results (107) and the 3-yr results 
(chapter 7) have shown not to affect adiponectin levels. Some other lifestyle interven-
tions did find an increase adiponectin levels, which seemed mediated by reductions in 
fat mass (115; 116) while others did not in diabetic or obese subjects (117; 118). 
Adiponectin, seems to be modestly affected by lifestyle changes while baseline adi-
ponectin seems a strong predictor of incident diabetes in the DPP (119). Physical 
activity does not seem to influence adiponectin levels, while considerable weight loss 
restores high adiponectin levels (120; 121). 
 Lifestyle interventions according to general recommendations for a healthy 
dietary intake and composition as well as a healthy physical activity level seem to have 
little effect on adipokine levels. However, adipokines seem to play a role in the dete-
rioration of glucose tolerance and insulin sensitivity, as shown in the SLIM study for 
leptin. Although more research is necessary to verify the role of adipokines in the 
development of type 2 diabetes, adipokines seem to reflect processes that influence 
metabolic status, e.g. adipocyte dysfunction, and do not seem to play an important 
role in lifestyle-induced improvements in glucose tolerance and insulin resistance 
during a long-term follow-up. 
9.7 Iron metabolism 
Already in the ancient world, Erasistratus of Chios (304 BC- 250 BC), a Greek anatomist 
and physician, theorized that many diseases were caused by plethoras, or overabun-
dances, in the blood, and advised that these plethoras be treated, by initially, exercise, 
sweating, reduced food intake, and vomiting. Herophilus advocated bloodletting. 
Nowadays, increasing exercise and reducing food intake remain the initial advice in the 
prevention and treatment of type 2 diabetes, while bloodletting has almost vanished 
as a therapeutic remedy. A possible therapeutic treatment of blood letting can be 
found in type 2 diabetic patients with high ferritin concentrations, in which blood 
Thesis C Roumen V12.pdf   147 14-9-2009   11:11:17
Chapter 9 
 148 
letting still seems effective in improving insulin sensitivity (122) and vascular dysfunc-
tion (123). Also in carriers of the hemochromatosis gene, blood letting, and subse-
quent iron depletion, ameliorates insulin secretion and sensitivity (124). Improvement 
of peripheral insulin sensitivity after blood letting may be due to decreased liver iron 
storage and decreased liver insulin resistance although more studies are warranted. 
 Markers of the iron metabolism, i.e. ferritin and transferrin, have been associated 
with the development of hyperglycemia and type 2 diabetes (122; 125; 126), while the 
mechanism behind these relationships are still unclear. Iron seems to have lipolytic 
properties (127) and is a catalyst in the formation of hydroxyl radicals, which are power-
ful prooxidants that attack cellular membrane lipids, proteins, and nucleic acids (128). 
Both processes may be related to insulin resistance. In SLIM, we observed a relationship 
between the 1-yr change in ferritin, the main intracellular iron storage protein, and the 
change in 2-hr FFA levels (chapter 8). This association suggests that ferritin may be 
involved in the stimulation of lipolysis, subsequent lipid overflow towards liver and 
skeletal muscle, and the development of insulin resistance (129). Transferrin, the blood 
plasma protein for iron ion delivery, was independently positively associated with 
changes in insulin resistance (chapter 8). Besides that transferrin may also have lipolytic 
properties giving lead to increased circulating free fatty acids concentrations and thereby 
promoting insulin resistance, we cannot exclude a bidirectional relationship. Therefore, 
insulin may upregulate transferrin production, as has been shown in human hepatocytes 
(130) and may stimulate iron uptake by fat cells (131). Overall, these findings merit 
further investigation to clarify causality and the mechanism behind the iron metabolism, 
insulin resistance and the development of type 2 diabetes. 
9.8 Implementation strategies 
Currently, subjects at risk for developing type 2 diabetes are detected by measuring 
fasting glucose levels or HbA1c levels in the general practitioners office. The measure-
ment of 2-hr glucose levels in general practice is time consuming and therefore may 
not be an even match for fasting glucose, which is easily performed. However, by not 
measuring 2-hr glucose levels, a considerable group at risk will be missed for preven-
tion purposes. A keen solution may be to incorporate a 2-hr glucose measurement in 
the increasingly popular health checks, allowing the subject at risk to take the glucose 
load at home, before coming to the general practitioners office. In any case, general 
practitioners should be aware and convinced of the clinical significance of IFG and IGT 
as risk factor for developing type 2 diabetes and the beneficial effects that lifestyle 
interventions can have on that process. Besides 2-hr glucose levels, risk scores have 
become an appealing tool to predict diabetes risk and several questionnaires have 
been proposed as a simple, practical, non-invasive and inexpensive way of identifica-
tion (62; 132; 133). These questionnaires include criteria of obesity, family history, age 
cardiovascular history, gestational history, drug history (62) and criteria of physical 
activity, fruit and vegetable intake (132; 133). The Finnish Diabetes risk score (FIN-
DRISC) seems to better predict diabetes incidence than metabolic syndrome (17) and 
the German Diabetes Risk Score (134). In the Netherlands, the Finnish questionnaire 
has been shown to be a reasonably good predictor of diabetes incidence (135). Smok-
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ing status, alcohol use, and physical activity do not seem to add to the predictive value 
of the variables age, BMI, waist circumference, family history of diabetes, history of 
hypertension, history of high blood glucose, all of which were used in the FINDRISC 
score (134). Until easy and time-limiting methods have been developed and proven to 
screen high-risk subjects more accurately than fasting glucose, fasting glucose levels 
remains the primary factor for screening, identification and treating at risk subjects for 
type 2 diabetes. 
 For successful implementation of lifestyle interventions, efforts are necessary 
from the individual and the health care sector as a whole. The private sector and the 
government can help by stimulating initiatives that stimulate a healthy behavior, i.e. by 
stimulating stair use and providing healthy food in the canteen. The combined efforts 
can help to create a stimulating environment for achieving a healthy lifestyle among 
most individuals (62). In popular words, diabetes prevention will prove effective when 
we are supportive of the saying: ‘All for one and one for all’. 
9.9 Recommendations for future research 
1. Subjects with a low socio-economic status are at risk for dropout to a lifestyle 
intervention, impaired quality of life and premature death, compared to subjects 
with a moderate-to-high socio-economic status. Therefore, future studies should 
investigate how subjects with low socio-economic status can be reached and moti-
vated to change their lifestyle. In addition, future studies should evaluate the rele-
vance and effect of changes in the direct environment to encourage a healthy life-
style, such as cheap and easy transportation to sports locations. 
2. Inadequate adherence is a problem for lifestyle intervention efficacy. The SLIM 
study shows that perceived susceptibility to getting diabetes and misconception 
about own adherence are associated with adherence to nutrition and physical ac-
tivity advices, although other factors like environment and social support may also 
play a role. Future studies should investigate how susceptibility of disease, concep-
tion of adherence and possible other behavioral factors can be influenced so that 
the person at risk has a truthful perception of their individual situation in which 
considerations are made. It may be helpful to stimulate high-risk individuals to dis-
cuss their (difficulties in) adherence to get a more truthful image of their suscepti-
bility of disease and adherence. 
3. Questionnaires and prediction algorithms based on biomarkers have been devel-
oped as a tool to predict diabetes incidence and may be used to predict lifestyle 
success. In recent years, molecular profiling has gained interest since biomarkers 
for the development of type 2 diabetes can be discovered, as a large number of 
genes and proteins can be analyzed by high throughput technologies (136). Bio-
markers may help to classify high-risk subjects, personalize the preventive actions 
and increase the success of lifestyle interventions. Although biomarkers may help 
to facilitate high-risk screening, prediction and prevention, much work remains be-
fore these biomarkers can be used in clinical practice. In general practice, fasting 
glucose levels remains the method for screening and treatment of high blood glu-
cose levels. Future studies are necessary to evaluate how short questionnaires and 
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possibly biomarkers can be effectively implemented in the general public health 
system for the benefit of both the subject at risk as well as the general practitioner. 
4. Current physical activity guidelines recommend at least 30 minutes of moderate-
intensity physical activity on most, preferably all days of the week. However, recent 
data suggest that high-intensity interval training may be more effective in improv-
ing metabolic disturbances associated with IGT. The effectiveness, efficacy and 
safety of this exercise method should be tested in large randomized trials with 
populations differing in age and co-morbidities. 
5. Inflammation factors, immune markers and adipokines may help to predict inter-
vention success or diabetes development more accurately. These factors may also 
be used to identify subgroups at risk and subgroups more or less responsive to life-
style interventions. However, future research should reveal the additional value of 
identification of subgroups. Like in breast cancer screening, identification may not 
lead to a better outcome, i.e. less mortality. 
9.10 What does it mean: the way of progress? 
The acknowledgement starts with a statement of Marie Curie: ‘The way of progress is 
neither swift nor easy’. Along with this statement, it should be emphasized that pro-
gress as a whole is not a direct consequence of developments in time. As time passes, 
old problems are solved whereas new ones become known. Therefore, ‘progress’ 
should only be used as a term referring to a specific topic in a certain time frame, 
acknowledging the relative contribution of man to ‘progress’ and acknowledging 
problems as exciting part of our passing lives. 
 Type 2 diabetes mellitus is one of those exciting problems, due to the metabolic 
complications, the worldwide scale and the multiple components involved in the 
pathophysiology. In this thesis, we show that lifestyle interventions according to 
general public health recommendations are effective after 3-6 years and that body 
weight and waist circumference seem the most important predictors for a reduction in 
diabetes risk. Lifestyle-induced beneficial changes in dietary composition and maximal 
aerobic capacity can be sustained with 3-6 years intervention. These factors have 
independent effects on the reduction of diabetes risk and are of utmost importance in 
sustaining weight reduction. However, this thesis also brings about new problems, or 
reinforces old ones. It is still unknown which manner is best to identify subjects at risk 
and measure their risk, although questionnaires may be promising. In addition, drop-
out to lifestyle intervention is a serious threat for effectiveness and implementation in 
the community. Low aerobic capacity, a low social economic status, time constraints 
and behavioral factors like lack of awareness, motivation and susceptibility may all be 
important for dropout, making adherence a complex problem. Even more complex is 
implementation of lifestyle programs. Health care at present is still primarily focused 
on the treatment of disease, rather than preventing them, exemplifying that a switch 
will be necessary towards prevention of disease. For this switch to take place, efforts 
will be necessary from all layers in the population, which amplify, not counteract each 
other’s efforts and thát may be the greatest challenge of all, given the diverse ideas 
about the challenge: type 2 diabetes mellitus.  
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